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Abstract
Background Wireless capsule endoscopy (CE) was introduced in clinical practice
just over a decade ago; it has since established a new era in the investigation and
diagnosis of small-bowel diseases. Nevertheless, the detection of small-bowel
pathology can be limited by issues related to the current level of CE technology.
Furthermore, the clinical validity of the use of surrogate markers of diagnostic yield
such as the ampulla of Vater (AoV), or that of various prokinetics, to increase the
completion rate - and theoretically, the diagnostic yield - have not been clearly
established. Other factors that could optimize the rate of detection of small-bowel
pathology in CE are: 'speedy' video sequence review, chromoendoscopy and/or the
application of three-dimensional (3-D) image-reproduction software. Three-
dimensional imaging in CE is not currently feasible due to hardware limitations.
However, software algorithms (shape-from-shading, SfS) that enable 3-D
reconstruction in CE are available.
Methods The database of capsule endoscopy examinations of our centre includes
procedures performed with two different models of capsule endoscopes. The
detection rate of the duodenal papilla was examined in the largest - to date - cohort
of small-bowel capsule endoscopy videos obtained with two different capsule
endoscopy systems. Using meta-analysis software, the impact of various prokinetics
was analysed. Furthermore, the validity and safety of QuickView pre-read was
examined. In regard to proprietary chromoendoscopy software, Blue Mode filter
offers better image enhancement when compared with Fujinon Intelligent
Chromoendoscopy (FICE).
Out of four publicly available SfS algorithms, Tsai's method is the one that gives the
better results. Tested on still-capsule endoscopy images, the application of a 3-D
reconstruction software leads to image enhancement for a significant proportion of
v
vascular, but less so for inflammatory and protruding, lesions. Furthermore, the
adjunct of 3-D reconstruction to the standard two-dimensional video reading
software significantly improves the performance of novice small-bowel CE readers
in distinguishing masses from mucosal bulges, thus potentially shortening their
learning curve.
Results This thesis demonstrates that the selective and judicious use of
prokinetics - and specifically that of metoclopramide with purgative and/or real¬
time viewer - in capsule endoscopy improves the completion rate. My results also
show that the persistently low rate of AoV detection using two different small-
bowel CE systems underlines the weakness of non-steerable CE. Although the
benefits of QuickView are outweighed to some extent by a decrease in the overall
detection rate, this mode can be used confidently in overt obscure gastrointestinal
bleeding in an urgent inpatient setting and in outpatients with occult obscure
gastrointestinal bleeding or suspected Crohn's disease. FICE (especially I) and Blue
Mode is useful for the characterization of small-bowel findings.
Conclusion There are limitations in the current commercially available software
for CE review. The inclusion of a 3-D representation algorithm may be of training
and diagnostic benefit. Until optics technology allows hardware-enabled three-
dimensional reconstruction, it seems a plausible alternative. Further clinical and




1. The problem of optimizing the use of capsule endoscopy in the
detection of small-bowel disease
2. Detection of the ampulla of Vater in small-bowel capsule endoscopy:
experience with two different systems
3. Do prokinetics influence the completion rate in small-bowel capsule
endoscopy? A systematic review and meta-analysis
4. Chromoendoscopy in small-bowel capsule endoscopy: Blue Mode or
Fuji Intelligent Colour Enhancement?
5. QuickView in small-bowel capsule endoscopy is useful in certain
clinical settings, but QuickView with Blue Mode is of no additional
benefit
6. Evaluation of 4 three-dimensional reconstruction algorithms in capsule
endoscopy images and use of enhancement algorithm to suppress
reflections in three-dimensional reconstruction
7. Three-dimensional representation software as image-enhancement tool
in small-bowel capsule endoscopy: a feasibility study
8. Revisiting the 'mass or bulge' question in small-bowel capsule
endoscopy with the help of three-dimensional reconstruction software
9. Conclusions and future directions
10. References





alt. h. alternate hours
ANOVA analysis of variance
AoV ampulla of Vater
ASGE American Society of Gastrointestinal Endoscopy











CTE computed tomography enterography




EFP electric field propagation
EPROM Erasable Programmable Read Only Memory
F females
FAP familial adenomatous polyposis
FDA U.S. Food and Drug Administration
FICE Fujinon Intelligent Chromo Endoscopy
FN false negative
FoV field of view
Fps frames per second
GI gastrointestinal
GTT gastric transit time
GUI graphical user interface
HBC human body communication
IA inter-observer agreement
IBD inflammatory bowel disease
IDA iron-deficiency anaemia
IMC Intelligent Microsystem Center
IV intravenous
LED light emitting diodes
ix




MeSH Medical Subject Headings
min minutes
MiroCam Mirco Intelligent Robotic Object Camera
MRE magnetic resonance enterography
MRI magnetic resonance imaging





NLH nodular lymphoid hyperplasia
NPV negative predictive value
OGD oesophagogastroduodenoscopy





PHE portal hypertensive enteropathy
Pk packet
PO per os
PPV positive predictive value
QV QuickView
QVBM QuickView Blue Mode
QVWL QuickView white light
RF radio frequency
RGB red green blue colour model
RLP right lateral position
ROC receiver operating characteristics
ROI region of interest
RR risk ratio
RTV Real Time Viewer
s2D standard two-dimensional
SBI suspected blood indicator














Table 1 Available types of small-bowel capsule endoscopes, specifications and
operating characteristics.
Table 2.1 Indications for small-bowel capsule endoscopy in our cohort and number
of small-bowel examinations per capsule endoscopy.
Table 2.2 Details on number and characteristics or small-bowel capsule endoscopy
per indication group in our cohort.
Table 2.3 Studies on the ampulla of Vater detection rate.
Table 3.1 Main characteristics of the included studies in the prokinetics meta¬
analysis.
Table 3.2 Studies characteristics as per prokinetic used (dose, mode of
administration), capsule device used and patients included.
Table 3.3 Exclusion criteria, reported capsule-retention episodes, bowel
obstruction/capsule-aspiration cases and adverse effects of the prokinetics used in
the studies of this meta-analysis.
Table 4.1 Demographics and indications for small-bowel capsule endoscopy small-
bowel CE, type of lesions examined with white light, FICE and Blue filter.
Table 4.2 Results of the study of FICE 1, 2 ,3 and Blue filter in image enhancement
in small-bowel CE.
Table 5.1 Demographics and indications for small-bowel capsule endoscopy in the
study cohort.
Table 5.2 Angioectasias, ulcers and polyps detected with each of the study's
viewing modes.
Table 5.3 Studies evaluating QuickView to date.
Table 7.1 Evaluated images in total and per small-bowel CE system used (PillCam®,
MiroCam®).
xiii
Table 7.2 Image enhancement with the three-dimensional image representation
software, as per small-bowel capsule endoscope system, image group and colour of
structure/finding.
Table 7.3 Sub-groups analyses performed for capsule endoscopy and non-capsule
endoscopy readers.
Table 7.4 Inter-observer agreement for all reviewers (and per CE reviewing
experience groups) for all images and per diagnostic category.
Table 8.1: Summative and mean score for 3-D reconstructed videos according the
angle of view.
Table 8.2 Performances (sensitivity, specificity, likelihood ratio positive and
negative) of novices and experts in reading 2-D and 2-D + 3-D reconstructed videos.
Table 8.3 Area under the ROC curve (AUC) of novices and experts in reading 2D
and 2-D + 3-D reconstructed videos.
xiv
LIST OF FIGURES
Figure 3.1 Flow diagram of the identification of studies and of the selection process
of this meta-analysis.
Figure 3.2 Jadad scores of the studies included in this meta-analysis.
Figure 3.3 Forest plot of CR, showing individual and pooled OR with 95% CI of
studies comparing capsule ingestion with prokinetics vs. no prokinetics.
Figure 3.4 Forest plot of CR, showing individual and pooled OR with 95% CI of
subgroup 1 studies: i.e. studies with more homogenous protocols in which purging
and/or real-time monitoring were not used, comparing capsule ingestion with
prokinetics vs no prokinetics.
Figure 3.5 Forest plot of DY, showing individual and pooled RR with 95% CI of
studies comparing capsule ingestion with prokinetics vs no prokinetics.
Figure 3.6 Forest plot of GTT, showing individual and pooled difference of means
with 95% CI of studies comparing capsule ingestion with prokinetics vs no
prokinetics.
Figure 3.7 Forest plot of SBTT, showing individual and pooled difference of means
with 95% CI of studies comparing capsule ingestion with prokinetics vs. no
prokinetics (data from studies reporting relevant data).
Figure 3.8 Funnel plot of studies included in this meta-analysis; evidence of
publication bias is present
Figure 4.1 Comprehensive collection of images with white light, FICE 1, FICE 2,
FICE 3 and Blue filter of: ulcer (row 1), polyp (row 2), angioectasia (row 3),
cobblestone mucosa (row 4).
Figure 6.1 (A, B) A) an angioectasia represented with the Tsai's SfS algorithm, and
B) the same lesion represented with the Ciuti's SfS algorithm.
Figure 6.2 (A, B) A) an angioectasia represented with the Barron's SfS algorithm,
and B) the same lesion represented with the Torreao's SfS algorithm.
xv
Figure 6.3 (A, B) A) shape-from-shading (SfS) principles B) Highlights removal
software.
Figure 6.4 (A, B) A) Phantom model, and B) task simulator setting.
Figure 6.5 (A, B) Three-dimensional representation of images captured for the 3
models: red, white and yellow. A) Original three-dimensional (3-D) represented
images, and B) The processed 3-D represented images using the highlight
suppression algorithm.
Figure 6.6 (A, B) A) Mathworks®Matlab program with a graphic user, and B) The 2
most voted SfS, Ciuti's (left) and Tsai's method (right).
Figure 6.7 Assessment results for the 4 shape-from-shading algorithms per lesion
category.
Figure 6.8 Relative distance of three-dimensional representation calculated over
images taken from various distances of the capsule from the models.
Figure 7.1 (A, B) Phantom simulator (A) and, phantom models (B).
Figure 7.2 The 3-D image representation software evaluation interface in a Matlab®
environment.
Figure 7.3 Example of phantom models in 2-D and their 3-D image representations.
Figure 7.4 Example of vascular lesions in 2-D and their 3-D image representations.
Figure 7.5 Example of inflammatory lesions (2-D) and their 3-D image
representations.
Figure 7.6 Example of protruding structures/lesions in 2-D and their 3-D image
representations.
Figure 8.1 Two 2-D small-bowel CE frames reconstructed in 3-D using the SfS
algorithm at the 7 angles (25°, 35°, 45°, 55°, 65°, 75°, and 85° degrees).
Figure 8.2 Two small-bowel CE frames depicting a mass (A) and bulging (B) with
their corresponding 55° 3-D reconstruction.
xvi
Figure 8.3 Flowchart of study phase 1 (left side) and phase 2 (right side).
Figure 8.4 (A, B) A) ROC curves for novices reading with 2-D (top figure) and 2-D +
3-D videos (bottom figure). B) ROC curves for experts reading with 2-D (top figure)
and 2-D + 3-D videos (bottom figure).
xvii
CHAPTER 1
The problem of optimizing the use of capsule endoscopy
in the detection of small-bowel disease
1.1 Brief history
1.2 Principles of capsule endoscopy technology
1.2.1 PillCam® small-bowel capsule endoscopy system
1.2.2 MiroCam® small-bowel capsule endoscopy system
1.3 Reading capsule endoscopy video sequences
1.4 Diagnostic yield and indicators
1.5 The issue of prokinetics in capsule endoscopy
1.6 Fujinon intelligent colour enhancement
1.7 QuickView and capsule endoscopy




The idea for a wireless endoscopic capsule device belongs to Gavriel Iddan, an
Israeli electro-optical engineer (Iddan et al. 2000; Eliakim 2013). Working
concurrently on the same fundamental idea in London, Professor Paul Swain
published the first conceptual studies on a wireless capsule in 1994 (Iddan and
Swain 2004). Swain's team possessed the necessary anatomical expertise and
medical knowledge for the demands and objectives that would be placed on such a
device, while Iddan was more familiar with the engineering and electro-optical
aspects of capsule endoscopy (CE) (Filip 2013). Eventually, the two teams joined
forces and the outcome of their combined efforts was the first wireless capsule
endoscope, which was presented and published at the Digestive Diseases Week
(DDW) of the Millennium in San Diego, USA, and in Nature, respectively (Iddan
and Swain 2004; Koulaouzidis, Rondonotti and Karargyris 2013).
Since its official introduction in clinical practice (2001), CE has drastically changed
clinical decision making and the diagnostic algorithms of investigating the small
bowel. A wealth of evidence has confirmed the validity of the use of CE in obscure
gastrointestinal bleeding (OGIB) - the latter accounts for 60-70% of all small-bowel
CE examinations worldwide - and Crohn's disease (CD; known and/or suspected).
Other clinical indications, although less common, are coeliac disease, small-bowel
polyposis syndromes and clinical suspicion of small-bowel neoplasia (Wang et al.
2013; Ladas et al. 2010; Sidhu et al. 2008). To date, more than 2 million capsules have
been ingested worldwide and more than 3,000 PubMed-listed publications have
appeared in the medical literature.
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1.2 Principles of capsule endoscopy technology
Overall, CE approaches an almost 'physiological' endoscopy; the capsule moves
passively - propelled by bowel peristalsis - and images the mucosa in a collapsed
state, as there is no air insufflation (Woods and Constandinou 2011). All
commercially available CE devices are constructed following the same baseline
principles. At first, the shape and volume of any CE device should be sufficiently
small to allow it to pass through the main anatomical sphincters (cricopharyngeous,
lower oesophageal sphincter, pylorus and ileocaecal valve) without becoming an
obstruction risk (Woods and Constandinou 2013). However, this size in conjunction
with the peristaltic movements of the small bowel, are also the 'Achilles heel' of the
capsule, as they predispose the capsule to rotate (or tumble) within the small-bowel
lumen resulting - frequently - in deficient luminal and mucosal coverage. The
tumbling movements of the capsule (oblique-forward, oblique-reverse,
perpendicular movements) often result in temporary visual interference that may
render the images unsuitable for diagnostic purposes (Filip 2013). Furthermore, it is
already know that even expert reviewers have a limited ability to recognize the
vector of capsule movement in the small-bowel lumen or through anatomical
sphincters (Koulaouzidis, Douglas and Plevris 2012; Kopylov et al. 2012).
The sheath is made of disposable and biocompatible plastic material, resistant to
digestive fluids (in order to seal and protect its internal components in the 'milieu'
of the GI tract) and weighs between 3.3-6 g (depending on the CE model: see Table
1) (Koulaouzidis, Rondonotti and Karargyris 2013). The internal compartment of
any CE device includes a complementary metal-oxide-semiconductor (CMOS)
imager or a high-resolution charge-coupled device-based chip camera (CCD), a
short focal-length (hemispheric) compact lens, a white light illumination system
(provided by 4-6 light emitting diodes (LEDs)), two silver oxide batteries and a
transmitter. The CMOS imager suits the packaging/ space constraints of the capsule
device due to its low light requirements (Swain 2010).
The CE's device imager, which has no shutter, operates by taking still frames in a
dark environment intermittently illuminated by LEDs throughout the capsule
passage. Capsule endoscopes offer an 8x magnification, and a minimum size of
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lesion detection in the range of 0.1-0.2 mm. Depending on the manufacturer, the
operating time of capsules can vary between 8-12 hours (Table 1) (Koulaouzidis,
Rondonotti and Karargyris 2013). The CE device is activated by its removal from a
magnetic holder. Commercially available small-bowel CE models can acquire and
transmit between 0.5-16 frames per second (fps) (Koulaouzidis, Rondonotti and
Karargyris 2013). This results in a total of 50,000-120,000 transmitted images that are
'stitched' together and converted into a continuous video that gives the illusion of
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1.2.1 PillCam® small-bowel capsule endoscopy system
The first commercially available CE device (M2A®) was developed by
Given®Imaging Ltd (Yoqneam, Israel) and it was approved for clinical use in
humans in Europe and the United States in August 2000. The first generation of
PillCam®SB - essentially a renamed M2A® - was released in 2001, while the second
generation of PillCam®SB was released in 2007 (PillCam®SB2). The latest
commercial small-bowel CE model of this company (PillCam®SB3) was released in
2013.
PillCam®SB2 measures 11 x 26 mm and weighs less than 4g (Koulaouzidis,
Rondonotti and Karargyris 2013; Wang et al. 2013). It contains a miniature colour
video CMOS-chip camera with four illuminating LEDs, two batteries, a
radiofrequency transmitter and an antenna. Images are captured at a rate of 2
frames per second (fps) for PillCam®SB2 or 4 fps (PillCam®SB2-4), while the battery
life is between 8 hours (PillCam®SB) and 12 hours (PillCam®SB2ex, see Table 1.)
(Wang et al. 2013). PillCam®SB2 has a broader mucosal coverage due to its
increased field of view of 156°degrees, as compared with the 140°degrees of its
predecessor, and an effective visibility distance of 30 mm (Metzger et al. 2009). The
image resolution of PillCam®SB is 256 x 256 pixels. Advanced optics and automatic
light control provide optimal image quality and illumination. Therefore, at a
reference working distance of 4.5 mm, the coverage mucosal area of PillCam®SB2 is
1,100 mm2' as compared with the 500 mm2 of its predecessor (Metzger et al. 2009).
The proprietary reading software of Given®Imaging Ltd is the RAPID™ Reader and
through repeated developments it has now reached its eighth version. This software
interface provides single, dual or quadruple window video review, as well as
additional diagnostic features and study reviewing aids. It contains an
improved user interface similar to the ribbon toolbar concept used in
Microsoft® products, the Lewis Score (LS) calculator, the Fujinon Intelligent Colour
Enhancement (FICE), the suspected blood indicator (SBI) (Koulaouzidis, Rondonotti
23
and Karargyris 2013), QuickView (QV), a thumbnail comparison feature, backwards
compatibility with studies from previous RAPID™ software versions, and an
improved progress indicator/localization guide.
The tracking of the capsule within the body is important for the localization of
abnormal findings and planning of further therapeutic interventions. Currently,
localization is based on transit time. Once the pylorus and caecum are identified, the
location of a lesion in the small intestine is an estimate based on the time from one
of these two points. Most commercially available software packages provide a two-
dimensional (2-D) tracking application of the capsule route. The output of these
localization modules is a graphic trajectory of the capsule while it moves along the
intestinal lumen (Fisher and Hasler 2012). This method uses signal strength analysis
from aerial antennae attached to the patient's abdomen which has been validated on
healthy volunteers against fluoroscopy (Fischer et al. 2004). However, this technique
has been criticized for its inability to definitively localize small-bowel lesions,
mainly because it is prone to inaccuracy due to differences in small-bowel transit
time or variant anatomy (Than et al. 2012). The average position error reported for
this technique is 37.7 mm, with a maximum error reaching 114 mm (Iakovidis et al.
2013).
1.2.2 MiroCam small-bowel capsule endoscopy system
MiroCam® (which stands for Mirco Intelligent Robotic Object Camera) has been
developed by the Intelligent Microsystem Center (IMC) established by the Korean
Ministry of Science and Technology in Seoul, South Korea, which was renamed to
IntroMedic Co Ltd in 2006 (Filip 2013). The company's small-bowel CE device
passed European medical standards and received certification (CE mark) in 2007; it
also received U.S. Foods and Drugs Administration (FDA) approval in May 2011
(Fisher and Hasler 2012). MiroCam®, currently version 2 with version 3 to be
released in 2014, utilizes a novel transmission technology, electric-field propagation
(EFP). This technology uses the capsule itself to generate an electrical field and the
human body as a conductive medium for data transmission in so-called 'human
body communication' (HBC). Perhaps this, in conjunction with the set array of
sensors, is the main reason for the persistent failure of this CE model to capture
24
upper-oesophageal and gastro-oesophageal junction (Z-line) images (Koulaouzidis
2013).
Specifications of the MiroCam® CE device include a size of 10.8 x 24.5 mm, a weight
of 3.4 g, a field of view of 170°degrees (150°degrees in the first model), a resolution
of 102,400 (320 x 320) pixels and an image capture rate of 3 fps (Koulaouzidis,
Rondonotti and Karargyris 2013). Illumination is provided by six LEDs. As a power-
saving method it incorporates two external electrodes and a single-skin electrode for
electric data conduction across the human body. Hence, it avoids the need for radio
frequency (RF) and allows for a long battery life without any need for image
compression and a safer use in the ever-increasing group of patients with
implantable pacemakers or in-situ defibrillator devices. Furthermore, MiroCam®
remains the smallest commercially available small-bowel CE device. The extra
available space (10% free internal space) could be used for additional internal
components, such as different sensors or stabilizing components for advanced CE.
The two systems have been repeatedly checked in head-to-head trials and have been
shown to have at least equivalent capability in detecting small-bowel disease
(Koulaouzidis, Rondonotti and Karargyris 2013).
MiroView™ v2.0, the proprietary reading software of IntroMedic Co Ltd, offers a
variety of tools and functions to aid reporting processes. For instance, the function
'Range View' displays a range of images to readily identify landmarks in the GI
tract. In this mode, the side bar images will move 1 image per/second while the
centre images will display images per user selection, i.e. 15 fps. Another function,
the 'Map View' which is similar to the Given®Imaging Ltd colour bar but uses a
different technology and patent, displays a range of thumbnail images to readily
identify landmarks in the GI tract. Furthermore, the 'Express View' eliminates
similar images and the Range View can be used to identify landmarks and disease
pathologies by viewing a total of nine images before and after the main image. In
the image-enhancement field MiroView™ offers the ALICE and colour-mode
functions. Admittedly, they have not attracted clinicians' attention or any clinical
studies.
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1.3 Reading capsule endoscopy video sequences
CE procedure is not operator dependent and does not require the same technical
skills as conventional GI endoscopy (Davison 2006; Drew et al. 2013). In fact,
capsule administration and swallowing requires only a couple of minutes.
Therefore, expertise with CE lies in the ability of an individual to read and interpret
the CE findings (Rajan et al. 2013). The average CE footage reading time varies
between 30 and 120 minutes depending on the small-bowel transit, the quality of
images, and the experience of the reader (Lo 2006). Moreover, a small-bowel lesion
may only be visible in just a few or even just a single frame (Rondonotti et al. 2012).
Therefore, this large amount of visual information requires focused and undivided
attention for careful evaluation by the CE reviewer (Lo 2006; Iakovidis et al. 2013).
Nevertheless, going (at low reviewing speed) through a rather monotonous video
recording, in a room with dimmed lights, is the perfect way for someone to become
hypnotized (Lo 2006). To date, there is limited data which can address errors in CE
interpretation (Lewis 2004; Lo 2006; Rondonotti et al. 2012; Koulaouzidis,
Rondonotti and Karargyris 2013). As such, there is much heterogeneity in
techniques used to interpret capsule endoscopy (Rondonotti et al. 2012).
Furthermore, there are limited published data concerning optimizing operator
performance for the interpretation of capsule endoscopy (Rondonotti et al. 2012). In
fact, the majority of current evidence on the best reading mode (single, dual or
quadruple view and reading speed) of CE video sequences comes from expert
opinion papers and/or performance comparison studies between physicians and
non-physician reviewers. Therefore, although the reporting time is a major clinical
issue, other factors such as the distance of the reviewer from the reviewing monitor,
the amount of ambient room light and/or the use of image-enhancement tools are
equally important to the final outcome.
One proposed strategy to reduce CE reading times would be to use trained non-
physician readers (e.g. endoscopy assistants/scientists) to pre-read the CE footage
(Dokoustidou et al. 2011; Shiotani et al. 2011; Drew et al. 2012). Another approach is
to use to special software programs to select significant images for subsequent
viewing (Shiotani et al. 2012; Koulaouzidis, Rondonotti and Karargyris 2013).
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Although several studies have showed that non-physician readers are at least as
competent as physician capsule endoscopists (Drew et al. 2013), the lack of an
homogeneous approach (viewing speed and/ or mode) in CE reviews seems to
account for some of the reported discrepancies in diagnostic yield (DY) and the
inter-observer agreement on CE video interpretation (Jensen et al. 2010; Jang et al.
2010; Rondonotti et al. 2012).
In light of all of the above, several attempts have been made to develop technical
software features, in order to make CE video analysis easier and shorter without
jeopardizing its accuracy or, in other words, its DY. The first software feature
designed for this purpose was the SBI, an automatic system able to pick up, in a
completely automatic fashion, frames containing several red pixels and, therefore in
theory to detect blood and/or other red-coloured lesions such as large
angioectasias. Nevertheless, the accuracy profile of this tool is suboptimal and, at
the present time, it can be used only as a supportive/addition tool in CE reporting
(Koulaouzidis, Rondonotti and Karargyris 2013).
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1.4 Diagnostic yield and key performance indicators
CE has advantages and disadvantages compared to other diagnostic modalities that
evaluate the small intestine (Dionisio et al. 2010; Triester et al. 2005; Marmo et al.
2005). The main advantage of CE is that it is a non-invasive technique with little or
no side effects or complications (Eliakim 2011). Perhaps one the main disadvantage
of CE is that its diagnostic accuracy is difficult to determine due to a lack of an
adequate 'gold standard'. Therefore, in the early days of CE, the term diagnostic
accuracy has been substituted with the term DY. Due to the unique and intriguing
nature of CE, DY is defined as the likelihood that a test or procedure will provide
the information needed to establish a diagnosis (Koulaouzidis et al. 2012).
In CE, the DY is influenced by several factors integral to the capabilities the capsule
device, for example, CE device technological specifications, quality and percentage
of intestinal mucosal coverage, and the challenging 'environment' of the small
bowel and the reviewer's performance. To date, human studies have compared
different methods of small-bowel examination, reporting their comparative DY
(Koulaouzidis, Rondonotti and Karargyris 2013). The true negative diagnostic rate
was defined as the number of cases in which both methods of examination were
negative. This is certainly an approximation of a true yield. Historically, the DY of
CE varies between 38-83% (Liao et al. 2010; Rondonotti et al. 2013).
One method to determine - and at a second stage, attempt to improve - the DY of
any diagnostic procedure is to use markers (at least some of which are in a difficult
position to be seen) that are present in every intestine and confirmed to be there
with another test. This was first done in 2000, when Appleyard et al. (2000) sewed
glass beads into the intestines of dogs and then performed capsule endoscopy and
push enteroscopy. The sensitivities were 64% and 37%, respectively. Another
solution (more applicable to humans) is to look for an anatomical finding, i.e. a
surrogate marker present in everyone (Cass 2006).
In conventional colonoscopy, caecal completion rate and withdrawal time are two of
the main performance indicators (Ward et al. 2014). It is known that a longer
withdrawal phase leads to a higher polyp detection rate (Butterly et al. 2014).
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However, other factors such as sleep deprivation of the endoscopist due to being on
call the night prior and/or performing an emergent procedure lead - despite longer
withdrawal times - to a significant 24% decrease in the adenoma detection rates.
Furthemore, it has been shown that colonoscopy quality-measure reporting is
important to patients, influencing colonoscopist selection (Solad et al. 2014).
In CE, currently an uncontrollable in regard to movement in the small-bowel, speed
and vector direction device, the above operator-dependent factors and performance
indicators cannot be applied. Therefore, over the last few years, clinical researchers
have highlighted the use of markers (some are in a position where they are difficult
to spot) which are present in the intestine as quality assurance indicators in small-
bowel CE. (Cass 2006). The major duodenal papilla, or ampulla of Vater (AoV),
which is present in all individuals who have not undergone duodenal resection and
is located on the posteromedial aspect of the duodenal sweep, 8-10 cm distal to the
pylorus, is a reasonable such candidate marker. It is difficult to see, as the
translucent dome of the propelled CE tends to point towards the outer aspect of
sharply angulated bowel loops. On the other hand, choosing the AoV as the marker
and extrapolating the results of the detection to polyp lesions may not be
completely reliable. The factors that make the AoV difficult to observe, such as the
proximal location, size/luminal protrusion and capsule transit speed, are at least
part of the reason why small-bowel lesions such as polyps may be missed in small-
bowel CE examinations (Clarke et al. 2008).
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1.5 The issue of prokinetics in small-bowel capsule
endoscopy
Maximum DY in small-bowel CE requires not only optimal visualization of the
intestinal mucosal surface but also complete capsule transit through the entire
small-bowel (Rokkas et al. 2009). Currently, one of the major limitations of small-
bowel CE is the high rate of incomplete examinations, i.e. the percentage of cases in
which the capsule does not reach the caecum by the end of the recording period
and/or exhaustion of the capsule's battery life. Recent systematic reviews showed
that the completion rate (CR) of small-bowel CE varies between 81.3-83.5% for
retrospective and prospective studies, respectively (Liao et al. 2010). If complete
enteroscopy is not achieved, concerns remain over missed small-bowel pathology
(Mergener et al. 2007). This could lead to repeated or new investigations increasing
health-care costs.
Risk factors for incomplete CE include intestinal dysmotility (e.g. prior small-bowel
surgery, diabetes mellitus), immobility/hospitalization, patient's age, moderate or
poor bowel cleansing, and a delayed gastric transit time (GTT)> 45 min (Yazici et al.
2012; Triantafyllou et al. 2009; Westerhof et al. 2009; Shibuya et al. 2012).
Furthermore, the presence of small-intestinal debris, chyme, biliary secretions,
and/or air bubbles can interfere with the visualization quality (VQ) and potentially
affect the DY. However, reducing small-bowel transit time (SBTT) may influence the
DY of CE. With colonoscopy, the detection rate of neoplastic lesions is higher when
the time to withdraw the colonoscope is longer (Fatima et al. 2008). It is conceivable
that a similar principle also applies for small-bowel CE.
Therefore, it is expected that decreasing GTT and SBTT will allow a capsule to
successfully reach the caecum by the end of its battery life. Therefore, different
prokinetic agents have been used. Metoclopramide remains the most commonly
administered prokinetic (Ladas et al. 2010). Domperidone, an antidopaminergic
agent, on the other hand, has not been widely used in small-bowel CE and the
evidence base is limited (Ladas et al. 2010). Unlike metoclopramide, it does not
readily cross the blood-brain barrier; hence it lacks extrapyramidal adverse effects
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(Champion et al. 1986). Recently, few studies evaluated the use of metoclopramide,
erythromycin, mosapride, chewing gum, lubiprostone, daikenchuto or even
postural 'tricks'.
The issue of improving CR in small-bowel CE is contentious. Although some
evidence exists, current guidelines indicate that there is no strict recommendation
on the use, type and/or mode of administration of prokinetics in small-bowel CE.
(Rondonotti et al. 2010). However, no systematic review or meta-analysis has
examined the role of prokinetics in combination with other modalities such as real¬
time viewer and/or purge, before or during a small-bowel CE procedure.
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1.6 Fujinon intelligent colour-enhancement (FICE)
In recent years, virtual chromoendoscopy techniques have been proposed to
enhance micro-vascular contrast and facilitate minute resolution of superficial
patterns and colour differences. In 2005, Fujinon Corporation (Saitama, Japan)
developed the FICE as a new type of image-enhanced endoscopy with the potential
to improve detection of lesions in the upper gastrointestinal tract and enhance
differentiation between neoplastic and non-neoplastic tissue (Pohl et al. 2008).
FICE is a digital-imaging technology based on arithmetical processing of ordinary
images; this is executed by external software and allows processing of ordinary
images that were captured by the standard video CE devices. The spectrum of
wavelength used for creation of optical images is influenced by several factors such
as the light spectrum of the light source, the optical device, and the spectral
sensitivity of the sensing elements. The wavelengths are associated with laminar
structures and blood flow in the GI mucosa that have been altered by inflammation
or neoplasm, which act as a scattering element and interfere with the reflectance
spectrum (Imagawa et al. 2011).
The FICE software was successfully implemented within the RAPID® Reader
reporting software (Given®Imaging Ltd, Yokneam, Israel). The CE reviewer can
select flexibly between standard imaging and three different FICE-enhanced settings
with different wavelength patterns by a simple push on the relevant toggle button
(Imagawa et al. 2011). Essentially, FICE can provide high-contrast images by
selecting the wavelength suitable for a specific structure of mucosal structures or
vessels. In CE, three FICE settings with different spectral specifications
(wavelengths) have been introduced.
An additional filter the RAPID® interface offers is the Blue Mode (BM) filter. BM
filter is a colour coefficient shift of light in the short wavelength range (490-430 nm)
superimposed on to a white (red, blue, green; RGB) light image. There is a growing
pool of experts' opinion that BM improves lesion visualization in the majority of
cases.
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Both the validity of FICE and BM in small-bowel CE, as well as the optimal settings
for improved image recognition in various small-bowel lesions, have been studied
only in a limited fashion to the present date (Pohl et al. 2010; Imagawa et al. 2011).
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1.7 QuickView (QV) and capsule endoscopy
Nevertheless, one of the limitations of small-bowel CE is the reading time required
for the interpretation of lengthy video streams. It is generally accepted that the
average time for video sequence analysis is between 40 and 120 minutes, depending
on the overall recording time and the reviewer's experience (Shiotani et al. 2012).
QV is a computational tool which scans all images and scores them according to the
possible level of significance. Eventually its output is CE images of potential interest
to the CE reader, providing a fast pre-viewing option (Westerhof et al. 2009). The
number of images to be considered 'frames of interest' can be set as a percentage
(5%, 10%, 20% ... 80%) of the full video. Then, according to the percentage level set
by the user, QV displays a shortened video compared with normal-mode view.
Recently published data give evidence that this target seems to be accomplished in
small-bowel CE video readings with a high sensitivity in the per-patient per-lesion
analysis (Shiotani et al. 2012).
However, the QV mode is still under clinical validation and there are only a handful
of studies that have examined the utility of this informatics algorithm (Shiotani et al.
2011; Saurin et al. 2012; Hosoe et al. 2012; Westerhof et al. 2009; Shiotani et al. 2012).
Furthermore, there is no evaluation of QV in combination with non-white light
images such as with the BM filter; the latter yields promising results and researchers
have recommended further study of this as the main viewing mode, especially in
cases of OGIB.
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1.8 Three-dimensional reconstruction in capsule endoscopy
To date, limited research has been carried out in developing methods and materials
that offer three-dimensional (3-D) representation of the digestive tract. Since the
capsule needs 6-8 hours to traverse through the small-bowel (Koulaouzidis and
Douglas 2009; Westerhof et al. 2012), cameras within the currently marketed capsule
endoscopes work at a capture rate of 2-3 fps in order to comply with power
requirements (Fisher and Hasler 2012). Nonetheless, this has an adverse effect on
the smoothness of motion between consecutive frames and creates a visually
unpleasant effect on the human eye (Karargyris and Bourbakis 2010; Woods and
Constandinou 2011). Furthermore, shape is an important element in human
perception; yet, unlike other diagnostic modalities, i.e. computed tomography and
magnetic resonance imaging, CE suffers from a lack of 3-D information
(Koulaouzidis and Karargyris 2011).
Three-dimensional (3-D) technology is currently in use, e.g. a magnetometer can
provide not only acceleration values on the three axes, but also the 3-D orientation
of the device. Commercial time-of-flight range cameras, i.e. Microsoft's Kinect
Project, already exist in the market and in the near future this may be further
improved and miniaturised for use inside a capsule endoscope (Karargyris and
Bourbakis 2011). These cameras offer information on depth and colour.
Furthermore, we should not forget that 3-D-guidance systems are already used for
endoscopic surgeries offering 3-D-position information of the sensor. Therefore,
using the acquired information (orientation, acceleration, depth values, position
etc.) from these miniature sensors in conjunction with sophisticated registration
software algorithms, an accurate 3-D representation of the digestive tract could be
created successfully (Koulaouzidis and Karargyris 2011).
In radiology, it is known that increasing the visual field of view angle to 120 degrees
allows for a decrease in the total number of supine and prone 3-D endoluminal fly-
through passes from four to two without negatively impacting on overall polyp
detection (Pickhardt, Schumacher and Kim 2009). Furthermore, 3-D CT
colonography interpretation using a unidirectional panoramic view is equally
accurate, but significantly faster than an interpretation based on a bidirectional
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standard view (Mang et al. 2011). Lastly, it has been shown that the addition of
video to static 2-D and 3-D images may lead to improved perception and
classification of CT colonography (McKenna et al. 2012).
For conventional endoscopy systems, stereo technology has been introduced to
capture stereo images and to create depth information and therefore 3-D
reconstruction of digestive structures. However, due to issues with size, such
systems have not been widely accepted (Kolar et al. 2010; Fisher and Hasler 2012).
Likewise, in CE there has been a hardware approach that provides in real time both
3-D information and texture using an infrared projector and a CMOS camera. The
major drawbacks of this system are its size, power consumption and packaging
issues (Fisher and Hasler 2012).
Therefore, in order to tackle the problem of the current hardware limitations, a
software approach based on monocular images - shape-from-shading (SfS) - has
been proposed to approximate a 3-D representation of digestive tract surface
utilizing current CE technology. The SfS technique, firstly proposed by Horn (Horn
and Brooks 1986), is a member of a family of shape-recovery algorithms called
shape-from-X techniques (Karargyris and Bourbakis 2011), and has the capability to
recover the shape of objects presenting a single image using the gradual variation of
shading. The SfS problem is to compute a 3-D shape from a greyscale image,
however, this is a problem that has no single solution (Koulaouzidis and Karagryris
2012). Hence, SfS techniques can be divided into four groups: minimization
approaches, propagation approaches, local approaches, and linear approaches.
Minimization approaches obtain the solution by minimizing an energy function.
Propagation approaches propagate the shape information from a set of surface
points. Local approaches derive the shape based on the assumption of surface type.




The aims of this thesis are to optimize the use of CE in the diagnosis and detection
of small-bowel pathology. Therefore, this thesis aims:
1. To evaluate the detection rate of the AoV by two different small-bowel CE
systems in our cohort and to compare the results from our centre with published
reports.
2. To assess the current evidence base on the use of prokinetics for CR and explore
their effect on GTT and SBTT by meta-analysing all relevant studies.
3. To assess the validity of FICE and BM filter in capsule endoscopy.
4. To assess the use of QV in certain clinical scenarios and in combination with the
BM filter.




Detection of the ampulla of Vater in small-bowel capsule
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Over the last decade, CE has been established as a very useful tool in the
investigation of small-bowel diseases (de Franchis et al. 2007). A recent pooled
analysis has demonstrated that a small-bowel CE has a minimal miss rate of < 1% for
small-bowel ulcers (Lewis et al. 2005). Although the small-bowel CE provides a high
information yield on mucosal lesions (Leighton et al. 2006), it does not permit the
assessment of small-bowel wall thickness or extraluminal findings (Hara et al. 2006).
As evidence of pathology detected by device-assisted enteroscopy, computed
tomography enteroclysis or magnetic resonance imaging, but missed by CE have
increased (Hakim et al. 2011; Gupta et al. 2010; Mavrogenis et al. 2011; Crook et al.
2009), concerns have arisen that the small-bowel CE may underestimate the number
of small-bowel polyps in patients with a known high polyp burden, such as patients
with hereditary or familial polyposis syndromes or other sinister pathologies
(Wong et al. 2006; Chong et al. 2006; Ross et al. 2008; Hakim et al. 2011). In CE, the
amount of information we get (or in fact, do not get) is a combination of its technical
limitations, i.e. its rigid structure, inability to insufflate, lack of directionality or steer
control and a set field of view (Clarke et al. 2008), SBTT, the amount and
transparency of intraluminal liquids and, finally, the degree of small-bowel
contraction.
Over the last five years clinical researchers have highlighted the use of markers
(some are in a position where they are difficult to spot) which are present in the
intestine as quality assurance indicators in an small-bowel CE (Cass 2006). The
major duodenal papilla, or AoV, which is present in all individuals who have not
undergone duodenal resection and is located on the posteromedial aspect of the
duodenal sweep, (Cass 2006) 8-10 cm distal to the pylorus, is a reasonable such
candidate marker. The factors that make the AoV difficult to observe during a CE
examination, such as the location, size/lumen protrusion, the capsule transit speed
and the fact that translucent dome of the propelled CE tends to point towards the
outer aspect of sharply angulated bowel loops (Cass 2006), are - at least in part - the
reasons why small-bowel lesions such as polyps may be missed in the small-bowel
CE examination.
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Therefore, the present study aims to evaluate the detection rate of the AoV by two
different small-bowel CE systems in a cohort of patients who underwent CE for the
purpose of clinical need and to compare the results from our centre with previously
published report.
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2.2 Patients and Methods
2.2.1 General information on CE procedures
Data of all the SBCE procedures that were carried out in our centre from March 2005
to June 2011 were reviewed retrospectively. Duplicate examinations, performed for
clinical needs, were included. The small-bowel CE was performed with a
PillCam®SBl/ SB2 (Given'®Imaging Ltd, Yokneam, Israel) and a MiroCam®
(IntroMedic Co, Seoul, Korea) CE, using the departmental procedural protocol
(Appendix 1). The AoV was detected by its distinct anatomical shape, i.e. a papilla-
shaped polypoid protrusion with a pin-point or slit opening at its tip. Every frame
in which the AoV appeared either in whole or in part was counted positive for
detection. In cases of concern, the opinion of a second experienced (JP) reviewer was
sought.
Also recorded were age, gender, AoV detection, the number of frames at which the
papilla was visible, the presence of bile spout, indication and date of the small-
bowel CE, the type of CE used, the type and dose of prokinetics used as well as
transit parameters including the time of duodenal entry, i.e. GTT, SBTT and the
transit time from pylorus-to-first duodenal papilla frame, the completion to caecum
or not and the quality of small-bowel cleansing (and, where available, the quantity
of laxatives used).
To date, there is no standardized bowel cleansing score for a small-bowel CE, hence
we adopted a modified four-point grading scale from the study by Park et al. (2010)
depending on the proportion of visualized mucosa and the extent of obscuration by
intraluminal food debris, turbid fluids, bubbles or bile, as follows: (1) Score 3 (very
good visibility), >75% mucosa visible; (2) Score 2 (good visibility), 50-75%; (3)
Score 1 (average visibility), 25-50%; and (3) Score 0 (poor visibility), < 25% mucosa
seen. Cleansing scores refer to the first 30 minutes of the small-bowel recording.
2.2.2 CE reviewing software
All the small-bowel CE sequences were reviewed using a detailed protocol for the
identification of the AoV, outlined below with the RAPID® v7 (Given®Imaging Ltd)
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and the MiroView™2.0 (IntroMedic® Co). Small-bowel CE video sequences were
not de-identified, but any previously captured thumbnails were deleted. For
maximal pick-up yield, the automatic viewing mode at the lowest possible speed
that allowed smooth video play (6fps) in a single frame mode with the reviewer
seated at arm's length from the screen in a room with dimmed light, was chosen.
Only a desktop spotlight was employed when illumination was required for data
input in the data-collecting Excel 2007 spreadsheet (Microsoft®, Redmond, WA,
USA). A 'roll-through' mode was utilized, where needed, to aid the delineation of
mucosal/surface details (Selby and Prakoso 2011). Fujinon intelligent colour
enhancement or Blue Mode in RAPID® software, ALICE or colour mode in
MiroView™, were not used in the study.
The predefined settings for the white-light CE video-sequence review with RAPID®
software in our centre are sharpness 1, brightness 1 and colour 2. Equivalent settings
for the MiroView™ software are 2, 0 and 0, respectively. Video reviews, from point
of duodenal entry, were prolonged from that of 15 minutes in a previous study
(Katsinelos et al. 2009) to 30 minutes to minimize the possibility of missing the AoV.
If the small-bowel CE was realized to be going into a to-and-forth movement after
its first duodenal entry (Nakamura 2009), the reviewing time was adjusted
accordingly to the start from the point of permanent duodenal entry.
2.2.3 Statistical analysis
Statistical analyses were carried out with StatsDirect™ 2.7.8 (StatsDirect,
Altrincham, UK). Continuous data were presented as mean ± standard deviation
(SD) and range. Student's f-test was used to compare parametric variables. A one¬
way ANOVA (analysis of variance) for independent samples was used to compare
the papilla detection rate based on indication and diagnosis. A two-tailed P value <
0.05 was considered statistically significant. Bonferroni and Sidak adjustment of
critical P-values was applied when performing multiple comparisons.
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2.2.4 Ethics consideration
This study was conducted in accordance with the Research Ethics Guidelines of the
UK. After being reviewed by the local ethics committee, further specific ethical
reviews and approval were not required, as the study was considered to be an audit
using data obtained as part of regular patient car
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2.3 Results
2.3.1 Baseline characteristics of the patients
A total of 839 small-bowel CE procedures performed in 758 patients were recorded
in our institution between March 2005 and June 2011. Due to the technical issues
(i.e. only initial written reports available, corrupt small-bowel CE video sequences
stored in compact disks and/or failure to re-download), 189 small-bowel CE videos
were not available for review. Another 22 examinations with gastric or proximal
duodenal capsule retention and nine of endoscopic capsule delivery in the
duodenum were also excluded. Therefore, a total of 619 small-bowel CE procedures
on 533 patients were included in this study for further analysis.
Of these, 208 (39.0%) were men and 325 (61.0%) were women, with a mean age of
52.8 years (range 14-90 years). Of the small-bowel CE procedures, 262 examinations
were performed with a PillCam®SBl, 148 with a PillCam®SB2 and the remaining 209
with a MiroCam®. The indications for the SBCE are presented in Table 1. More than
half the examinations were performed for overt and/or occult gastrointestinal
bleeding.
In 591 procedures (95.5%), pre-procedure bowel preparation was used. A total of
273 procedures (44.1%) were performed without the use of prokinetics. Of the
remainder, 267 (43.1%) were done with the administration of domperidone (mean
dose 5.6 mg) and 79 (12.8%) with metoclopramide (mean dose 5.3 mg).
The mean small-bowel cleansing score for the first 30 minutes was 2.14. Out of the
619 small-bowel CE, 540 CE (87.2%) were realized at the caecum by the end of the
recording. The positive diagnostic yield for all indications was 34.6%.
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Indications for small-bowel CE CE procedures, n (%)
Obscure GI bleeding 138 (22.3)
Iron deficiency anaemia 206 (33.3)
Clinical suspicion of CD 101 (16.3)
Reassessment of known CD 30 (4.8)
Polyposis syndrome 11 (1.8)
Coeliac disease 12 (1.9)
Others 121 (19.6)
Type of CE model PillCam ®SB1 PillCam® SB2 MiroCam®
Small-bowel CE (n) 262 148 209
Detection of AoV, n (%) 28 (10.7) 13 (8.8) 18 (8.6)
Frames AoV visible (mean ±SD) 36.35 +73.24 42.46 ±69.30 87.20 ±248.40
Table 2.1: Indications for small-bowel capsule endoscopy in our cohort and number of
small-bowel examinations per capsule endoscopy.
Abbreviations: CE, capsule endoscopy; Gl, gastrointestinal; CD, Crohn's disease; AoV,
Ampulla of Vater; SD, standard deviation.
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2.3.2 Detection of the AoV
The AoV was detected in 59 small-bowel CE procedures (9.5%; Table 2.1). No
difference was observed in the detection rate between either of the two generations
of PillCam®SB (P = 0.07) or the two technically different small-bowel CE systems
(PillCam® vs MiroCam®, P = 0.095). Furthermore, the mean number of frames of the
duodenal papilla visualized was 53.2 (range 1-1056), with no significant difference
between either of the two generations of PillCam® (P = 0.103) or the two different
small-bowel CE systems (P = 0.07). Bile spout was detected in 62.2% of small-bowel
CE (385/619) and in 81.4% of the procedures (48/59) in which the AoV was seen (P
= 0.003). The mean time of AoV detection after the first duodenal image capture was
3.56 minutes (range 0.05-29.60 min for the whole cohort), and there was no
statistical difference between the two small-bowel CE systems (3.53 ± 5.65 min for
the PillCam® vs 3.63 ± 5.40 min for the MiroCam®; P = 0.95). The detection rate of
papilla was independent of the indication for small-bowel CE, the type of CE
system used, DY, patients' characteristics, and use of prokinetics or gut transit
parameters. Furthermore, there was no significant difference in the detection rates
of the AoV among the small-bowel CE in regard to either caecal completion or
small-bowel cleansing (P < 0.05; Table 2.2).
Interestingly, the detection rate of duodenal papilla in small-bowel CE performed
after bowel preparation was lower than that in patients who received no bowel
preparation for the test (small-bowel CE [43/509, 8.4%] vs small-bowel CE [6/28,
21.4%]; P = 0.033), demonstrating that patients who received bowel preparation had
a more rapid movement of CE.
Finally, in the group of patients who for the purpose of clinical work-up/care (n =
17) had a repeat small-bowel CE with a different CE system from that initially
employed, the AoV detection rate was identical (PillCam®: MiroCam® = 1:17). Eight
patients had repeat examinations with the same type of CE, including four with a
PillCam®SBl, one with a PillCam®SB2 and three with a MiroCam®. The AoV was
not identified in any of the first examinations and in only one of the repeat studies
with a PillCam®SBl. Interestingly, four patients underwent CE examinations with
all the three small-bowel CE types, and in one patient, the AoV was visible with
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2.4 Discussion
In the current study, the biggest single-centre study on the detection rate of the AoV
to date, we included small-bowel CE examinations with different CE systems and
confirmed results from the existing literature. Firstly, the AoV detection in
unselected patients is a difficult task in CE; and secondly, visualization of the AoV
is not related to the CE system, the indications, DY, caecal completion,
administration of prokinetics or patient characteristics such as age and gender.
Interestingly, the DY in our study, which included more than 300 small-bowel CE
procedures performed for overt/occult gastrointestinal bleeding, was lower than
that of a previous report (Clarke et al. 2008). This probably represents not only
accumulated experience in CE reporting, hence avoidance of over-interpretation of
clinically insignificant findings, but also a more widespread use of CE with easier
access to the service and implementation of CE sooner in the diagnostic work-up.
Bile spout, as described earlier (Kong et al. 2006; Crook et al. 2009), is a reliable
marker and the main factor that helps in the identification of the AoV, although bile
spurting is an accidental phenomenon in endoscopy. Essentially, the spurting of bile
physiologically occurs when the duodenal wall, together with the smooth muscle of
the sphincter of Oddi, is relaxing. Therefore, bile spout should be seen as a
surrogate marker of reduced mucosal folding, slower capsule propulsion and,
hence, greater detection ability. However, it is likely that patients with slower
capsule propulsion who have not taken a purgative preparation may explain the
higher AoV detection in this group, compared with those who had been given
laxatives for small-bowel cleansing.
Although two different small-bowel CE systems were used, their performances, as
reflected by the detection rate of the AoV, were similar. Despite the similar size and
weight, the two systems have a different transmission technology, image capture
rate and pixel resolution. At a working distance of 2.2 mm from the tip of the
translucent CE dome, PillCam®SBl and SB2 and MiroCam® offer a field of view of
140°, 165° and 150° (recently replaced with version 2 of 175°), respectively. Their
mucosal coverage area at 4.5 mm working distance is 500 mm2, 1100 mm2 and 202
mm2, respectively (Metzger et al. 2009).
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Several authors recommend the AoV detection rate as a quality assurance
measurement for CE. Kong et al. (2006) performed a retrospective study on the
detection rate of the AoV in 110 consecutive small-bowel CE patients. An inclusion
criterion was a normal - in shape and position - duodenal papilla, as confirmed by
conventional oesophagogastroduodenoscopy (OGD); those with an abnormally
positioned papilla, or whose papilla was not readily identified by an OGD, were
excluded. Therefore, it is not surprising that although they used a high video
sequence reviewing speed (15 fps) and only the first generation M2A®
Given®Imaging Ltd model, they detected the AoV in 43.6% of the patients (48/110).
As visualization of the AoV by conventional front-viewing endoscopes is not always
an easy task, it is likely that this study suffered from significant selection bias, as
only the more prominent and, hence, easy to detect AoV were included for CE.
Clarke et al. (2008) repeated the study with a similar number (n = 125) of
consecutive small-bowel CE patients (again with M2A®; Given®Imaging Ltd) and a
more realistic setting. Two reviewers, blinded to each other, used the lowest
possible automated viewing speed (5 fps) and found that the AoV was detected in
10.4% of the patients (13/125). Wijeratne and Condon have demonstrated that the
AoV is identified only in 6% of small-bowel CE examinations (9/138) ( Wijeratne
and Condon 2006). Lee et al. reviewed 30 small-bowel CEs performed with a
PillCam® SB and the same number of examinations with a PillCam®SB2 and
concluded that the AoV detection rate was 46.6% (28/60), equivalent for both
PillCam® types (Table 3) (Lee et al. 2010). Elowever, other investigators presented
with less favourable results (Iaquinto et al. 2008; Selby and Prakoso 2011). One
would think that results should improve with advanced CE technical characteristics,
but the experience from studies using double-headed CE with improved optics and
frame acquisition rate are only partially concordant (Koulaouzidis, Douglas and
Plevris 2011; Selby and Prakoso 2011; Karagiannis et al. 2010). Furthermore,
although different generations of small-bowel PillCam® models and types have
been scrutinized with regard to the AoV detection rate, other CE systems have not
been put under the test (Metzger et al. 2009; Lee et al. 2010; Selby and Prakoso 2011;
Park et al. 2012).
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The limitations of this study are its retrospective nature and the use of a single CE
reviewer, although the small-bowel CE evaluation was performed using a strict
protocol and blinded review to any archived thumbnail images with a second
opinion available on demand. Furthermore, a large number of studies were not
available for review due to either corrupt compact discs or loss of sequences during
the transfer from one large-capacity storage device to another. Of note, the inclusion
of repeat CE examinations can be seen as another potential source of bias. However,
this group was included because of its unique nature (same anatomy), which could
potentially highlight CE examination-related factors. Moreover, the fact that the
comparison was not done on the same patients (other than a subgroup of 17
patients) and the same day, together with the unavailability of systematic
endoscopic confirmation of visibility of the papilla by a conventional side-viewing
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2.5 Conclusion
In conclusion, this study raises awareness regarding the limitations of CE. More
specifically, it raises important issues on the usefulness of CE in the detection of
periampullary lesions. In such cases, standard practice remains to use a side-
viewing duodenoscope for inspection of these areas if a standard forward-viewing
endoscope cannot provide satisfactory views. This study also highlights the
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Optimal DY in small-bowel CE requires not only optimal visualization of the small-
bowel mucosal surface and lumen but also complete capsule transit through the
entire small-bowel, i.e. total enteroscopy (Kaffes 2009; Wu et al. 2011; Hoog et al.
2012). If results are negative and/or inconclusive and complete enteroscopy is not
achieved, concerns remain over missed small-bowel pathology. Recent systematic
reviews showed that small-bowel CR varies between 81.3-83.5%, for retrospective
and prospective studies, respectively (Liao et al. 2010; Rondonotti et al. 2010).
Besides small-bowel structural integrity, hospitalization, advancing age and
diabetes are considered high-risk factors for incomplete enteroscopy with small-
bowel CE (Enns 2007; Triantafyllou et al. 2009; Westerhof et al. 2009). Therefore, it is
expected that decreasing the GTT and SBTT will allow a capsule to successfully
reach the caecum by the end of its battery life (Kaffes 2009). Hence, prokinetics, e.g.
metoclopramide and erythromycin, as well as postural 'tricks', i.e. change of patient
position following capsule ingestion, have been applied to improve small-bowel CE
CR (Villa et al. 2006).
Erythromycin, a macrolide antibiotic with an appealing safety profile, acts on
motilin receptors of the endocrine cells of the duodenum (Caddy et al. 2006) and has
well-known prokinetic properties. It induces high amplitude gastric propulsive
contractions. As a result, it accelerates gastric emptying for both liquids and solids
including that of non-digestible particles (Niv et al. 2008). Its commonest side effect
is nausea, which in the case of SBCE may limit its use (Selby 2005).
Metoclopramide, a dopamine D2 receptor agonist, has a combination action of
relaxing the pyloric sphincter and improving the antro-duodenal co-ordination
(Schwarzberg 2005). It has a good rapid oral absorption (Almeida et al. 2010), with a
peak plasma concentration at 567min and half-life of 5 h. Tardive dyskinesia and
other extrapyramidal/dystonic reactions have been - not infrequently - reported as
idiosyncratic adverse effects of its use.
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Mosapride citrate is a prokinetic agent that acts as a serotonin 5-
hydroxytryptamine-4 (5-HT4) agonist that is mostly available in Asia and increases
gastrointestinal motility.
Tegaserod, another 5-HT4 agonist is available in Western countries (Ida et al. 2012).
The latter was initially approved by the FDA in 2002, but it was subsequently
removed from the market in 2007 due to FDA concerns about possible adverse
cardiovascular effects
(http://www.fda.gov/NewsEvents/Newsroom/ PressAnnouncements/2007/ ucml
08879.htm). A few years earlier, cisapride - an effective gastrokinetic agent - was
associated with fatal arrhythmias in susceptible individuals and was withdrawn by
the FDA in 1999 (Wysowski et al. 2001).
Lubiprostone (Amitiza, Takeda Pharmaceuticals North America, Deerfield, IL, USA)
activates selectively the type 2 chloride channels in the apical membrane of the GI
epithelium, resulting in net fluid secretion (Flooks 3rd et al. 2009). It has been
approved by the FDA for the treatment of chronic idiopathic constipation and
constipation-predominant IBS. Recent studies revealed that it accelerates small-
bowel transit as well as colonic transit time (Camilleri 2011).
Daikenchuto (DKT) is well known in Japan as an effective treatment for reduced GI
motility, but the mechanism of action remains largely unknown. However, one of
the ingredients in DKT, Sancho (Xanthoxylum piperitum) promotes acetylcholine
release at the neuromuscular junction of the digestive tract. It also increases motilin
release, hence gastrointestinal peristalsis (Nakaji et al. 2011).
Chewing gum, as a proxy for sham feeding, acts by a cephalic-vagal axis. It
increases salivary flow leading to increased gastric emptying. It also increases the
motility of the small-bowel and the colon (Schwarzberg 2005). Apostolopoulos et al.
(2008) used commercially available sugarless chewing gum, containing xylitol as the
sweetener.
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Recent meta-analyses on the use of bowel preparation in small-bowel CE showed -
in subgroup analysis - that there is no difference in the use of erythromycin (Niv
2008; Rokkas 2009; Belsey 2012). Although some evidence exists, current guidelines
indicate that there is no strict recommendation on the use, type and/or mode of
administration of prokinetics in small-bowel CE (Enns 2007). Moreover, no previous
systematic review and/or meta-analysis have been carried out to address whether
adding prokinetics prior to capsule ingestion can increase the CR of the small-bowel
CE and/ or the DY. This study was performed to assess the current evidence base on
the use of prokinetics for CR and explore their effect on GTT and SBTT by meta-
analysing all relevant studies.
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3.2 Materials and methods
3.2.1 Literature search strategy
A recursive search of PubMed/Medline, Embase and Scopus databases for studies
published up to the end of November 2012 was performed. The last computerized
search was carried out on 30th November 2012. No language, start date or age.
search limits were applied. In order to capture as many articles as possible, a broad
search strategy was employed, using the MeSH term 'capsule endoscopy' (with
'automatic explosion' and 'all fields' search) linked in simple search strings by 'AND'
with the following text terms:
'antiemetic', 'completion', 'domperidone', 'erythromycin , 'gastric emptying1,
'ingestion', 'intramuscular', ' metoclopramide', 'ondansetron', 'oral/liquid',
'preparation','prokinetic','promotility', 'retention','tegaserod', and 'transit.
Furthermore, a combined recursive/manual search of all pertinent review articles
and recently published editorials was performed.
3.2.2 Publications selection
After retrieving the full text of selected papers, data were extracted by the first
author (AK) using a predefined form and were (at parts) verified by another author
(KJD). A full manual search for potentially suitable references was also performed
in the reference list of all retrieved original studies. As no language restriction was
applied, publications were translated into English as required by one of the authors
(DEY). In the event of uncertainty, any discrepancies were resolved by discussion
with the senior co-author and consensus.
3.2.3 Selection criteria
Inclusion and exclusion criteria were drafted before commencing the literature
search. Therefore, studies eligible for inclusion in this meta-analysis were those
meeting all of the following criteria:
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o published as full articles, reporting (prospective or retrospective) comparative
data;
o used prokinetics in (at least) one of the reported patient subgroups;
o contained information on the type of the small-bowel CE system/model used;
o specified the type, mode of administration and dose of prokinetics used, and;
o contained data on one or more of the following SBCE parameters: CR, DY, GTT,
and SBTT.
DY was defined as the total number of positive (diagnostic and suspicious) findings.
GTT was defined as the time interval between the first gastric image and the first
duodenal image. SBTT was defined as the time interval between the first duodenal
images and the first caecal image.
Studies not meeting the aforementioned inclusion criteria - those examining the
effect of postural 'tricks'; and/or duplicate publications - were excluded. We also
excluded cohort studies with no control arm, review articles, and/or case reports or
case series. It was decided that when two papers reported the same study, the most
recent and/or the more informative publication would be selected. A flow chart
describing the process of data/study identification and selection is shown in Figure
3.1.
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Cohort studies (no control arm): 2, RTV-driven0:
1, RLPaevaluation: 1, non-relevant/non-
extractable data: 6
Figure 3.1: Flow diagram of the identification of studies and of the selection process
of this meta-analysis.
Abbreviations: wRTV-driven, real-time viewer driven; =RLP, right lateral position; CT,
computed tomography; MRI, magnetic resonance imaging.
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3.2.4 Statistical analysis
Pooled odds ratios (ORs) and 95% confidence intervals (CIs) were calculated and
the outcomes of individual studies were compared by using the fixed-effects model
- Mantel-Haenszel method - unless significant statistical heterogeneity was
detected where the random-effects model was applied - theDerSimonian-Laird
method (Mantel and Haenszel 1959; DerSimonian and Laird 1986). Heterogeneity
was assessed using the inconsistency index (I2) and the chi-square (y2) test for
heterogeneity; evidence of heterogeneity was considered to be present if Pl< 20.10
(Higgins et al. 2003). In case of significant heterogeneity in the study design, results
were pooled using the DerSimonian-Laird random-effects model. This is preferable
to a fixed-effects model (Mantel-Haenszel method), as it takes into account the
differences between studies and treatments when estimating 95% CI and P values.
Apart from adjusting for heterogeneity by applying the random-effects model,
reasons for heterogeneity were explored. This leads to the stratification of the
studies into more homogeneous groups, and therefore more reliable estimates
(Moayyedi 2004). The candidate factors for stratification were: the randomization
quality (Jadad score); the study design (prospective vs retrospective); the use of
bowel purging (bowel purging and prokinetic vs prokinetic alone); and the most
readily available, and therefore more frequently used, prokinetics, metoclopramide
and erythromycin versus the rest (Jadad et al. 1996).
A sensitivity analysis was performed in order to evaluate the consistency of our
results. Firstly, to evaluate any possible excessive influence of a single study, we
examined whether the exclusion of this study substantially altered the magnitude or
heterogeneity of the summary estimate. This was achieved by repeating the meta¬
analysis with exclusion of each individual study one at a time, and to assess the
overall effect of the exclusion on the pooled ORs (Sutton et al. 2000). Forest plots
were constructed for the visual display of ORs across selected studies. Statistical
analysis was performed by using the Metan package of Stata version 12.1
(StataCorp, College Station, TX, USA) (Harris et al. 2010).
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3.2.5 Publication bias assessment
The likelihood of publication bias was assessed by constructing funnel plots, which
were obtained by plotting the log ORs versus SE (log [OR]) of individual studies
(Sterne and Egger 2001).
3.2.6 Methodological quality assessment
The methodological quality of randomization of the studies was assessed and
graded according to criteria described in the Jadad scale which has already been
extensively described elsewhere (Jadad et al. 1996). Therefore, the following items
were independently scored for each study:
o Was the study described as randomized (this includes words such as
randomly, random, and randomization)? (0/1);
o Was the method used to generate the sequence of randomization described
and appropriate (table of random numbers, computer-generated, etc)? (0/1);
o Was the study described as double-blind? (0/1);
o Was the method of double-blinding described and appropriate (identical
placebo, active placebo, dummy, etc.)? (0/1), and;
o Was there a description of withdrawals and dropouts? (0/1).
Furthermore, one (1) point was deducted for each of the following two:
o if the method used to generate the sequence of randomization was described
and it was inappropriate (patients were allocated alternately, or according to
date of birth, hospital number, etc.); and
o if the study was described as double-blind but the method of blinding was
inappropriate (e.g. comparison of tablet vs injection with no double
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Furthermore, it is known that evidence based on retrospective studies begins as low
quality, with a potential to decrease further because of study limitations,
inconsistency of results (heterogeneity), impression and other considerations,
including publications bias (Leontiadis et al. 2013). Therefore, the overall quality, for
each study, was a combination classified as high, moderate or low, according to a
combination of Jadad scores and types of study design.
3.2.7 Data extraction
For each included study, the following variables were extracted and entered into an
Excel data sheet: author, year of publication, number of participants, type of SBCE
system, use of prokinetic/ promotility agent, dose, mode and time of administration
(in regard to capsule ingestion), GTT, SBTT, CR or rate of total enteroscopy and DY.
Furthermore, the retention/obstruction rate (RR), where reported, was extracted.
Relevant studies were analysed according to the type of prokinetic used with the
following primary and secondary end-points: (a) CR, (b) GGT, (c) SBTT, and (d) DY.
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3.3 Results
3.3.1 Descriptive assessment and study characteristics
A total of 703 titles were initially identified with the aforementioned search strategy.
Of those, 402 were excluded after preliminary review of the titles and/or abstracts,
leaving 301 articles for further/detailed evaluation. Of those, 278 were excluded
following thorough review of the abstracts. Moreover, a further two articles were
identified from reference review. Therefore, the full text of 26 articles (with
potentially extractable data) was evaluated further. Consequently, 17 articles met
the inclusion criteria and entered this meta-analysis (Selby 2005; Leung et al. 2005;
Caddy et al. 2006; Wei et al. 2007; Apostolopoulos et al. 2008; Niv et al. 2008;
Postgate et al. 2009; Hooks 3rd et al. 2009; Almeida et al. 2010; Song et al. 2010;
Iwamoto et al. 2010; Nakaji et al. 2011; Zhang et al. 2011; Hosono et al. 2011; Shiotani
et al. 2011; Xiong et al. 2012; Ida et al. 2012). The main characteristics of the studies








































































A total of 1899 individuals (1859 patients and 40 healthy participants; 1028 subjects
ingested the capsule with no prokinetic [n = 1008] or placebo [n = 20] and 876 with a
prokinetic; 982 males/917 females; mean age: 54.73 ±21.1 years) were included in
these studies. There were fifteen studies which were retrospective (n = 1690 subjects)
(Selby 2005; Leung et al. 2005; Caddy et al. 2006; Wei et al. 2207; Apostolopoulos et
al. 2008; Niv et al. 2008; Postgate et al. 2009; Hooks 3rd et al. 2009; Almeida et al.
2010; Iwamoto et al. 2010; Nakaji et al. 2011; Zhang et al. 2011; Hosono et al. 2011;
Shiotani et al. 2011; Ida et al. 2012) and published in English and two (n = 209
patients) (Song et al. 2010; Xiong et al. 2012) in the Chinese language. All, apart from
one study (Niv et al. 2008), were single-centre papers; ten studies (58.8%) were
conducted in the Far East, i.e. five studies in China (Wei et al. 2007; Leung et al.
2005; Song et al. 2010; Zhang et al. 2011; Xiong et al. 2012) and five studies in Japan
(Iwamoto et al. 2010; Nakaji et al. 2011; Hosono et al. 2011; Shiotani et al. 2011; Ida et
al. 2012), two in Australia (Selby 2005; Caddy et al. 2006) and one in each of the
following countries: Greece, Israel, Portugal, UK and USA (Apostolopoulos et al.
2008; Niv et al. 2008; Almeida et al. 2010; Postgate et al. 2009; Hooks 3rd et al. 2009)
Fourteen of them (Selby 2005; Caddy et al. 2006; Wei et al. 2007; Apostolopoulos et
al. 2008; Niv et al. 2008; Postgate et al. 2009; Hooks 3rd et al. 2009; Almeida et al.
2010; Iwamoto et al. 2010; Nakaji et al. 2011; Zhang et al. 2011; Hosono et al. 2011;
Shiotani et al. 2011; Ida et al. 2012) were prospective and three (Leung et al. 2005;
Song et al. 2010; Xiong et al. 2012) were retrospective studies. Capsule endoscopy
was performed with M2A® and/or PillCam®SB capsule-endoscope models
(Given®Imaging Ltd, Yokneam, Israel) in all but two Chinese studies (Zhang et al.
2011; Xiong et al. 2012), including a total of 286 patients, where the OMOM® capsule
endoscope (Jinshan Science and Technology Company, Chongqing, China) was
used. Furthermore, in one study both EndoCapsule® (Olympus Medical Systems,
Tokyo, Japan) and PillCam®SB were utilized (Ida et al. 2012). Nine studies (Selby
2005; Postgate et al. 2009; Almeida et al. 2010; Song et al. 2010; Iwamoto et al. 2010;
Zhang et al. 2011; Hosono et al. 2011; Shiotani et al. 2011; Xiong et al. 2012)
evaluated the use of metoclopramide; three studies (Leung et al. 2005; Caddy et al.
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2006; Apostolopoulos et al. 2008) evaluated the use of erythromycin; two studies
(Wei et al. 2007; Ida et al. 2012) that of mosapride; and from one the effect of
chewing gum (Apostolopoulos et al. 2008), lubiprostone(Hooks 3rd et al. 2009), and
the combined effect of deikenchuto + metoclopramide (Nakaji et al. 2011), the latter
post real-time viewer check.
All subjects were prepared with overnight fasting and in nine studies purgatives
were used either prior to and/or during capsule endoscopy (Selby 2005; Caddy et
al. 2006; Wei et al. 2007; Postgate et al. 2009; Nakaji et al. 2011; Zhang et al. 2011;
Hosono et al. 2011; Xiong et al. 2012; Ida et al. 2012). Furthermore, in five studies
simeticone was administered for capsule ingestion (Selby 2005; Leung et al. 2005;
Almeida et al. 2010; Nakaji et al. 2011; Hosono et al. 2011). Lastly, a real-time viewer
(RTV) was utilized in the protocol of five studies (Nakaji et al. 2011; Zhang et al.
2011; Hosono et al. 2011; Shiotani et al. 2011; Xiong et al. 2012), although external
RTV should be considered instrumental only in the protocol of two metoclopramide
studies (Shiotani et al. 2011; Xiong et al. 2012).
Lastly, eight studies (four on metoclopramide, two on erythromycin, one on
lubiprostone and one on mosapride) (Leung et al. 2005; Wei et al. 2007; Niv et al.
2008; Postgate et al. 2009; Hooks 3rd et al. 2009; Almeida et al. 2010; Song et al. 2010)
examined the usefulness of the aforementioned prokinetics, without potential
external interference/bias effect by laxatives, RTV and/or complex study protocols,
and are considered separately in the sensitivity analysis (subgroup 1). Overall, in
the meta-analysed studies, there were 17 sets of primary endpoint data (CR) and 24
sets of secondary endpoint data (GGT: 8, SBTT: 9, and DY: 7).
3.3.2 Primary endpoint
3.3.2.1 Small-bowel CE CR
Small-bowel CE CR was defined as the capsule reaching the caecum. All included
studies presenting such data (17 sets), examining the small-bowel CE CR in 1028
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subjects who ingested the capsule without a prokinetic as opposed to 876
individuals who received a prokinetic. There was evidence of heterogeneity
between study results (I2 =37.9%, P=0.058; Figure 3.3). Because of heterogeneity, the
DerSimonian-Laird random-effects model was used for the pooling of results; this
model is recommended - as the method of choice - by the International Cochrane
Collaboration (Leontiadis et al. 2013; Hayden et al. 2006) in order to avoid
unrealistically low 95% CIs that may arise from a fixed-effects model analysis
(Leontiadis et al. 2013). The results indicated that the odds of having a complete
small-bowel CE were superior for patients who ingested the capsule with a
prokinetic than for those who did not receive a prokinetic agent; OR (95% CI)=1.96
(1.38-2.78), Figure 3.3. Furthermore, studies of the same prokinetic were grouped
together; for the erythromycin studies (Leung et al. 2005; Wei et al. 2007; Niv et al.
2008), no heterogeneity - in study design or results - was detected (P=37.6%,
P=0.201; Figure 3.3) and the pooled OR (95% CI) was 1.36 (0.61-3.03). In the
metoclopramide group (Selby 2005; Postgate et al. 2009; Almeida et al. 2010; Song et
al. 2010; Iwamoto et al. 2010; Nikaji et al. 2011; Zhang et al. 2011; Hosono et al. 2011;
Shiotani et al. 2011; Xiong et al. 2012), evidence of heterogeneity between the studies
was weak but present (I2-38.3%, P=0.103; Figure 3.3); the pooled random-effect
estimate of the OR (95% CI) for small-bowel CE CR was 2.08 (1.35-3.21). Lastly, for
the remaining four studies, some evidence of heterogeneity was detected (P=58.7%,
P=0.064; Figure 3.3); the random-effect estimate of the OR (95% CI) was 1.89 (0.75-
4.82).
Studies that used prokinetics with no bowel purge and a straightforward study
protocol (subgroup 1) (Leung et al. 2005; Wei et al. 2007; Niv et al. 2008; Postgate et
al. 2009; Hooks 3rd et al. 2009; Almeida et al. 2010; Song et al. 2010) were chosen to
investigate further the reasons for heterogeneity. In order to exclude any possible
influence of a single study, we repeated the meta-analysis with exclusion of each
individual study one at a time. This did not alter the pooled results. Moreover, we
performed sensitivity analyses by stratifying studies by factors which could
potentially influence the pooled results, i.e. study design (prospective vs
retrospective), use of bowel purge (bowel purge+prokinetic vs prokinetic alone), the
most frequently and readily available prokinetics used (metoclopramide vs
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erythromycin vs rest), and Jadad scores. The results of these subgroup analyses are
shown in Figure 3.4. The number of included studies was not sufficient to draw a
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Study,year Metoclopramide Songetal,2010 Almeidaetal,2010 Postgateeal,2009
No No No
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3.3.3 Secondary endpoints
3.3.3.1 Diagnostic yield (DY)
Seven studies (Selby 2005/ Wei et al. 2007; Postgate et al. 2009; Almeida et al. 2010;
Iwamoto et al. 2010; Hosono et al. 2011; Shiotani et al. 2011) examined small-bowel
CE DY in 401 patients who ingested the capsule with prokinetics (371
metoclopramide/30 mosapride) as opposed to 434 patients who did not use
prokinetics for capsule ingestion. Six of the seven meta-analysed studies used
metoclopramide as the prokinetic. There was no evidence of heterogeneity between
these studies (I2=0, P=0.914), therefore, the fixed-effects model was used for
synthesis and presentation of pooled results. There was a weak trend that the small-
bowel CE DY ratio (pooled DY in the group who receive prokinetic/ total number of
cases in the prokinetic group)/(pooled DY in the control group/total number of
control cases) was superior for the patients who received prokinetics for capsule
ingestion as opposed to controls, pooled RR (95% CI)=1.10 (0.96-1.27) (Figure 3.5).
This may be due to the small number of studies and the heterogeneity due to the
different prokinetic agents used and diverse study designs.
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3.3.3.2 Gastric transit time (GTT)
Eight studies (Selby 2005; Lueng et al. 2005; Apostolopoulos et al. 2008; Niv et al.
2008; Hooks 3rd et al. 2009; Iwamoto et al. 2010; Hosono et al. 2011; Shiotani et al.
2011) measured the average small-bowel CE GTT (min) in 391 subjects who ingested
the capsule with prokinetics (250 metoclopramide/74 erythromycin/20
lubiprostone/47 chewing gum) as opposed to 410 subjects (20 placebo) who used no
prokinetic for capsule ingestion. There was evidence of heterogeneity between
studies (Z2=64.5%, P=0.006). More specifically, heterogeneity was detected in the
erythromycin group (Leung et al. 2005; Niv et al. 2008) (f2=73.8%, P=0.051) and
lubiprostone/chewing gum studies (Apostolopoulos et al. 2008; Hooks 3rd et al.
2009) (Z2=87.2%, P=0.005). However, no difference between prokinetic and control in
GTT was noted. In the metoclopramide studies group, there was no evidence of
heterogeneity and the use of metoclopramide seemed to affect GTT over controls;
pooled difference in the means in this group (GTT of control - GTT of prokinetic
group) was 16.83 (14.30-19.37) (Figure 3.6). It is noteworthy that although the latter
group included the two studies that had RTV in their protocol (Hosono et al. 2011;
Shiotani et al. 2011), a clear effect of metoclopramide on GTT was also evident in the
studies (Selby 2005; Iwamoto et al. 2010), which did not utilize real-time monitoring.
3.3.3.3 Small-bowel transit time (SBTT)
Nine studies (Selby 2005; Leung et al. 2005; Apostolopoulos et al. 2008; Niv et al.
2008; Hooks 3rd et al. 2009; Almeida et al. 2010; Iwamoto et al. 2010; Hosono et al.
2011; Shiotani et al. 2011) measured the average small-bowel CE SBTT (min) in 438
subjects who ingested the capsule with prokinetics (297 metoclopramide/74
erythromycin/20 lubiprostone/47 chewing gum) and 458 controls (20 placebos)
who did not receive prokinetics for capsule ingestion. There was no evidence of
heterogeneity within the prokinetic groups. More specifically, the erythromycin
studies (Leung et al. 2005; Caddy et al. 2006; Niv et al. 2008) showed Z2=0%, P=0.342
(and lubiprostone/chewing gum I2=0%, P=0.8616) in the heterogeneity test. In the
erythromycin group, no difference between prokinetic and control in SBTT was
noted (pooled difference in the means [95% CI]: -20.41 [-54.28, 13.45]). In the
metoclopramide group, there was no evidence of heterogeneity (Z2=37.3, P=0.173)
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and its use had an effect on SBTT over controls; pooled difference in the means
(GTT of control - GTT of prokinetic group) [95% CI])=24.30 [20.90-27.70] (Figure
3.7).
3.3.4 Publication bias
Evidence of publication bias was also present (Figure 3.8) as, when looking at the
metoclopramide group, small studies with small effect were not found in the
literature review.
76
Study,yearControl Metodopramide SelbyW.2005No Hosonoeta .2011N -NRTV Shiotanietal,2011No Iwamotoetal,2010N l-VSubtotal(t-squared=0%,p.435) Erythromyan Leungta ,2005No NivEetal.2008o l-VSubtotal(l-squared=73.8%,p0.051) D+LSubtotal Otherprokinetic Hooksetal,2009Pl cebo Apostolopoulosetal,2008N l-VSubtotal(l-squared=87.2%.p0.005} D+LSubtotal Heterogeneityb tweengroups:p=0.070 l-VOverall(l squared=54.5%.p0.006) D+LOverall








GTT(95%Q) 1710(1446974) 30(-1309.1969) 1800(-51,36} 1850(482,32.18)
% Weight 0-V) 8079 210 164 3.01
1683(1430.19.37)754 540(7.7 ,101.26)0.26 7.28(-0.4 .15 04}935 855(09,162 )6 25.03(-19.80.69 6) -4380(2.60.-5. 0)037 1560(0. 1,309)2.47 780(-627.1.86).85 -11.30(-69.25.46.65) 15.78(13.41.18.15)000 12.47(498.95)
1~
100
Figure3.6:orestplofGTT,showingindividualandpooleddifferencefmeanw th95%CIstudiec mparingps linge t withprokineticsvsnoprokinetics(datafromstudi srepor nglevantda a). Abbreviations:GTT,gastrictrans time;CI,confidenceinterval ;RTV,eal-timevi w rPEGpolyethylengl c ;st timm dia lyp st- ingestion.
77
-10010
Figure3.7:orestplofSBTT,showingindividualando leddifferencmeanswith95%CItu icompar gps le ingestionwithprokineticsvsni tics(da afromstud sr portinglevantda a). Abbreviations:SBTT,small-b weltransiti e;CI,confidencinterval ;RTV,r al-timviewerPEGpoly thylglycst t,imm di lyst ingestion.
78





















































Figure3.8:unnelplotofstudi sinclu edthismeta-analysis;evide cfp blicationbiai res nt. Abbreviations:SE,standarderr r;ORod sr t
79
3.3.5 Safety
No fatal complications were reported in any of the studies included in this meta¬
analysis. More specifically, cases of capsule retention were reported (Hoog et al.
2012), but no capsule aspiration was recorded and no bowel obstruction (Table 3.3).
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3.3.6 Discussion
There have been data to suggest that it is in fact the prolonged small-bowel passage
that may be associated with increased DY (Buscaglia et al. 2008; Westerhof et al.
2012). Therefore, various techniques and interventions have been developed aiming
to improve the clinical chances for total enteroscopy (Kaffes 2009). To date, there are
three published meta-analyses (Niv 2008; Rokkas et al. 2009; Belsey et al. 2012)
showing that purgative cleansing of the small-bowel before SBCE significantly
improves the quality of mucosal visualization, in comparison to a clear fluid diet,
although it does not seem to affect the small-bowel CE completion rate (Rokkas et
al. 2009). In fact, data suggest that up to 20-25% of patients undergoing small-bowel
CE have an incomplete examination (Liao et al. 2010; Eliakim 2013). As a direct
comparison, if we were to measure colonoscopy caecal intubation rates <80%, this
would undoubtedly be considered very low, and every effort would be made to
improve it (Kaffes 2009). It is possible that hypertonic purge regimens may delay
gastric emptying (Postgate et al. 2009). With all that in mind, several prokinetics
(Villa et al. 2006; Enns 2007) have been assessed, yet there is still no consensus on
their use in SBCE. At the ICCE Consensus Meeting in Miami (2006), it was
recognized that although there were several studies involving promotility
preparations and manoeuvres, this remains to date a contentious issue (Villa et al.
2006; Enns 2007). Although different in regard to weight/size (3.6g vs
6.2g/llx26mm vs 13x27.9mm, for PillCam®/EndoCapsule® and OMOM®,
respectively), all these systems have comparable battery life (8h) (Fisher and Hasler
2012).
Our study demonstrates a lack of consensus in using prokinetics in SBCE as well as
a variety in study designs, which included different mode (oral or parenteral) and
timing of administration of prokinetics (Villa et al. 2006). We found that
erythromycin studies (Leung et al. 2005; Caddy et al. 2006; Niv et al. 2008) were
more homogeneous in terms of study design (no RTV used, no concurrently
administered prokinetic or postural tricks), but there were only a few studies
regarding numbers of participants. On the other hand, metoclopramide-based
studies (Selby 2005; Postgate et al. 2009; Almeida et al. 2010; Song et al. 2010;
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Iwamoto et al. 2010; Nakaji et al. 2011; Zhang et al. 2011; Hosono et al. 2011; Shiotani
et al. 2011; Xiong et al. 2012) were higher in number and larger in terms of
participants, yet they were more heterogeneous in design and mode/time of
administration of the medication. Lastly, prokinetics used in a number of studies
(Wei et al. 2007; Hooks 3rd et al. 2009; Nakaji et al. 2011; Ida et al. 2012) are not
widely available (Wei et al. 2007; Nakaji et al. 2011; Ida et al. 2012) and/or
associated with mild or significant side effects (Hooks 3rd 2009). Another one,
Tegaserod, considered as the 'Western-world counterpart' of mosapride, has been
since withdrawn due to its potential cardiovascular side effects.
Pooled results on CR show that ingesting the capsule with prokinetics leads to a
higher rate of complete small-bowel examination than in controls (OR [95% CI]: 1.96
[1.38-2.78]). More specifically, metoclopramide is associated with higher CR (OR
[95% CI]: 2.8 [1.35-3.20]); no such effect is seen with erythromycin (OR [95% CI]:
1.36 [0.61-3.03]). Furthermore, when a smaller group of 'clear', i.e. more
homogeneous in design, studies were examined (subgroup 1), where bowel purging
and real-time monitoring were not used (Leung et al. 2005; Wei et al. 2007; Niv et al.
2008; Postgate et al. 2009; Hooks 3rd et al. 2009; Almeida et al. 2010; Song et al. 2010),
the effect of either prokinetic (metoclopramide and erythromycin) on completion
rate was not significant (Figure 3.2); metoclopramide CR pooled OR (95% CI): 1.16
(0.58-2.33), erythromycin CR pooled OR (95% CI): 2.27 (0.79-6.47) and for the whole
group pooled OR (95% CI) for CR of prokinetic versus control was 1.52 (0.71-3.23).
With regard to capsule transit parameters (GTT and SBTT), the effect of prokinetics
over control was clear for both parameters. Metoclopramide administration for
capsule ingestion resulted in a shorter GTT and SBTT (pooled difference in the
means [95% CI]: 12.47 [4.98-19.95] and 19.31 [5.96-32.67], respectively). When the
RR of DY was calculated, there was no evidence that the use of prokinetics confers
any benefit in increasing the DY.
In order to avoid further bias, we have excluded abstracts and cohort studies that
may have reported further useful results on the field (Westerhof et al. 2012).
Furthermore, we excluded studies published as full papers, that looked mainly at
the effect of positional tricks, i.e. right lateral position at capsule ingestion (Aparicio
et al. 2009; Liao et al. 2008). There were only four studies using a more rational and
flexible approach by means of external or integrated real-time monitoring
(nowadays an indispensable accessory in small-bowel CE practice) and only two
used the combination approach of certain predefined non-invasive interventions
prompted by RTV results. The latter method should be considered most applicable
in selected inpatients with poor mobility, advanced age and/or diabetes. Moreover,
some retrospective studies excluded the participants who developed gastric capsule
retention and/or prolonged gastric stasis of the capsule. Although it is unlikely that
future research will refute the results of existing evidence, it is worth noting that as
technology advances and batteries are getting smaller and more potent, incomplete
small-bowel CE (due to slow transit time) will probably be phased out.
Furthermore, future studies should evaluate specifically the benefit of a complete
small-bowel CE in patient management.
The present study had certain limitations. As with every meta-analysis, conclusions
are as reliable as the underlying evidence available. The majority of the included
studies were heterogeneous and of low quality with regard to randomization and
design for the purpose of meta-analysis. It is noteworthy that patient populations
are heterogeneous as some studies have excluded participation of individuals with
diabetes mellitus (Caddy et al. 2006; Wei et al. 2007; Zhang et al. 2011), one of the
main patient groups to get benefit from the use of prokinetics. Furthermore,
although we studied the pooled DY in our meta-analysis, we did not examine the
effect of prokinetics on image quality and mucosal visualization for two reasons: (a)
prokinetics are unlikely to have any significant effect on the intraluminal content
(quantity and/or consistency), and (b) there is no standardized or validated scoring
system for visualization/ preparation quality of small-bowel CE.
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3.3.7 Conclusion
In conclusion, the results of this meta-analysis show that the use of prokinetics in
small-bowel CE, and specifically that of metoclopramide with purgative and/ or
RTV, improves completion rate. Although CR may appear as less of a problem, due
to new capsule technology with extended battery life as described in this
manuscript, it is important, at this stage, to conclude on the efficacy of prokinetics.
Therefore, our results complement similar, and extensive, recent work in the field,
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Virtual chromoendoscopy (VC) techniques are applied to enhance the micro¬
vascular contour and improve resolution of surface patterns and colour differences
(Pohl et al. 2007). The two VC modalities in current clinical use are narrow-band
imaging (NBI) (Gono et al. 2004) and computed VC with the Fuji Intelligent Colour
Enhancement (FICE) system (Pohl et al. 2007). Computed VC technology, developed
at Chiba University by Miyake et al. (Haneishi et al. 2000), is based on the selection
of spectral transmittance with a dedicated wavelength by narrowing the bandwidth
of white light to narrowed blue and green light. In contrast to NBI though, where
the bandwidth of the spectral transmittance is narrowed by optical filters (Gono et
al. 2004), in computed VC, imaging is based on a new spectral estimation technique
that replaces the need for optical filters. In essence, the computed VC software takes
a conventional endoscopic image from the video processor and arithmetically
processes the reflected photons to reconstitute virtual images for a choice of
different wavelengths (Haneishi et al. 2000; Pohl et al. 2007).
Over the past few years, several studies have examined the efficacy of VC in the
detailed analysis of mucosal pit pattern, vascular intensity and enhancing detection
and differentiation of neoplastic and non-neoplastic lesions of the upper and the
lower GI tract (Haneishi et al. 2000; Pohl et al. 2008; Pohl et al. 2009; Osawa et al.
2009; Togashi et al. 2009; Parra-Blanco et al. 2009; East et al. 2008; Yoshida et al.
2010). FICE has been used both in upper and lower GI endoscopy and proved to be
effective in improving diagnostic yield by enhancing contrast between background
and surface abnormalities.
In the upper GI tract, the wavelength that generated the optimal difference of the
spectral reflectance between the normal gastric mucosa and the early gastric cancers
was 530 nm. The score of the FICE observation improved in 46% of cases (Mouri et
al. 2009). In trans-nasal endoscopy, the FICE system wavelengths settings [RBG; 470
nm, 500 nm, 550 nm] enables greater colour difference between palisade vessels and
provides better contrasting images of the demarcation between the Barrett's
oesophagus mucosa and the gastric mucosa, and thus contributes to easier diagnosis
of endoscopic Barrett's, comparing with white-light endoscopy (Osawa et al. 2009).
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The classification of colorectal tumours by FICE (RGB wavelengths of 540, 460, and
460 nm) with magnification correlated well with the histopathological diagnoses,
whereas the findings were similar to NBI magnification (Yoshida et al. 2010).
Currently in the published literature, there is no agreement evaluating the accuracy
of FICE, especially in regard to the optimal wavelength filters (Oka et al. 2011). In
one recent study, FICE-filter 4 [red, green, and blue (RGB) wavelengths of 520, 500,
and 405 nm, respectively] with magnification, has been shown to improve the image
quality of the colonic vascular patterns obtained with white-light endoscopy (Parra-
Blanco et al. 2009). In another one, the combination of the following three FICE
wavelengths (RBG): 420 nm, 490 nm, and 540 nm proved to be superior to
conventional endoscopy for capillary-pattern diagnosis but not adding much to pit-
pattern diagnosis, in regard to prediction of histology for small colourectal polyps
(Togashi et al. 2009).
Although VC is widely applied in conventional bidirectional endoscopy and
recently studied in double-balloon enteroscopy as well (Neumann et al. 2009), its
role in the detection of small-bowel lesions has not yet been clearly established (Pohl
et al. 2010). Furthermore, the application of NBI (a real-time imaging modality) in
CE - with its current level of technology - is limited. In contrast, FICE does not
require re-engineering of the capsule device as such, but only integration of the
FICE software in the reading platform (Pohl et al. 2007). The integration of the FICE
digital processing system in the RAPID® versions 6.0 and 7.0 (Given®Imaging Ltd,
Yoqneam, Israel) enables an instant switchover between an unmodified image and a
FICE image, at a click of a tab at the workstation.
The spectrum of wavelength used for the creation of optical images differs between
flexible endoscopy and CE, thus up to three mode settings have been selected as
most suitable wavelengths required for the evaluation of the CE (Pohl et al. 2010).
Both the validity of FICE in small-bowel CE as well as the optimal settings for
improved image recognition in various small-bowel lesions have been studied only
limited to present (Pohl et al. 2010; Oka et al. 2011). Blue Filter (BF), an additional
setting incorporated into the RAPID® software, is a colour coefficient shift of light in
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the short wavelength range (490-430 nm) superimposed onto a white (red, blue,
green; RGB) light image.
The aim of this retrospective study was to qualitatively evaluate the use of modified
imaging with enhanced vascular and mucosal contrast (FICE and BF enhancement)
by examining lesion characterization/visibility on FICE-derived images obtained
during small-bowel CE and comparing them with similar images under white light
(predefined settings-Quick Adjust) without any filters.
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4.2 Materials and methods
We evaluated FICE and BM filter, using images captured as thumbnails during
small-bowel CE examinations performed in our department between December
2008 and January 2010. These images were selected from CE video sequences of
consecutive patients who underwent small-bowel CE as part of their regular
diagnostic work-up. Patient demographics and clinical characteristics, as well as
SBCE indications and types of lesions examined, are summarised in Table 4.1.
Small-bowel CE was performed with Pillcam®SBl/SB2 (Given®Imaging Ltd,
Yoqneam, Israel) capsule endoscopes, using the predefined for our unit small-bowel
preparation regimen and procedural protocol (Appendix 1). One of the authors
(SD), with extensive experience in CE reading, selected thumbnail frames depicting
pathology from a total of 200 consecutive small-bowel CE examinations, and
classified them in six different lesion-groups. These groups were: ulcer/aphthae,
villous oedema, intraluminal blood, lesions of indeterminate clinical significance,
angioectasias/arterio-venous malformations, and mucosal cobblestoning. Normal- or low-
quality images were excluded from further review. This author did not participate
in further evaluation of the images.
4.2.1 Review and FICE settings
Two certified gastroenterologists, both familiar with small-bowel CE (CK) with
SBCE reviewing experience >50 videos and (AK) with extensive SBCE reviewing
experience >700 CE video sequences, evaluated the images using the RAPID®
version 7 software and were blinded to each other. Both authors are familiar with
FICE and use it regularly in conventional endoscopy.
The images were initially examined with white light and thereafter with the FICE
mode. The FICE settings used were as follows:
FICE 1 [RGB wavelength, nm (595, 540, 535)];
FICE 2 [RBG wavelength, nm (420, 520, 530)]; and
FICE 3 [RBG wavelength, nm (595, 570, 415)].
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4.2.2. Blue mode filter
In addition, BF (wavelength 490-430 nm) was also applied. Patient demographic,
clinical characteristics and indications for small-bowel CE were also recorded. We
had previously found that a specific combination of sharpness level (grade 3) and
brightness level (grade 0) enhanced all images, even before the application of any
filters, and therefore we agreed to adopt those settings as our standard baseline for
this study (Quick Adjust settings) (unpublished author's data).
White light (with Quick Adjust toggle button on) small-bowel CE images were
compared with FICE and BF images applying the following criteria:
(a) the visibility of blood vessels;
(b) the contrast of the mucosal surface; and
(c) the demarcation of lesion borders.
The side-by-side comparison between white light and FICE or BF images was
qualitatively evaluated using three quality scores: Improved, Similar and Worse.
o Improved was defined as: 'improved visualization, aiding lesion
characterization, and enhanced delineation of lesion surface or borders',
o Similar was defined as: 'no change in any of the aforementioned
parameters'.
o Worse was defined as: 'poor visualization or inability to characterise a
specific lesion'.
4.2.3 Statistics
The f-test for continuous variables and the chi-square (y2) test for categorical
variables were used. A P value of <0.05 was considered statistically significant.
Inter-observer agreement between two rates was calculated using Cohen's kappa
(K) coefficient. Kappa < 0.4 was considered as poor agreement, whereas between
0.41-0.6 as moderate, 0.61-0.80 as substantial and 0.81-1.00 as excellent agreement.
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4.3 Results
A total of 167 small-bowel images/lesions, from 52 patients (21 male/31 female,
mean age 56.13 ± 19.13 years; median age: 58 years) who underwent SBCE for a
variety of indications, were included in our study (Figure 4.1).
Overall, with BF, as compared with white light, image improvement was observed
in 83%, no change in 12% and worse in 3%.
With FICE 1, an improvement was observed in 34%, no change in 8.9% and worse in
55.9%. With FICE 2, an improvement was observed in 8.6%, no change in 13% and
worse in 77.5%. With FICE 3, an improvement was observed in 7.7%, no change in
12% and worse in 79.9%.
Inter-observer agreement was 0.786 for BM, 0.646, 0.617, 0.669 for FICE 1, FICE 2,
FICE 3, respectively.
In the ulcer/aphthae images group: BF offered an image improvement in 93%, no
change in 5.8% and made it worse in 3.3%.
With FICE 1, an improvement was observed in 36.6%, no change in 9% and worse in
54%. With FICE 2, an improvement was observed in 3%, no change in 13% and
worse in 83%. With FICE 3, an improvement was observed in 3%, no change in 6.6%
and worse in 90%.
Inter-observer agreement was 0.476, 0.487, 0.710 and 0.642 for BF, FICE 1, FICE 2
and FICE 3, respectively.
In the villous oedema images group: with BF, an improvement was observed in 73.5%,
no change in 26.4% and worse in 0%.
With FICE 1, an improvement was observed in 14.7%, no change in 14.7% and
worse in 70.6%. With FICE 2, an improvement was observed in 5.8%, no change in
14.7% and worse in 79.5%. With FICE 3, an improvement was observed in 14.7%, no
change in 0% and worst in 85.3%.
Inter-observer agreement was 0.549, 0.625, 0.553 and 0.767 with BF, FICE 1, FICE 2
and FICE 3, respectively.
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In intraluminal blood images group: with BF, an improvement was observed in 73.3%,
no change in 20% and worse in 6.7%.
With FICE 1, an improvement was observed in 56.6%, no change in 6.6% and worse
in 30%. With FICE 2, an improvement was observed in 20%, no change in 6.6% and
worse in 73.4%. With FICE 3, an improvement was observed in 13.3%, no change in
6.6% and worse in 80%.
Inter-observer agreement was 0.4, 0.528, 0.675 and 0.643 with BM, FICE 1, FICE 2
and FICE 3, respectively.
In lesions of indeterminate clinical significance (LICS) images group: with BF, an
improvement was observed in 92.3%, no change in 7.7% and worse in 0%.
With FICE 1, an improvement was seen in 50%, no change in 7.6% and worse in
42.4%.
With FICE 2 an improvement was observed in 19.2%, no change in 19.2% and worse
in 61.6%.
With FICE 3, an improvement was observed in 11.5%, no change in 3.8% and worse
in 84.7%.
Inter-observer agreement was 1, 0.610, 0.604 and 0.536 for BF, FICE 1, FICE 2 and
FICE 3, respectively.
In the angioectasias/arterio-venous malformations (AVM) images group: with BF, an
improvement was observed in all patients (100%). For FICE 1, an improvement was
observed in 77.7%, no change in 8.3% and worse in 11.1%. For FICE 2, an
improvement was observed in 27.7%, no change in 13.8% and worst in 50%. For
FICE 3, an improvement was observed in 5.5%, no change in 38.8% and worse in
55.57%.
Inter-observer agreement was 1 in BF, 0.557 in FICE 1, 0.688 in FICE 2 and 0.583 in
FICE 3.
In the mucosal cobblestoning images group: with BF, an improvement was observed in
86.36%, no change in 13.6% and worse in 0%. For FICE 1, no improvement was
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observed, no change was observed in 13.6% and worse in 86.36%. For FICE 2, an
improvement was observed in 9%, no change in 0% and worse in 91%. For FICE 3,
worse images were observed in all patients.
Inter-observer agreement was 0.621 in BF, 0.621 in FICE 1, 0.633 in FICE 2 and 1 in
FICE 3.
A summary of the results is presented in Table 4.2.
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Figure 4.1: Comprehensive table of images with white light, FICE 1, FICE 2, FICE 3 and
Blue filter of: ulcer (row 1), polyp (row 2), angioectasia (row 3), cobblestone mucosa
(row 4).
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No. of patients (M/F) 52(21/31)
Age (years) mean ±SD, median 56.1 ±19.1, 58
Indications for SBCE Nine patients presented with >1 indication
Iron deficiency anaemia 30
Obscure GI bleeding 9
Chronic abdominal pain 6
Diarrhoea 4
Weight loss 3








Lesions of indeterminate clinical significance
Lymphangiectasias 13
Polypoid lesion/structure 3







Table 4.1: Demographics and indications for small-bowel capsule endoscopy, small-
bowel CE, type of lesions examined with white light, FICE and Blue filter.
Abbreviations: SBCE, small-bowel capsule endoscopy; M/F, male / female; SD, standard
deviation; Gl, gastro-intestinal; PHE, portal hypertensive enteropathy.
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Improved (%) Similar (%) Worse (%) I/A (kappa)
FICE 1
Ulcer/aphthae 36.6 9 54 0.487
Villous oedema 14.7 14.7 70.6 0.625
Blood in lumen 56.6 6.6 30 0.528
LICS 50 7.6 42.4 0.610
AVM 77.7 8.3 11.1 0.557
Cobblestoning 0 13.6 86.3 0.621
Overall 34 8.9 55.9 0.646
FICE 2
Ulcer/aphthae 3 13 83 0.710
Villous oedema 5.8 14.7 79.5 0.553
Blood in lumen 20 6.6 73.4 0.675
LICS 19.2 19.2 61.6 0.610
AVM 27.7 13.8 50 0.688
Cobblestoning 9 0 91 .633
Overall 8.6 13 77.5 .617
FICE 3
Ulcer/aphthae 3 6.6 90 0.642
Villous oedema 14.7 0 85.3 0.767
Blood in lumen 13.3 6.6 80 0.643
LICS 11.5 3.8 84.7 0.536
AVM 5.5 38.8 55.6 0.557
Cobblestoning 0 0 100 1.0
Overall 7.7 12 79.9 0.669
Blue filter
Ulcer/aphthae 93 5.8 3.3 0.476
Villous oedema 73.5 26.5 0 0.549
Blood in lumen 73.3 20 6.7 0.4
LICS 92.3 7.7 0 1.0
AVM 100 0 0 1.0
Cobblestoning 86.3 13.6 0 0.621
Overall 83 12 3 0.786
Table 4.2: Results of the study of FICE 1, 2, 3 and Blue filter in image
enhancement in small-bowel CE. (All observations had statistical significance, P
<0.001.)
Abbreviations: CE, capsule endoscopy; FICE, Fujinon intelligent colour enhancement,
IA, inter-observer agreement; LICS, lesions of indeterminate clinical significance; AVM,
anterio-venous malformations.
4.4 Discussion
There are only limited data in the literature evaluating the use of FICE system in
small-bowel capsule images (Pohl et al. 2010; Oka et al. 2011). Furthermore, there
are no studies examining the validity of BM in image enhancement. Therefore, we
conducted a study of the newly developed computed VC system (incorporated in
RAPID® versions 6 and 7), in order to confirm whether the application of FICE led
to enhanced micro-vascular contour, and improved resolution of surface patterns
and colour differences, thereby leading to better characterization of a variety of
small-bowel lesions/findings.
Furthermore, we sought to confirm the validity of BM in CE.
FICE was only partially effective in the ulcer/aphthae group with an image
improvement in 36.6% of cases. In that respect, our results differ from those
reported in the study by Oka et al. 2011, where a much higher image-enhancement
rate (55.3%) was perceived. There was no significant image improvement in other
lesion subgroups. FICE 2 and FICE 3 were ineffective in improving images (overall
8.6 and 7.7% improvement in FICE 2 and 3, respectively) with a significant
agreement between the two readers. These results differ completely from the study
by Oka et al. 2011, reporting image-quality improvement of FICE 2 settings in 87%
and 25.5% of AVM and ulcerations, respectively. Thus, our opinion is that the use of
FICE in the small-bowel capsule is limited.
Moreover, FICE 1 improved the definition in 34% of the images. FICE was effective
in improving images in 56.6, 50 and 77.7% in blood in lumen, LICS and AVM,
respectively. The inter-observer agreement was similar in these three subgroups.
The results regarding AVM are comparable to the recent study by Oka et al. 2011,
reporting an improvement in 87% of cases.
BM improved most of the images (overall image enhancement 83%), with a range
between 73.3% and 100%, in different lesions groups. Although we report an overall
substantial inter-observer agreement of 0.786, the K coefficient varied between
different groups. Ulcers, villous oedema, and blood in lumen presented a moderate
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inter-observer agreement, Crohn's mucosal cobblestoning, substantial agreement,
whereas angioectasias/ AVMs and LICS, excellent agreement.
There are certain limitations in this study: the model of using two reviewers is open
to bias. Furthermore, the side-by-side review of the images in WL, FICE and BM
may have led to memory or bias and interfered with assessment. Lastly, one might
consider the fact that only still images (for lesion/finding characrerization with
FICE/BF) were reviewed, and not video clips for assessment of lesion detection rate
and outcome, as possible limitations of this study.
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4.5 Conclusion
FICE 1 was only partially effective in the ulcer/aphthae image group. There was no
significant image improvement in other lesion subgroups. FICE 2 and FICE 3 was
ineffective in improving images. On the contrary, BF showed promising results and
its use as the main viewing mode, especially in cases of obscure GI bleeding, should
be further examined in regard to feasibility and in connection with the DY.
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CHAPTER 5
QuickView in small-bowel capsule endoscopy is useful in
certain clinical settings, but QuickView with Blue Mode is
of no additional benefit
5.1 Introduction
5.2 Materials and methods
5.2.1 Patients and small-bowel capsule endoscopy procedure




5.3.1 Results - Obscure gastrointestinal bleeding
5.3.2 Results - Suspected/known Crohn's disease





In most centres, CE remains the first-line option over more invasive tools that is,
deep (or device-assisted) enteroscopy (Sidhu et al. 2012). One of the limitations of
small-bowel CE is the reading time required for the interpretation of lengthy video
streams. It is generally accepted that the average time for video sequence analysis is
between 40 and 120 minutes, depending on the overall recording time and the
reviewer's experience (Shiotani et al. 2011).
Because of high workloads, attempts have been made to reduce physician
involvement through the use of assistants/extenders for the preliminary review of
the video sequence or through the use of software that aids interpretation (Shiotani
et al. 2011; Davison 2006). The main question with the latter approach is whether a
rapid review, where a percentage of images are discarded, would miss clinically
relevant pathology? The current version of RAPID® capsule review software
incorporates the QV mode, allowing a speedy video review.
However, the QV mode is still under clinical validation and there are only four
studies that have examined the utility of this informatics algorithm (Shiotani et al.
2011; Saurin et al. 2012; Hosoe et al. 2012; Westerhof et al. 2009; Shiotani et al. 2012).
In chapter 4 it was shown that small-bowel CE evaluation with BM filter yields
promising results and further study of this is recommended as the main viewing
mode, especially in cases of OGIB (Krystallis et al. 2011). BM or a blue filter is a
colour coefficient shift of light in the short wavelength range (490-430 nm)
superimposed onto a white light (WL) [red, blue, green (RGB)] image. It can be
applied easily through the quick adjust toggle button menu.
Therefore, there is immense interest in techniques and methods that reduce the
evaluation time in capsule endoscopy without jeopardizing diagnostic accuracy.
Software approaches have been developed to fulfil this requirement. One example is
the QV reading mode. QV creates a preview of the entire video sequence, thus
allowing a fast-forward-type review of interesting sites. It highlights sample images,
using different sampling rates, within each region of the video by analysing colours
and patterns. RAPID® current version allows the reviewer to set the QV sampling
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rate from 5% to 80% of video images at 5% increments. To date, studies have shown
conflicting results in the clinical use of QV (Table 5.3) (Shiotani et al. 2011; Saurin et
al. 2012; Hosoe et al. 2012; Westerhof et al. 2009; Shiotani et al. 2012; Schmelkin 2006;
Diaz et al. 2006; Appalaneni et al. 2007).
The aim of this study was to assess the validity of QV under white light (QVWL)
and QV under BM (QVBM) reading mode, in a group of patients who had
undergone small-bowel CE in our centre, by comparing it with the standard
(reference) video-sequence reviewing by experienced small-bowel CE readers.
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5.2 Materials and methods
5.2.1. Patients and small-bowel capsule endoscopy procedure
Between August 2008 and November 2011, 248 patients underwent small-bowel CE
with PillCam®SB in our centre (132 performed with PillCam®SBl and 116 with
PillCam®SB2; Given®Imaging Ltd, Yokneam, Israel). The demographics and clinical
characteristics of this group are presented in Table 5.1. Our standard procedure
protocol is presented in Appendix 1.
For the purpose of this study, only small-bowel CE videos with complete small-
bowel transit were included for further QV analysis. The videos had already been
reviewed - for the purpose of regular clinical care - by at least one of two
experienced in small-bowel CE readers (AK and SD >800 reviews each). Our
standard viewing mode is Single View or Dual View on automatic speed at 12-20
fps, respectively.
A research fellow (with experience in both conventional and capsule endoscopy;
>200 SBCE reviews), who had not been involved in either patient care or the initial
small-bowel CE review, analysed the video sequences with QV (under both WL and
BM). The reviewer was blinded to any previously captured landmark or
thumbnailed findings and to patients' clinical history and indications for the test.
QV mode reading SBCE analysis was performed using the RAPID®7 workstation
(Given®Imaging Ltd). One reviewer (AS) used only QV, selecting landmarks and
thumbnailing abnormal images. All pathological images and times were entered in
a spreadsheet. The reviewer used QVWL first (for the entire cohort) and QVBM
second, reviewing sequences in a random order to minimize observer bias. He used
QV with an image-sampling rate (sensitivity) of 35% in the Dual View display mode
at 18 fps, sitting at arm's length from a 19-inch monitor in a quiet room with
dimmed lights.
The small-bowel evaluation time (time from entry to exit from the small-bowel) was
recorded for each patient. This included both the reading time and the thumbnail
capture time for each of the two QV modes. To minimize reviewer tiredness,
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reviewing sessions were restricted to 10 video sequences per day. The results of
QVWL and QVBM reviews were compared with the results of the conventional
(reference) reviews, by checking each thumbnail against all previously captured
thumbnails, by two reviewers (AK and AS).
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Male 85 (42.5) 22
Age (±SD) 57.5 (±14.2) 63.1 (±13)
SBCE with PillCam®SBl 125 (62.5) 30 (62.5)
Indications for CE
OGIB 106 (53) 21 (43.7)
CD (suspected or known) 81 (40.5) 26 (54.2)
Polyposis syndromes 4(2) 0
Coeliac disease 3(1.5) 0
Possible lesion or mass 6(3) 1 (3.4)
Table 5.1: Demographics and indications for small-bowel capsule endoscopy in the
study cohort. Abbreviations: CE, capsule endoscopy; SD, standard deviation; CD: Crohn's
disease; OGIB: obscure gastrointestinal bleeding; SBCE: small-bowel capsule endoscopy.
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5.2.2 Classifications of lesions
Findings in the OGIB group were classified as PO (non-pathological), PI
(low/intermediate) or P2 (high bleeding potential) lesions (Saurin et al. 2003) To
avoid reporting bias, in the suspected or the known CD group, only the most
objective CE parameters and descriptors of mucosal inflammation were used, that is
ulcer (defined as any pale or yellow-based mucosal break surrounded by a red or a
pink collar) less than 1/4 of the intestinal lumen circumference, ulcer 1/4-1/2 of the
lumen circumference, ulcer more than 1/2 of the lumen circumference ± luminal
stenosis, as defined by the Lewis score (Granlek et al. 2008).
The performance of QV was defined as concordance between frames thumbnailed
by the QV reader and frames selected during the standard/conventional review.
The sensitivity, specificity, negative predictive value (NPV) and positive predictive
value (PPV) for QVWL and QVBM - compared with the reference review - for
clinically relevant (i.e. P1/P2) vascular lesions and for mucosal ulcers of any size
were calculated in the OGIB and suspected/known CD referral groups,
respectively.
5.2.3 Ethics consideration
This study was carried out in accordance with UK research ethics guidelines. After
review by the local ethics committee, further specific ethical review and approval
were not required, as the study was considered a retrospective clinical audit work
using data already obtained as part of regular patient care.
5.2.4 Statistical analysis
Values are expressed as mean ±SD. A two-sided P value less than 0.05 was
considered statistically significant. Statistical analysis was performed using the




A total of 200 SBCE examinations were completed to the caecum and included in
this study. The mean evaluation time (including reading and time to mark
thumbnails) in this cohort was 475 (±270) s and 450 (±156) s for QVWL and QVBM,
respectively (P =0.363). If all findings (i.e. any P category lesion, any size ulcer and
any size polyp) were counted; QVWL detected 129 lesions (49.6%), QVBM detected
135 lesions (51.9%) and the conventional (reference) review detected 260 lesions (P
<0.0001) (Table 5.2).
5.3.1 Results - Obscure gastrointestinal bleeding
One hundred and six (53%) SBCEs were performed for OGIB, 21 (10.5% included
videos) for overt OGIB and 85 (42.5% of included videos) for occult OGIB. With
QVWL, 54 (55.1%) lesions [P0 (28), PI (18), P2 (8)] were detected, whereas with
QVBM, 63 (64.3%) lesions were detected [P0 (48), PI (13), P2 (2)]. Standard
(reference) SBCE reading detected 98 lesions [P0 (67), PI (23), P2 (8)] (P = 0.0506).
Concordant results (normal SBCE i.e. no findings and/or P0 lesions only) between
QVWL and reference reading were observed in 101/106 (95.3%) cases and
discordant results in five (4.71%), and 4/5 false negatives with QVWL. With QVBM
reading, concordant results (for no findings and/or only P0 lesions) between QVBM
and reference reading were observed in 89/106 (84%) cases and discordant results
in 17 (16%), and 14/17 false negatives with QVBM.
For QVWL, the sensitivity, specificity, PPV and NPV for P1+P2 lesions (as
compared with reference reporting) were 92.3%, 96.3%, 96% and 92.8%,
respectively. For QVBM, the above values were 91%, 96%, 96.2% and 90.6%,
respectively.
5.3.2 Results - Suspected/known Crohn's disease
Eighty-one (40.5%) patients underwent SBCE for small-bowel evaluation on the
basis of a clinical history of suspected or known CD. With QVWL, 71 (45.8%) [<1/4
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(62), 1/4-1/2 (3), >1/2 (6)] mucosal ulcers were detected, 68 (43.9%) [<1/4 (51),
1/4-1/2 (9), >1/2 (8)] with QVBM, as compared with 155 [<1/4 (137), 1/4-1/2 (10),
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Concordant negative results (i.e. no findings/non-specific findings and/or <3 small
ulcers) between QVWL and reference reading were observed in 73 (90%) and
discordant results in eight (9.9%), 8/8 false negative with QVWL. Concordant
negative results between QVBM and reference reading were observed in 73 (90%)
and discordant results in eight (9.9%), and 7/8 false negatives with QVBM.
In the suspected CD category (15 patients; 12 mucosal ulcers with reference review
of which ulcers <1/4: 10, ulcers>l/4: 2), the overlooked lesions (ulcers<l/4: 6)
would have potentially changed the diagnosis in one case. When analysing QVWL
and ulcer size (i.e. <1/2, 1/4-1/2 and >1/2 luminal circumference), the sensitivity
was 42%, PPV 97% (as compared with reference reporting), increasing to 100% for
large ulcers (1/4-1/2 and >1/2).
For QVBM, the sensitivity and PPV were 52% and 91%, respectively, again
increasing to 100% for large ulcers (1/4-1/2 and >1/2).
5.3.3 Results - Polyposis syndromes
Ten (5%) patients underwent SBCE for the evaluation of polyposis syndromes or
because of a strong clinical suspicion of a primary or a secondary small-bowel
mass/tumour lesion. With QVWL and QVBM, four polypoid lesions were detected




Although there is no strict guidance for the best standard/conventional small-bowel
CE reading technique and speed, the unique features of small-bowel CE require the
reader to be intensely focused and alert (Lo 2006). Nevertheless, lapses in
concentration or distractions cannot be prevented in lengthy reading sessions. In
most tertiary, high case-volume centres, small-bowel CEs are usually reviewed by
examiners who may not be further involved in the patient's management. This
requires a quick turnaround time from capsule-to-report (for the non-urgent cases)
and reviewer availability/flexibility (Lo 2006). Furthermore, there are clinical
settings where a timely report is crucial for further clinical management that is, in¬
patients with OGIB and patients with severe CD.
Recently, VC has been reported to improve the performance of small-bowel CE. We
have shown that BM, a form of VC that is incorporated into the RAPID® software,
improves the definition of mucosal lesions and possibly increases the detection rate
(Krystallis et al. 2011; Spada et al. 2011). The two features, that is, QV and BM
should be considered as 'quantitative' and 'qualitative' as they aim to decrease the
reviewing time and enhance the detection of small-bowel lesions, respectively. The
combination of QV and VC (BM) has not been studied to date.
Consequently, we aimed to evaluate the utility of combining the QV mode with BM
and WL. Notably, this is the first study to check the QV reading on version 7 of the
RAPID® software. Moreover, a detailed and strict protocol was followed (single
reviewer, not more than 10 video reviews/session, low reading speed of 18 fps in a
dual mode view on the viewing speed slider and Dual View frame mode for all
reviews), whereby we included a large number of SBCEs and did not restrict the
study to a single indication to have a realistic representation of everyday clinical
scenarios.
In our OGIB group, all P2 lesions were detected with QVWL; therefore, when
urgent SBCE analysis is necessary- for further immediate management planning -
the QV mode can provide an accurate diagnosis within a few minutes in the
majority of cases. Furthermore, in this clinical setting, our study shows that BM
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does not confer any additional advantage over WL. QV has a high PPV (all P2
lesions and large ulcers were detected); however, the NPV was just above 90% (for
small angioectasias), although this should be interpreted with caution as the clinical
relevance of missing such lesions is not necessarily significant on clinical grounds
(Frieling 2006; Hindryckx et al. 2008; Maeda et al. 2010).
Conversely, QV showed only 50% sensitivity for small ulcers and aphthae in the
known/suspected CD group. In the suspected CD category, lesions that were
detected with the reference review and missed by QVWL or QVBM review would
have resulted in a different diagnosis in only one case. These results are in
agreement with those of other groups who advocate the use of QV solely in the
suspected CD group, when multiple and widespread lesions of mucosal
inflammation are present (Westerhof et al. 2009).
Moreover, we found that BM, despite excellent results in lesion characterization
(Shiotani et al. 2012), does not confer any additional benefit (over WL) in lesion
detection in a QV setting. This is not dissimilar to a recently published study from
our centre, where BM did not confer any added benefit over WL in Lewis score
calculation (Koulaouzidis et al. 2012). Furthermore, this is not in agreement with
recently reported data of Abdelaal et al. (2010), although admittedly, the video-
reviewing setting was different.
An inherent limitation of this study, similar to previous studies, is that QV has been
compared against 'conventional / standard' viewing. Although the initial review
was performed by experienced capsule endoscopists and at a low speed for the
purpose of regular clinical care, it is not possible to determine whether strict
reviewing conditions (similar to those applied by AS in the QVWL/QVBM review)
were implemented constantly. Another intrinsic limitation of the present study is
the use of a single, less experienced reviewer, for both QV modes (QVWL and
QVBM, albeit not in a consecutive manner for each video stream), which increases
the risk of interpretation bias. Moreover, although the review was performed in a
random order, this has not offset the potential for observer bias. Flowever, it is
noteworthy that recent studies have shown that the small-bowel CE detection rate is
not necessarily linked to medical background or reviewer experience (Sidhu et al.
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2007; Dokoutsidou et al. 2011; Zheng et al. 2012). We should also acknowledge that
by including only small-bowel CE with complete small-bowel transit, we have
introduced potential applicability limitations.
Furthermore, two generations of PillCam®SB have been used in this study and one
should keep in mind the improvement in the field of view from SB1 to SB2
(although this does not alter our results). Lastly, this chapter is based on the number
of lesions detected; as it is common to find several 'repetitive' lesions in the same
patient, an overestimation of the concordance between the two reading modes may
occur. In an attempt to overcome this, we reported the change in the diagnosis of
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5.5 Conclusion
Our study confirms the safety of QV pre-read in urgent cases, but fails to show any
benefit in other clinical scenarios. Although the benefits of QV are outweighed to
some extent by a decrease in the overall diagnostic yield, this mode can be used
confidently in overt OGIB in an urgent inpatient setting and in outpatients with
occult OGIB or suspected CD. As the usefulness of QV may vary, depending on the
number of small-bowel lesions, standard review settings are still recommended in
all other cases. Furthermore, the present study confirms that BM does not confer
any additional advantage in the QV setting.
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Capsule endoscopy has changed our diagnostic approach for small-bowel diseases
(Iddan et al. 2000; Eliakim 2013). Although more accurate and of higher diagnostic
yield than other modalities (Mata et al. 2008; Koulaouzidis et al. 2013), there are still
occasions where pathology is either missed or misinterpreted (Mavrogenis et al.
2011; Hakim et al. 2011; Triantafyllou et al. 2011). Furthermore, reports have shown
that 3-D reconstruction can facilitate diagnosis by enhancing textural features of
mucosal structures or intestinal abnormalities (Koulaouzidis and Karargyris 2012).
However, accurate 3-D reconstruction of the GI tract requires the use of stereoscopic
cameras that can simulate human binocular vision (Kolar et al. 2010). With the
current level of technological investment in CE though, i.e. camera size, packaging
constraints and power consumption, accurate 3-D imaging of the intestinal lumen in
small-bowel CE is still unfeasible (Fisher and Hasler 2012; Koulaouzidis et al. 2013).
Three-dimensional reconstruction may be helpful in conjunction with other image-
enhancement tools, e.g. virtual chromoendoscopy (FICE and/or colour (blue) mode
analysis of CE videos (Koulaouzidis et al. 2013; Koulaouzidis, Rondonotti and
Karargyris 2013; Spada et al. 2011).
Therefore, software approaches that offer 3-D representation of conventional
monocular 2-D CE frames have been developed (Zhang et al. 1999) and proposed
for use in CE (Karargyris et al. 2010). Shape-from-shading (SfS) algorithms recover
the 3-D shape from a single monocular image (two-dimensional image). Such
approaches, e.g. SfS algorithms, are members of a family of shape-recovery
algorithms called shape-from-X techniques (Tsai and Shah 1994). Given a single 2-D
image, these algorithms recover the shape of objects using the gradual variation of
shading (Zhang et al. 1999; Karargyris et al. 2010). This recovered shape is expressed
either with the surface normal (nx, ny, nz) or the surface gradient (p, q). All of the
SfS algorithms use a minimization function and constraints on a local or a global
scale. Hence, the recovered 3-D shape is an estimate of the real shape of an object
and technically not the real physical shape.
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Essentially, surface reconstruction with SfS is achieved through a mathematical
representation that is inverted in order to recover dense surface distance and
normal information by the gradual variation of shading (Karargyris et al. 2010;
Koulaouzidis and Karargyris 2012). In the next four paragraphs, the four publicly
available SfS algorithms that we use in the clinical experiments are briefly
discussed.
6.1.2 Tsai's SfS algorithm
Since images of most surfaces in the real world can be approximated by Lambertian
reflectance, the majority of SfS methods use the Lambertian reflectance model
(Zhang et al. 1999). Lambertian reflectance is the property that defines an ideal
'matte' or diffusely reflecting surface. The apparent brightness of such a surface to
an observer is the same regardless of the observer's angle of view (Tsai and Shah
1994). The important parameters in Lambertian reflectance are albedo and
illuminant directions. Commonly, the albedo is assumed to be constant. These
constraints make calculations easier. Tsai's algorithm consists of an initial discrete
approximation of the surface gradients (p, q), and once incorporated into the
Lambertian reflectance equation linear approximations based on Taylor series
expansions along points (x, y) produce the depth map Z which is the recovered 3-D
shape. The depth Z recovery is based on an iterative algorithm which is a form of
the Newton-Raphson method. It converges quadratically when provided with a
sufficiently accurate initial approximation and since it operates on a local basis it is
highly parallelizable and therefore computationally efficient (Figure 6.1A).
6.1.3 Ciuti's SfS algorithm
The laparoscopic camera was first calibrated to characterize its radiometric response
and internal parameters to discover any deviations from the Lambertian reflectance
model (Ciuti et al. 2012). They adopted the modeling proposed by Visentini-
Scarzanella et al. (Visentini-Scarzanella 2012) where a single light source - instead of
two - away from the optical centre is considered. The resulting SFS partial
differential equation is characterized with the information from the camera and
light calibration procedure and then solved through a Lax-Friedrichs sweeping
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scheme (Visentini-Scarzanella 2012). In contrast to the formulation in which the
recovery of the albedo relies on robust separation of specular and diffuse
components, with additional calibration of the camera, it is possible to recover this
scale factor prior to the procedure and dynamically apply it for in-vivo monocular
metric structure recovery. They finally retrieve albedo values between consecutive
depth-recovered endoscopic images (Figure 6.1B).
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Figure 6.1 (A, B): A) an angioectasias represented with the Tsai's SfS algorithm, and
B) the same lesion represented with the Ciuti's SfS algorithm
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6.1.4 Barron's SfS algorithm
Barron and Malik (2012) proposed a unified shape recovery SfS algorithm using
shape - S(Z,L), illumination - L, and reflectance R from shading of a single image.
Colour constancy can be viewed as a subset of the intrinsic images problem:
decomposing a single image into its constituent 'images': shape, reflectance and
illumination (Barron and Malik 2012). They assume Lambertian reflectance for their
modelling. The unknowns Z, R, L are approximated through a minimization
function subject to the log-intensity image I = R + S (Z,L). They additionally use a
reflectance smoothness model to constraint the minimization function. It is based on
a multivariate Gaussian scale mixture (GSM) placed on the differences between
each reflectance pixel and its neighbours (Figure 6.2A).
6.1.5 Torreao's SfS algorithm
This SfS algorithm is biologically inspired by being formulated in terms of a model
of linear-non-linear neuronal responses (Torreao and Fernandes 2011). The input
image to a linear filter was followed by non-linear transformations modelled on the
tuning curves of the disparity-selective binocular neurons. More specifically, the
linear filter output is next submitted to non-linear transformations, in order to yield
the shape estimate. The second non-linear stage was so chosen in order to establish




Figure 6.2 (A, B): A) an angioectasias represented with the Barron's SfS algorithm,
and B) the same lesion represented with the Torreao's SfS algorithm
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6.1.6 Highlights removal algorithm
Light reflections on the surface of the digestive tract are still a significant problem,
not only for 3-D representation but also for traditional 2-D CE. When light falls on
to a surface, some of the beams are reflected back straight away (specular
reflection), while the rest of the beams penetrate it before being reflected (diffuse
reflection). As most digestive tract structures/surfaces are dielectric and
homogeneous, they display both types of reflections. As mentioned above, most SfS
methods work better on images following the Lambertian reflection model.
However, the intensity distribution of diffuse reflections approximately follows
Lambert's law (Lambert 1760).
Tan and Ikeuchi (2005) proposed a method to separate the two reflection
components; diffuse and specular. This method behaves optimally since it does not
require colour segmentation as other methods do. Additionally, another advantage
is that it runs on two neighbouring pixels minimizing the error of the outcome.
Basically, the methodology creates a normalized image containing only the pure
specular component of the original image. It also creates a specular-free image out
of the normalized picture by using the maximum chromaticity. A logarithmic
differentiation of the two images gives the diffuse image, which is the original one





Figure 6.3 (A, B):
A) Shape-from-shading (SfS) principles. Capturing a surface using a camera removes
depth information. SfS techniques try to reproduce the missing depth information
from a given two-dimensional image.
B) Highlights removal software. Three-dimensional representation image before (left)
and after application of highlights removal software (right).
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6.1.7 Aims
Currently, there are four publicly available SfS algorithms (Tsai and Shah 1994;
Torreao and Fernandes 2011; Barron and Malik 2012; Ciuti et al. 2012). To date, no
comparative study using images obtained during clinical small-bowel CE has been
performed.
Therefore, this study aims to evaluate the performance of four publicly available SfS
algorithms for 3-D representation in CE, by comparing 3-D reconstructed images
with their equivalent conventional 2-D images of small-bowel structures/lesions
obtained during small-bowel CE. This is in order to identify which of the four
algorithms is more helpful in facilitating identification and distinction between
lesion and surrounding mucosa. Furthermore, we aim to validate a highlight-
suppression algorithm testing its use on to CE images generated by the best-
performing 3-D representation algorithm (Tan and Ikeuchi 2005).
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6.2 Materials and methods
6.2.1 Phase 1
Between January 2011 and January 2012, 262 small-bowel CE procedures were
performed at the Royal Infirmary of Edinburgh (tertiary referral centre for CE for
the south-east of Scotland, United Kingdom) in 249 patients (mean age: 52.6 ± 12.1
years). Out of them, 140 were performed with PillCam®SB2 (Given®Imaging Ltd,
Yokneam, Israel) and 122 with MiroCam® (IntroMedic®Co, Seoul, South Korea). A
total of 54 images (27 obtained with MiroCam® and 27 with PillCam®SB) were
selected on the basis of the overall quality, i.e. brightness, absence of air bubbles,
debris, or opaque luminal fluid and clarity of findings (lesions or structures).
Thereafter, images were classified in the following image groups: (1) vascular
lesions i.e. angioectasias (n = 16); (2) inflammatory lesions, i.e. ulcers, erosions,
aphthae, cobblestone, fold and/or villous oedema (n = 18); and (3) protruding
lesions/structures, i.e. polyp/mass, nodular lymphoid hyperplasia, cluster of focal
lymphangiectasias, chylous cysts, and AoV, (n = 20).
6.2.2 Phase 2
For the second phase, a phantom task simulator was created. A stomach ulcer
anatomical model (manufacturer: Anatomical Chart Company G200) was used; the
stomach model has a red-coloured base ulcer (l/2"diameter and 3/16"depth;
Figure 6.4A); the latter was thereafter coloured buttercup yellow using quick-drying
spray paint (Tor Coatings®Ltd, UK) and white (using flat white spray from Plasti-
Kote®Ltd). A PillCam®SB2 (Given®Imaging Ltd, Yoqneam, Israel) was mounted on a
plastic tube and held (with the use of a regular laboratory stand) at 0, 5, 10, 15 and
20 mm from the ulcer base (usual working distance of the CE in vivo, Figure 6.4B).
The images were uploaded to a workstation and they were categorized based on
distance and ulcer base colour (red, yellow and white). The aim was to check
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Figure 6.5 (A, B):
Three-dimensional representation of images captured for the 3 models: red, white and
yellow.
A) Original three-dimensional (3-D) represented images; and
B) The processed 3-D represented images using the highlight-suppression algorithm.
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6.2.3 Three-dimensional image representation software
All selected images were reconstructed in 3-D by means of all four SfS algorithms.
Three reviewers (ER, GM, AK), with extensive experience in CE and blinded to each
other, participated in this study. In order to facilitate the evaluation process, a
Mathworks® Matlab program with a graphic user interface (GUI) was developed
(Figure: a video presenting the evaluation process is provided as supplementary
material via this link:
https://dl.dropboxusercontent.eom/u/7591304/EvaluationVideo.mov). The
program consisted of two windows in which the conventional 2-D small-bowel CE
image (Figure: single frame at the right side/window of the GUI screen) and its
corresponding 3-D represented images (four, one for each of the four SfS under
evaluation) are presented to the reviewer (Figure 6.6 A, left side/ window of the
GUI screen).
The 3-D SfS representations appeared in random order. The reviewers had the
ability and freedom to rotate and zoom in on each of the 3-D represented images. At
the bottom of the GUI screen, a single 'task request': 'Choose the 3-D representation
you consider most helpful in distinguishing the finding (seen in 2-D) from the
surrounding mucosa' appeared. This prompted reviewers to choose one among the
four 3-D reconstructed images, each generated by a different 3-D algorithm. After
selecting the best SfS representation, the reviewer had to click 'next' to proceed to
the next case. This process was repeated until the program reached the last case,




Figure 6.6 (A, B):
A) For the evaluation phase, a Mathworks©Matlab program with a graphic user
interface was developed. The program consists of two windows in which the
conventional two-dimensional capsule endoscopy image (single frame at the right
side/window of the graphic user interface screen) and its corresponding three-
dimensional represented images (four, one for each of the four shape-from-shading
under evaluation) were presented to the reviewer.




Reviewers were asked to evaluate 54 images. The following subgroup analyses were
performed: (1) evaluation of 3-D representation according to the type of finding
(vascular vs inflammatory vs protruding); and (2) evaluation according to the
system generating the 2-D image (PillCam® vs Mirocam®). Furthermore, inter-
observer agreement was calculated.
6.2.4.2 Phase 2
SfS algorithms cannot measure the real distance of the camera to the model's surface
but they give the relative distance (z) to the black frame background. For each
image, the region of interest (ROI) was selected of the ulcer model on the 3-D
representation and the average depth (z) for each ROI was calculated.
6.2.5 Ethics consideration
This study was conducted in accordance with United Kingdom research ethics
guidelines. After review by the local ethics committee further specific ethical review
and approval were not required, as the study was considered an evaluation of
previously collected endoscopy images, using data already obtained as part of
regular clinical care.
6.2.6 Statistical analysis
For numerical variables, values are presented as mean ±SD. Where necessary, the
Fisher exact test was calculated. A two-tailed P value < 0.05 was considered
statistically significant. Inter-observer agreement was calculated using an online
kappa calculator (available from http://justusrandolph.net/kappa/), which
provides the calculation of Randolph's free-marginal multi-rater kappa (k),
applicable when raters are not forced to assign a certain number of cases to each
category. Values of k can range from -1.0 to 1.0, with -1.0 indicating perfect
disagreement below chance, 0.0 indicating agreement equal to chance, and 1.0
indicating perfect agreement above chance. More specifically, the interobesrver
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agreement is classified per K as poor < 0.20, fair 0.2-0.40, good 0.41-0.60, very good
0.61-0.80 and, excellent 0.81-1.00 (available from
http://justusrandolph.net/kappa/). All other statistical analyses were performed




Of the four SfS algorithms, Tsai's 3-D algorithm outperformed the rest (selected as
the best in 45/54 images), followed by Ciuti's (best performing SfS in 7/54 images)
and Torreao's (in 1/54 images): there was a single image for which each reviewer
selected as best performing a different 3-D representation algorithm. Of note, not
once was Barron's 3-D algorithm selected as best performing (Figure 6.7). In 26/54
images, Tsai's algorithm was unanimously selected as the best performing 3-D
representation SfS software. Tsai's 3-D algorithm superiority was independent of
lesion category (protrusion/inflammatory/vascular; P = 0.678) and/or CE system
used to obtain the 2-D images (MiroCam®/PillCam®; P = 0.558). Lastly, the inter-
observer agreement was good (kappa = 0.55).
6.3.2 Phase 2
Since the Tsai's method gave us really satisfying results, we considered improving it
by adding a reflectance model transformation as a preprocessing step to make
endoscopy images specular free and, therefore, follow the Lambertian reflection
model. The results (charts, Figure 6.8) confirm that as the distance of the camera
from the model surface increases, so does the relative distance (z) on the 3-D
representation. This effect is more evident for the white and yellow ulcer models.
However, relative distance does not follow a similar trend for the red-based ulcer
model. This is likely to be due to the saturation of the red colour creating variations
to the shading: the red colour appears darker or lighter. Finally, from the charts we
conclude that the highlight-suppression algorithm improved the quality of the
images.
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SIS method PillCam" MiroCam" PillCam" MircCam" PillCam" MiroCam"
Tsai 7 7 7 6 8 10
Gut 1 0 1 0 1 4
Torreao 0 0 1 0 0 0
Barron 0 0 0 0 0 0
None Selected 0 1 0 0 0 0
Figure 6.7 :
Top: Assessment results for the four shape-from-shading algorithms per lesion
category. In the Y-axis, lesion categories (protrusion, inflammatory, vascular) and
the system (PillCam or MiroCam) used in each case. In the X-axis, the absolute
selection numbers.




































Figure 6.8: Relative distance of three-dimensional representation calculated over
images taken from various distances of the capsule from the models.
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6.4 Discussion
In the present study, we compared the performance of four publicly available 3-D
'reconstruction' algorithms (SfS software) (Tsai and Shah 1994; Torreao and
Fernandes 2011; Barron and Malik 2012; Ciuti et al. 2012), using 54 conventional 2-D
CE images. The evaluation criterion was subjective, i.e. the perceived visualization
improvement (3-D representations offered over and above the corresponding
conventional 2-D images) as ascertained by three experienced CE reviewers. Based
on this evaluation, Tsai's algorithm is the 3-D representation model recommended
for use in CE. This outcome directly supports Tsai's SfS model theoretical
advantages: (1) able to produce good results for round surfaces, which is the case
for most digestive tract shapes; and (2) it behaves quite well with bright surfaces
(Zhang et al. 1999).
Depth information is an important aspect of human vision; it helps the human brain
to analyse and comprehend the surrounding environment. Images captured with
conventional (non-stereoscopic) cameras 'discard' the third dimension (depth) as
conventional cameras can only save two dimensions (height and width). Therefore,
depth information is lost; and moreover, most imaging algorithms perform less
efficiently.
To date, engineers have not been able to equip capsule endoscopes with
stereoscopic cameras for the following reasons: (1) packaging/space limitations; (2)
low-depth resolution of stereoscopic or time-of-flight cameras; and (3) power
consumption issues. However, it is almost certain that in the foreseeable future
these hardware-related limitations will be overcome (Kolar et al. 2010) and
eventually 3-D CE will be a commodity. Nevertheless, until hardware changes are
widely implemented, several efforts have been made to convert 2-D images into 3-D
images (3-D representation or 'reconstruction') through software and dedicated
algorithms.
There are software algorithms that offer a fair trade-off between 2-D images and
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hardware-enabled 3-D images. SfS algorithms can be divided into four groups: (1)
minimization approaches; (Ciuti et al. 2012; Torreao et al. 2011; Barron and Malik
2012); (2) propagation approaches; (3) local approaches; and (4) linear approaches
(Tsai and Shah 1994). It is important to remember that each of the four SfS
algorithms evaluated herein utilizes a different approach to recover the shape from
a conventional 2-D image. More specifically, Tsai's algorithm (Tsai and Shah 1994)
described a repetitive update of the depth using a linear approximation of the
reflectance function. Ciuti et al. (2012) used a camera model with perspective
projection and a light source close to the surface and away from the optical centre to
measure depth. Torreao et al. (2011) applied a linear-non-linear biological model
that mimics neuronal responses to estimate shape. Finally, Barron and Malik (2012)
proposed a unified model for recovering shape, reflectance and optional
illumination while using local smoothness, global scarcity or entropy, and the
absolute colour of each pixel. Although Tsai's (Tsai and Shah 1994) method is very
straightforward and to an extent simplistic, it provides satisfying results. The
algorithm of Ciuti et al. (2012), on the other hand, uses a more advanced model
(incorporating a camera model with perspective projection) that makes things in the
background appear further back than in Tsai's model (Figure 6.6).
Since, for a given 2-D image, light source and surface shape are not known, these
algorithms try to model how the 2-D image was created from the 3-D environment
to finally produce an approximation of this 3-D depth. The above modelling has a
significant impact on the resulting 3-D representation. During the SfS process
additional constraints need to be applied on the surface shape parameters or the
light conditions to find the surface characteristics.
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6.5 Conclusion
In conclusion, we showed previously that 3-D representation software offers a
plausible alternative for 3-D representation of conventional CE images (until optics
technology matures enough to allow hardware-enabled 'real' 3-D reconstruction of
the GI tract). In the present study we compared four publicly available SfS methods.
Three-dimensional reconstruction is attracting interest in CE, especially as newly
developed and/or under development CE becomes available, with greater potential
due to imager and optics for 3-D software (Fisher and Hasler 2012).
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CHAPTER 7
Three-dimensional representation software as image-
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Over the past decade, CE has revolutionized the evaluation of small-bowel diseases
(Iddan et al. 2000; Fisher and Hasler 2012). In recent years, research has been carried
out to produce 3-D reconstructions of the GI tract in conventional video endoscopy
using stereoscopic cameras (Mueller-Richter et al. 2004; Tsutsui et al. 2005): several
reports have shown that it can facilitate diagnosis by enhancing mucosal textural
features and abnormalities (Bhandari et al. 2004; Taylor et al. 2006). However, due to
the current technological limitations of capsule endoscopes (packaging and size
constraints and power consumption), hardware-enabled 3-D reconstruction of the
intestinal lumen in small-bowel CE is yet to be available. Therefore, a software-
based approach (SfS) has been proposed that helps approximate a 3-D
representation from monocular 2-D images. These algorithms recover the shape of
objects from 2-D images using a gradual variation of shading (Zhang et al. 1999).
Eventually, amongst four publicly available SfS algorithms, (Barron and Malik 2012;
Visentini-Scarzanella et al. 2012; Torreao and Fernandes 2011; Tsai and Shah 1994)
Tsai's method performed better based on preliminary results (see previous chapter).
Therefore, we conducted a two-phase, feasibility study in order to assess:
1) the accuracy of 3-D representation, by using CE images from phantom paradigms
(Phase 1); and
2) whether 3-D representation improves visualization (of surface/textural aspects)
of small-intestine structures/lesions, by using of a group of selected SBCE images
from clinical practice (Phase 2).
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7.2 Methods
7.2.1 Phase 1 - Phantom simulator design
For the accuracy assessment of the software, a task simulator was constructed: 2-D
images of phantom models were obtained by using CE and compared with their 3-D
representation counterparts. Overall, the simulator was designed based on the
following principles: (a) to be constructed with readily available materials, e.g.
cardboard boxes and stationery office supplies; (b) to allow minimal external light
for simulation of clinical CE; and lastly (c) phantom models to be representative of
the variety of colours and shapes of structures/lesions encountered in SBCE. A
cuboid cardboard box (12 x 30 * 45 cm) was used to simulate the abdominal wall
and allow the placement of CE sensors for video capture. A frame was cut open at
the top side of the box to allow insertion of a cardboard cuboid tube (6 x 9 x 42 cm)
which was to act as the main function chamber/bowel simulator.
Furthermore, a 4 x 6 cm rectangular frame was cut open in the lower part the side of
the tube facing the open lids of the box. This was done to allow placement of the
phantom-model plates on the reviewing surface during CE video capture (Figure
7.1A). Finally, following placement of CE sensors, a real-time viewer was used to
monitor progress of video/images capture.
7.2.2 Phase 1 - Phantom simulator models
As aforementioned, phantoms were made with commercially available stationery
material. Therefore, red-, yellow- and white-coloured, flat-headed drawing pins
(Figure 7.1B), as well as blocks of white, red and yellow Pritt® sticky tack (Henkel
AG and Co. KGaA, Dusseldorf, Germany) and an ibuprofen tablet (Nurofen®
400mg) were used as phantom models. Phantoms were placed on cardboard panels




7.2.3 Phase 1 - Phantom simulator output
A PillCam®SB2 (Given®Imaging Ltd, Yokneam, Israel) CE was mounted on a small
hemispheric plastic cap with Pritt® sticky fixer, and a commercial cotton string was
used to suspend the capsule 1.5 cm above the phantom object plates. From the video
obtained, 60 two-dimensional images of high quality (20 for each of the 3 colours,
i.e. red, yellow and white) were selected by an experienced CE reader (AK),
converted into 3-D images and reviewed for evaluation by another investigator
(Al.K), who was unaware of the surface type of each image, i.e. if the imaged object
was flat or protruding.
7.2.4 Phase 2 - Clinical study, patients
From January 2011 to January 2012, 262 small-bowel CE procedures in 249 patients
(67 males/182 females; mean age: 52.6 ±12.1 years) have been performed at the
Royal Infirmary of Edinburgh (part of NHS Lothian's University Hospitals
Division). Out of those, 140 were performed with PillCam® (Given®Imaging Ltd,
Yokneam, Israel) and 122 with MiroCam® (IntroMedic® Co, Seoul, South Korea).
7.2.5 Phase 2 - Clinical study, capsule endoscopy procedure
The technical characteristics of capsules, CE procedure and methodology for review
of CE images have been described in detail previously (Koulaouzidis et al. 2012;
Metzger et al. 2009). In essence, SBCE was performed with PillCam®SB2 and
MiroCam® capsule endoscopes using an established, for-our-unit procedure
protocol, i.e. strict liquid diet the day prior to the test, combined with purge (2 1
polyethylene glycol; Moviprep®, Norgine Ltd, Middlesex, UK) and overnight fast.
The capsule is ingested with 100 mg of anti-foam (Simeticone) and 5 mg of liquid
prokinetic suspension (domperidone), unless in exceptional circumstances. The
patients are allowed to drink clear fluids after two hours and consume a light
meal/snack after four hours. Written informed consent was obtained from all
patients prior to the procedure as part of their regular clinical care.
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7.2.6 Phase 2 - Images selection and images groups
An experienced small-bowel CE provider (SD), familiar with both aforementioned
SBCE systems, selected and de-identified a group of images by reviewing the
thumbnails of all 262 videos. Images were selected on the basis of their overall
quality, i.e. brightness, no bubbles and/or luminal debris or opaque luminal fluid
and findings (lesions or structures) clarity. An expert CE reviewer (ER) acted as
second selector. Eventually, only images for which there was complete agreement
between the two reviewers in terms of image quality, colour and type of depicted
finding, were included.
Therefore, a total of 192 small-bowel CE images (84 obtained with PillCam®SB2 /
108 obtained with MiroCam®), covering a wider spectrum of findings seen in SBCE,
entered 3-D reconstruction. These images were classified as per:
1. Predominant colour of the depicted structure/lesion into 4 image-groups: red,
white, mixed (red+white) and a group with lesion colour similar to that of the
surrounding mucosa;
2. Surface morphology of the depicted structure/lesion into the following groups:
a) convex surface morphology, i.e. polyp/neoplastic, chylous cysts, nodular
lymphoid hyperplasia (NLH), fold oedema, and AoV (n = 67);
b) flat or concave surface morphology, i.e. mucosal ulcer, erosion, aphthae, villous
oedema and angioectasias (n = 103); and
c) combi-surface morphology, i.e. cobblestone and lymphangiectasias (n = 22).
3. Diagnostic category into the following groups:
a) vascular, i.e. angioectasias; (n = 50);
b) inflammatory, i.e. ulcers, erosions, aphthae, cobblestone, fold/villous oedema; (n
- 73); and
c) luminal protrusion i.e. polyp/neoplastic, NLH, cluster of focal lymphangiectasias,
chylous cysts, and AoV; (n = 69), (Table 7.1).
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4. Lastly, each diagnosis was examined separately.
7.2.7 Three-dimensional image-representation software
Three-dimensional visualization software was developed in Mathworks©Matlab; it
can process a 576 * 576 image in less than 2 seconds. The software allows a reviewer
to load capsule endoscopy images from a folder. Then, the software processes each
image and exports its corresponding 3-D represented image in a proprietary format
of Matlab®(.fig extension). For the evaluation process, another Matlab® program
with a user interface was devised. The program consists of two windows in which
the conventional 2-D small-bowel CE image and its corresponding 3-D represented
image are given (Figure 7.2). The reviewer can rotate and zoom in on the 3-D
images. At the bottom of the screen, a single question regarding the efficiency of the
3-D representation is given. Five possible answers to choose from are also
presented. After selecting the desired answer the reviewer clicks next to proceed to
the next case. This process is performed until the program reaches the last case after
which each separate evaluation is concluded.
7.2.8 Raters and outcome measures
Seven reviewers - each with substantial experience in GI endoscopy, but variable
experience in the interpretation of CE images - participated in Phase 2. Reviewers
were unaware of each other's evaluations. Each of the 3-D representation images
were scored for textural enhancement of the depicted finding and therefore
categorized as improved/non-improved. To evaluate whether the 3-D
representation tool improves visualization of small-bowel CE images, reviewers
were asked to compare each 3-D represented image with a corresponding 2-D
counterpart and to rate it according to the following scale:
+2 or definitely improved;
+1 or somewhat improved;
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0 or no different/equivalent to conventional 2-D image;
-1 or somewhat worse; and
-2 or definitely worse.
Thereafter, reviewers' scores were tallied and the average score for each image was
calculated (Imagawa et al. 2011). To simplify analysis the data are presented in
three categories:
1) improved if average score > V,
2) same if average score was 0.99 to -0.99; and
3) xvorse if average score < -1.
The following subgroup analyses were performed: evaluation of 3-D representation
according to groups described above, i.e. predominant colour of depicted structure,
surface morphology, diagnostic category and diagnosis; the equipment generating
the 2-D image (PillCam® vs Mirocam®); and the CE experience of raters. Inter-
observer agreement was calculated for each image group (vascular, inflammatory
and protuberant).
Furthermore, reviewers were advised to leave each 3-D image at an angle most
consistent with their grading so that mean angles for right/left and up/down (for
each image group) could be calculated.
7.2.9 Ethics consideration
This study was conducted in accordance with UK research ethics guidelines. After
review by the local ethics committee, further specific ethical review and approval
were not required, as the study was considered an evaluation of previously
collected images, using data already obtained as part of regular patient care.
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7.2.10 Statistical analysis
For numerical variables, values are expressed as mean (istandard deviation, SD).
The f-test for continuous variables and the chi-square (y2) test for categorical
variables were used. A two-tailed P value <0.05 was considered statistically
significant. Pearson's agreement correlation was used for phase 1 of this study. For
phase 2, inter-observer agreement was measured by free-marginal multi-rater
kappa statistics (Viera, Garrett 2005) using an online Kappa Calculator, available at
http://justusrandolph.net/kappa/; (accessed November 24, 2012). A sample size of
192 images provides a margin of error of 7.04% (as calculated by an online sample
size calculator, available at http://www.raosoft.com/samplesize.html). Kappa < 0.4
was considered as slight agreement whereas between 0.41-0.6 as moderate, 0.61-
0.80 substantial, and 0.81-1.00 as excellent agreement. All other statistical analyses









7.3.1 Phase 1 - results
Overall, phantom experiments showed that the SfS algorithm was 90%, 70% and
45% (P = 0.14) accurate in interpreting the protruding or non-protruding surface
nature of red, yellow and white phantom models, respectively (Figure 7.3).
Sensitivity and specificity of the above evaluation was 80% and 100% for red-
coloured objects; 81.3% and 25% for yellow-coloured objects; 100% and 21.3% for
white-coloured objects. Lastly, Pearson's correlation was 0.93, 0.63 and 0.35 for red,
yellow and white, respectively.
7.3.2 Phase 2 - selected CE images
The number of images selected for each category, according to the SBCE system
used, and the type of findings is tabulated in Table 1. Overall, there was no
statistically significant difference in the number of images included per diagnostic
category for vascular, inflammatory and protruding structures/lesions, (P = 1.0,
0.359, 0.435, respectively).
7.3.3 Phase 2 - image evaluation and sub-analysis
For the entire image group (n = 192) and all (n = 7) reviewers, 51/192 (27.6%) was
evaluated as improved (better) with 3-D representation and 141/192 (73.4%) as
equivalent to their 2-D counterparts. Sub-analysis per predominant colour revealed
that 3-D representation improved red, white, mixed and lesions with colour similar
to the surrounding mucosa in 53.7% (29/54), 21.8% (12/55), 17.3% (5/29), and 9.2%
(5/54) of cases, (P <0.0001).
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Diagnostic category N Small-boivel CE
PillCam® - MiroCam®
P value
VASCULAR (n= 50) 25-25 1.0
Angioectasias 50 25-25
INFLAMMATORY (n= 79) 28-45 0.36
Mucosal cobblestone 9 4-5
Mucosal breaks/aphthae 21 11-10
Mucosal ulcers 25 7-18
Mucosal fold/Villous oedema 18 6-12
PROTRUDING (n= 69) 31-38 0.43
Lymphomas 3 0-3
Polyps 10 5-5
Chylous cysts 11 5-6
Lymphangiectasias 13 8-5
Lymphoid hyperplasia 15 5-10
AoV 17 8-9
Table 7.1: Evaluated images in total and per small-bowel CE system used (PillCam"-
MiroCam®).
Abbreviations: AoV: ampulla of Vater; N: number; CE: small-bowel CE.
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Sub-analysis per surface morphology showed that 3-D representation was felt to
improve evaluation in 14/67 (20.9%) of convex findings, 33/103 (32%) of
flat/concave findings and 4/22 (18.2%) of combi-surface morphology findings, P =
0.1929.
o Sub-analysis per diagnostic category; 56% (28/50) of vascular, 23.2% (16/69) of
protruding, and 9.6% (7/73) of inflammatory lesions were evaluated as showing
enhanced textural features on 3-D representation (Figures 7.4-6, Table 7.2).
o Sub-analysis per diagnosis revealed that evaluation of angioectasias with 3-D
representation showed improved visualization in 56% (28/50); chylous cysts 36.36%
(4/11); polyps/neoplastic lesions 30.76% (4/13); LNH 26.6% (4/15); mucosal
cobblestone 22.2% (2/9); lymphangiectasias 15.38% (2/13); AoV 11.76% (2/17);
mucosal ulcers/erosions/aphthae 8.69% (4/46); and villous/fold oedema 5.55%
(1/18), (P <0.0001).
o Sub-analysis per SBCE system revealed that 3-D representation led to enhanced
visualization in 20.2% (17/84) of images obtained with PillCam® and 31.5 %
(34/108) of images captured by Mirocam®, P = 0.099.
o Sub-analysis per CE reviewer experience (for the entire image series); there was
statistically significant difference between the rating from experienced CE and non-
CE readers (77/192 vs 51/192, P <0.007). For both evaluators' sub-groups though,
no image was perceived as worse than its 2-D equivalent. The results of the
comparison between CE and non-CE readers according to type of lesion and SBCE
equipment generating the 2-D images are summarized in Table 7.3. Inter-observer
agreement was at <0.4 for the entire group of images, as well as when each
diagnostic category was examined separately. The kappa statistics for all raters, CE
readers and non-CE readers is presented in Table 7.4.
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All readers ti/N (%)










Mixed (Red + White) 5/29 (17.3)
Colour similar to mucosa 5/54 (9.2)
Overall 51/192 (26.6)
Table 7.2: Image enhancement with the three-dimensional image representation
software, as per small-bowel capsule endoscope system, image group and colour of
structure/finding.
Type of finding CE readers (%) Non-CE readers (%) P value
Vascular 38/50 (76.0) 24/50 (48.0) 0.007
Protuberant 31/69 (44.9) 12/69 (17.4) 0.008
Inflammatory 8/73 (10.9) 15/73 (20.5) 0.172
Overall 77/192 (40.1) 51/192 (26.6) 0.006
Table 7.3: Sub-groups analyses performed for capsule endoscopy and non-capsule
endoscopy readers. Abbreviations: CE, capsule endoscopy.
Raters groups All images Diagnostic Category
Vascular Inflammatory Protuberant
All readers (n=7) 0.182 0.163 0.193 0.185
CE readers (n=3) 0.164 0.358 0.115 0.082
Non-CE readers (n=4) 0.301 0.3 0.318 0.29
Table7.4: Inter-observer agreement for a 1 reviewers (and per CE reviewing experience
groups) for all images and per diagnostic category. Abbreviations: CE, capsule
endoscopy.
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Figure 7.3 Example of phantom models in 2-D and their 3-D image representations.
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Figure 7.5: Example of inflammatory lesions (2-D) and their 3-D image representations
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Hardware-based reconstruction is based on stereoscopic vision, where multiple
image sensors are used to provide the necessary information for depth retrieval.
Stereoscopic approaches utilize at least two images - of the same target - at two
different angles of view. Hence, a typical 3-D imaging system comprises two
independent cameras, each camera contributing one viewpoint. However, inclusion
of two cameras within a CE device to create a stereo-image can be unwieldy (Fisher
and Hasler 2012). Therefore, a couple of important 3-D hardware-enabled
endoscopy technologies have been proposed (Kolar et al. 2009), presenting a system
that can give - in real time - both 3-D and texture information using an infrared
projector and a CMOS camera; the major disadvantages of this system are its size
and power consumption. Lately, thera are promising reports for endoscopic 3-D
imaging that uses a single lens system. This technique creates two viewpoints in a
single-lens camera by placing a bipartite filter at the limiting aperture, but this is
still to be incorporated in a small-bowel CE device.
Therefore, in the current absence of a hardware-enabled 3-D reconstruction
Karargyris et al. (2011), recently proposed the use of a 3-D software-enabled
technique (SfS) for CE videos. The algorithm is very fast and 'behaves' reasonably
well with specular textures (Koulaouzidis and Karargyris 2012). Eventually, all SfS
techniques, such as the linear method of Tsai, take a single 2-D input signal, i.e. a
conventional small-bowel CE image and through a series of mathematical
transformations (energy minimization) produce a corresponding 3-D representation
image. Strictly from a mathematical point of view, since 3-D represented images are
derived from monocular 2-D conventional CE images, only visualization changes.
Essentially, this means that the image information does not change.
In order to assess the usefulness of this 3-D representation approach in small-bowel
CE, we conducted a feasibility study including (a) a task simulator and (b) a clinical
part. In the latter, we included reviewers from a wider endoscopic audience and not
only CE readers. Moreover, the clinical small-bowel CE images we selected cover a
wide range of findings in CE, and they were categorised as per group/type of
finding and type of small-bowel CE system used to produce the 2-D image.
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Overall, the simulator showed that 3-D representation software gives a 90%, 70%
and 45% accuracy when it comes to predicting the protruding, or not, nature of red,
yellow and white phantom models, respectively. Furthermore, the clinical study
showed that in using 3-D representation software in images obtained from small-
bowel CE, about a quarter (26%) of them present enhanced visualization features, as
compared to their 2-D conventional counterparts. This effect is independent of the
type of small-bowel CE system used (see Table7.2).
Having observed increased accuracy of the 3-D software for red-coloured phantoms
and less so for yellow- and white-coloured, it is not surprising that major
improvement is observed for vascular lesions (56%), whereas moderate (23%) and
low (<10%) is noted for inflammatory and protruding findings, respectively.
Recently, it has been reported that vascular lesions represent the majority of small-
bowel pathology identified by means of capsule endoscopy and account for about
50% of small-bowel CE diagnostic yield in patients with obscure GI bleeding (Liao
et al. 2010). An improved visualization using 3-D reconstruction was shown only for
vascular lesions. It is of course to an extent inopportune that findings presenting
better delineation with 3-D enhancement, i.e. angioectasias, are those most easy to
recognize using a standard visualization. This is likely to be due to the fact that
vascular lesions, even those of small size, present a clear margin, a well-defined
lesion border and a definite colour difference with the surrounding mucosa. One
could argue that regularly implementing this image-enhancement tool in small-
bowel CE could lead to improved vascular lesion detection. Furthermore, perhaps it
would be clinically relevant to further investigate whether 3-D representation may
provide a classification of such lesions in order to identify those at higher risk of
bleeding (Spada et al. 2011).
The most difficult lesions to be visualized and categorized are flat/concave lesions
and/or neoplastic lesions where the improvement of 3-D reconstruction seems to be
marginal. One might expect that a 3-D representation would perform best in
enhancing differences between flat and protruding lesions; certainly, the results of
the task simulator were reassuring in this regard. This has not become evident
though in our second-stage clinical assessment. A plausible explanation is that real-
life protruding small-bowel structures or lesions are not necessarily entirely, or
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solely, red and more likely to have mixed colouring or be similar to that of the
surrounding mucosa (e.g. AoV, small-bowel polyps or masses etc.). Furthermore,
lack of insufflation in SBCE often causes a protruding lesion to appear only in part
in the video frames as a 'fold between folds', i.e. not as a defined luminal
protrusion. Even for experienced CE readers, protruding lesions often represent a
significant diagnostic challenge, particularly when the distinction between masses
and bulges is at stake (Girelli et al. 2011). Nevertheless, readers with CE experience
noted a significantly higher improvement as compared to non-CE readers (44.9% vs
17.4%).
Interestingly, when we analysed the evaluation results based on the assessor's SBCE
experience, it became obvious that physicians experienced in CE review, i.e.
assessors most used to 2-D SBCE images of small-bowel pathology, described a
significantly higher image improvement with the use of the 3-D enhancement tool,
38/50 vs 24/50 (P = 0 .007) and 31/69 vs 12/69 (P = 0 .008), for angioectasias and
protruding findings, respectively. Conversely, in the inflammatory lesions image
group, both CE and non-CE readers agreed that 3-D offered only a limited
textural/feature enhancement with 8/73 vs 15/73 respectively, P = 0 .172. These
results may simply reflect familiarity with SBCE reviewing software and/or image
manipulation or merely enthusiasm bias. In that respect, we believe that including a
diverse group of GI endoscopists - all with advanced image-interpretation skills but
variable experience in CE images interpretation - provides a more balanced
evaluation of this enhancement tool.
The present study has few limitations: firstly, in order to test the performance of the
3-D software, we selected high-clarity small-bowel CE images; hence, we do not
know if our results can be reproduced with images obtained in everyday SCBE
practice, where the presence of intraluminal debris or opaque fluid can affect the
overall visibility and 3-D representation of small-bowel findings. Secondly, the
heterogeneous group of raters/assessors could be considered by some as a potential
limitation of this evaluation. Thirdly, although we attempted a subgroup analysis
per type of small-bowel CE system, raters where not blinded to the brand of small-
bowel CE used to obtain the 2-D image, as eventually the two small-bowel CE
systems produce images with different characteristics. Furthermore, some inherant
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limitations of the software should be taken into account, i.e. many objects in the real
world are dielectric and homogeneous, hence displaying dual reflections. In fact,
this might be responsible for the only fair inter-observer agreement of this study.
Most digestive structures fall into this category. Therefore, when the light beams fall
on to such an object, some of them reflect back immediately, creating the specular
reflection; the rest firstly penetrate the object and then reflect, creating the diffuse




Until optics technology matures enough to allow a hardware-enabled 3-D
reconstruction of the GI tract (Barkhoudarian et al. 2013; Kolar et al. 2010), 3-D
representation software offers a plausible alternative for 3-D representation of
conventional CE images. The present study, the first of its kind, examines the
potential usefulness of 3-D representation based on subjection evaluation by
experienced CE reviewers. However, further analysis of the clinical validity of 3-D
on diagnostic accuracy is needed; therefore, the main aim of the following chapter is
to evaluate the effect of 3-D software application on diagnostic accuracy.
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CHAPTER 8
Revisiting the 'mass or bulge' question in small-bowel
capsule endoscopy with the help of three-dimensional
reconstruction software.
8.1 Introduction
8.2 Materials and methods
8.2.1 Phase 1 - choosing the optimal angle for 3-D video reconstruction







8.3.1 Phase 1 - choosing the optimal angle for 3-D reconstruction





Since its introduction in clinical practice in 2001, small-bowel CE has become a
prime mode for the evaluation of the small-bowel in several clinical settings such as
OGIB and CD (Wang et al. 2013). In this context, small-bowel CE has a high DY and
a positive impact on cost-effectiveness and patient management (Marmo et al. 2007;
Gerson 2012). The commonest small-bowel findings, i.e. angioectasias, ulcers
and/or luminal stenosis, are easy to recognize and they are rarely missed (Lewis et
al. 2005). Conversely, large small-bowel protruding lesions, e.g. small-bowel mass
lesions can be missed by CE; hence the value of a negative small-bowel CE in
excluding sinister small-bowel pathology remains unclear (Chong et al. 2006; Baichi
et al. 2007; Postgate et al. 2008; Lewis et al. 2008; Zagorowicz et al. 2013).
Furthermore, those of us who routinely read SBCE studies will attest that luminal
protrusions in SBCE are a common finding.
Luminal protrusions with changes in colour (erythema) and signs of mucosal
disruption (exudates, erosions and ulcers) are highly suggestive of a neoplastic
process; in the majority of cases though, the CE appearance of mass lesions is not
dissimilar to that of innocent mucosal bulges (MB). MB are defined as round,
smooth, large-based luminal protrusions with ill-defined boundaries, resulting
either from loop angulations and/or impression from adjacent loops/structures
(Girelli and Porta 2008; Mergener et al. 2007). They are benign endoscopic findings
of no clinical significance (Wang et al. 2013; Islam et al. 2013). Therefore, an accurate
distinction between masses and MB is crucial, as missing a tumour can eventually
jeopardize a curative resection and patient prognosis; on the other hand,
misclassifying an innocent small-bowel MB as a neoplastic mass may lead to
unnecessary, invasive and - most of the time - expensive procedures.
Therefore, software tools, e.g. FICE, Blue Mode and/or SBI have been developed to
assist capsule reviewers with the, so called, 'difficult' to characterize small-bowel
lesions (Koulaouzidis et al. 2013). Furthermore, research has been recently carried
out to produce 3-D reconstruction of the GI tract using stereoscopic vision methods
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(Kolar et al. 2010). However, as aforementioned (chapters 6 and 7), due to
technological limitations, i.e. packaging in capsule-size endoscopes and power-
consumption constraints, hardware-enabled 3-D reconstruction of the intestinal
lumen is yet to be available (Karargyris and Bourbakis 2011; Koulaouzidis and
Karargyris 2012). Over the last few years, software that enables 3-D
representation/approximation (SfS) from monocular 2-D small-bowel CE images
has been developed. This software recovers the shape of objects from 2-D images
using gradual variation of shading (Tsai and). In the previous chapter, it is evident
that the application of such software in CE leads to improved visualization/image
enhancement for a significant proportion of vascular and protruding small-bowel
lesions (Koulaouzidis et al. 2013). However, this reconstruction has been applied
only to still images, not to video segments, and it is not clear whether the subjective
enhancement is associated with a clear clinical impact; furthermore, the majority of
studies performed thus far were focusing more on technical aspects, i.e., quality of
images/visualization (Fan et al. 2010; Prasath et al. 2012; Koulaouzidis et al. 2013)
than on clinical issues, i.e. reaching a diagnosis (Ciaccio et al. 2013).
In this two-phase study, we aimed to evaluate whether coupling the standard 2-D
(s2-D) video clips with a 3-D reconstruction enhanced the performance of small-
bowel CE readers (with different levels of CE experience) in distinguishing masses
from innocent MB.
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8.2 Materials and methods
8.2.1 Phase 1 - choosing the optimal angle for 3-D video reconstruction
PillCam®SB2 (Given®Imaging Ltd, Yoqneam, Israel) captures two 2-D fps. These
images are displayed in sequence, as the relevant proprietary software (RAPID®)
generates a video that gives the impression of movement of the capsule through the
small-bowel. In order to recreate 3-D video clips for the purpose of this study, short
2-D video segments were selected and 'broken down' into the frames that
constituted them. Individual frames were 3-D reconstructed and recompressed to
relevant 3-D videos. For this task, dedicated 3-D visualization software was
developed in a Mathworks©Matlab environment. It should be noted that when a
single image is reconstructed in 3-D, the user can manipulate the viewing angle and
rotate at 360°degrees and zoom in/ out, whereas there is no freedom to rotate the
viewing angle of all the 3-D images stitched together in a 3-D video. For this reason,
before proceeding with the main evaluation, it was necessary to decide which is the
optimal viewing angle for 3-D reconstruction of individual frames before they are
stitched back again into a 3-D video.
To select the best angle for reconstruction, 10 three-minute-long, 2-D small-bowel
CE videos (containing about 360 frames each), depicting small-bowel luminal
protrusions (small-bowel cancer 1; polyps 3; bulging 4 and AoV: 2) were selected by
an expert small-bowel CE reviewer (GM), de-identified and stored in a folder for
further processing. Using the aforementioned software, for each standard s2-D
video clip, a corresponding 3-D clip was reconstructed at 25°, 35°, 45°, 55°, 65°, 75°,
and 85° degrees. This resulted in a total of 70 short 3-D video clips (Figure 8.1).
Three experienced small-bowel CE reviewers (AK, SD, ER), all with extensive
experience in small-bowel CE and blinded to each other (but aware of the finding
depicted in each video-clip), reviewed the clips in random order. Prompted by the
question:
166
'Is this 3-D reconstructed video clip helpful in facilitating the elevated
lesion/structure from the surrounding mucosa in the clip?'
they were asked to assign a number between 1 (not helpful) and 5 (very helpful), for
each of the seven different angles of 3-D reconstruction of each 2-D video.
Thereafter, the scores were tallied (the maximum score for each group of ten 3-D
reconstructed videos - at a certain angle - was 50); the 3-D reconstruction angle
with the higher score was used for the rest of the 3-D video reconstructions in phase
2 of this study.
8.2.2 Phase 2 - evaluation of 3-D video reviews
8.2.2.1 Video selection
For phase 2 of this study, three gastroenterologists experts in small-bowel CE (CG,
MS, LF) selected and de-identified short (5 min) video clips (from an equal number
of SBCE examinations performed in two centres CG and LF - Ospedale Busto
Arsizio, Milano; MS - Ospedale San Carlo Borromeo, Milan, Italy) containing either
masses or MB. If obvious endoscopic markers of possible malignancy (i.e. mucosal
disruption, surface ulceration, active bleeding) were identified, the videos were
excluded. All small-bowel CE examinations were performed with the capsule
system used in the first phase of the study. Small-bowel CE was carried out after an
overnight fast and bowel cleansing by 2 1 of polyethylene glycol (PEG) solution,
taken the afternoon prior to the small-bowel CE investigation. As per manufacturer
protocol, liquids are allowed two hours into the study and a light meal four hours
following the ingestion of the capsule.
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Figure8.1:Two2-Dsmall-b welCEfra esreconstructedi3u ingthSfSalgorithm7ngle(25°,5°,456 d85° degrees).Abbreviations:2-D,two-dimen ional;CEcapsuleendosc py3hree dim l;SfSshape-from- had ng.
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8.2.2.2 Video evaluation
Videos clips were de-identified, encoded to ensure blind review and stored in a
dedicateci Dropbox™ folder. The Matlab® software reconstructed the 3-D videos at
the optimal 3-D viewing angle (as per the first phase of the study). These videos
were uploaded to the shared folder on Dropbox™. The folder was shared among
the reviewers for easier access.
Two small-bowel CE readers groups were involved in the evaluation: a group of
small-bowel CE experts (n = 3; all >1,000 small-bowel CE reviews; more than 10
years of experience), and a group of novice readers (n =3; competent in conventional
digestive endoscopy, familiar with the SBCE system, who received training on CE
for the purpose of this study, but not completed >10 SBCE reviews, nor working
with SBCE in routine clinical practice) (Rajan et al. 2013). To avoid any possible
'referral bias' in evaluating video clips, the readers were unaware of the clinical
indication to small-bowel CE.
All readers, blind to each other and in a random order, reviewed first the s2-D
small-bowel CE videos (provided to them in avi. format) and then 5-7 days later, in
order to minimize the 'recall' bias, the 'combined' 2-D+3-D video clips (Figure 8.2).
In the 'combined' 2-D+3-D view the reader was able to visualize side to side the 2-D
and the reconstructed 3-D video of the same patient; he/she was free to visualize
them in sequence or at the same time and to repeat the visualization several times.
For each case, the diagnosis (mass or MB) reached after s2-D and 2-D+3-D review -
by each individual reader and group - was compared with that of the reference
standard (RS) (Figure 8.3).
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Figure 8.2: Two small-bowel CE frames depicting a mass (A) and bulging (B) with their
corresponding 55° 3-D reconstruction. Abbreviations: CE, small-bowel capsule
endoscopy; 3-D, three-dimensional.
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Figure 8.3: Flowchart of study phase 1 (left side) and phase 2 (right side).
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8.2.3 Reference standard
In our study, the presence of a small-bowel mass has to be confirmed by histology
(reference standard for positive diagnosis) or excluded after a complete diagnostic
work-up and clinical follow-up (reference standard for negative diagnosis). For
these purposes all the included patients receiveci an individualized diagnostic
work-up including computed tomography enterography (CTE), and/or magnetic
resonance enterography (MRE), and/or antegrade or retrograde double-balloon
enteroscopy, and/or surgical exploration, as necessary. If after the diagnostic work¬
up no mass was found, patients were clinically followed-up for a period of six
months prior to medical discharge, and the finding identified by small-bowel CE
was therefore defined as an innocent MB (Figure 8.3).
8.2.4 Statistics
Individual and per-reader group (experts/novices) sensitivity, specificity, positive
and negative likelihood ratios (LR) were calculated for each of the reviewers.
Diagnostic accuracy [true positive (TP) + true negatives (TN)/TP + false positive
(FP) + false negative (FN) + TN)] and precision (TP/TP+FP) were also calculated. In
addition, individual and summative receiver-operating characteristics (ROC)
analysis was undertaken. The ROC curve is initially constructed by plotting the
sensitivity and the false positivity (1-specificity) for each reviewer. The ROC curve
is then constructed to fit these points. The area under the ROC curve (AUC) is then
calculated. An AUC close to 1.0 signifies that the test has near perfect discrimination
and AUC close to 0.5 suggests poor discrimination (Plarrell et al. 1996). The AUC
comparison was performed by comparing the square of their standardized
difference to the quartiles of the chi-square distribution. The analyses were
performed with stata 13 (©Copyright 1996-2013 StataCorp LP, Texas, USA) using
the function roccomp as described in detail elsewhere (Hanley et al. 1983; DeLong et
al. 1988).
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Inter-observer agreement, for each group and each reviewing session, was
measured by the kappa statistic using the Randolph's free-marginal multi-rater
kappa; k (Randolph 2005). In 1981, Brennan and Prediger suggested using free-
marginal k when raters are not forced to assign a certain number of cases to each
category and using fixed-marginal k when they are (Brennan and Prediger 1981). A
negative value represents agreement worse than chance, whereas values in the
range of 0 to 0.25, 0.25-0.50, 0.50-0.75 and 0.75-1.00 represent poor, fair, good and
near perfect agreement, respectively (Landis and Koch 1977).
8.2.5 Ethics consideration
This study was conducted in accordance with established research ethics guidelines.
After review by the local ethics committee, further specific ethical review and
approval were not required, as the study was considered an evaluation of
previously collected endoscopy images, using data already obtained as part of
regular clinical care. Patients gave their written, informed consent for the studies
undertaken a part of clinical workup.
8.3 Results
8.3.1 Phase 1 - choosing the optimal angle for 3-D reconstruction
The 3-D video reconstruction at 55° obtained the highest score from each of the
three experts individually (38/50, 28/50 and 33/50 respectively) as well as
summative (109/150) and mean score (3.7/5). Scores obtained by the three expert
readers are tabulated in Table 8.1.
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Videos reconstructed at 25° degrees 11/50 13/50 23/50 47/150 1.6
Videos reconstructed at 35° degrees 18/50 16/50 19/50 53/150 1.8
Videos reconstructed at 45° degrees 27/50 21/50 25/50 73/150 2.4
Videos reconstructed at 55° degrees 38/50 38/50 33/50 109/150 3.7
Videos reconstructed at 65° degrees 36/50 29/50 32/50 97/150 3.2
Videos reconstructed at 75° degrees 23/50 37/50 32/50 92/150 3.0
Videos reconstructed at 85° degrees 15/50 31/50 29/50 75/150 2.5
Table 8.1: Summative and mean score for 3-D reconstructed videos according the
angle of view. Abbreviation: 3-D, three-dimensional.
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8.3.2 Phase 2 - Distinguishing between mass and bulge (with 3-D
review)
Thirty-two short videos were selected (25 contributed by CG and LF; 8 by MS).
Thirteen of them were classified by the RS as depicting masses and 19 MBs. More
specifically 6 neuroendocrine tumours, 5 gastrointestinal stromal tumours and 2
adenocarcinomas were finally diagnosed.
The sensitivity, specificity, positive and negative LR for individual reviewers is
presented in Table 8.2. In the 2-D video reviews, the summative diagnostic
accuracy/precision for experts and novices were 0.87/0.65 and 0.79/0.5,
respectively. In 'combined' 2-D+3-D video reviews, the relevant values for experts
and novices were 0.81/0.52 and 0.87/0.79, respectively.
The summative AUC for the expert and novice groups with s2-D review was 0.74
and 0.5, respectively (P = 0.0053). The summative AUC for the expert and novice
groups with 'combined 2-D+3-D' review was 0.70 and 0.57, respectively (P =
0.1846). Comparing the 2-D and the 2-D+3-D video reviews, no statistical difference
in the AUC was observed among experts (P = 0.245), while a significant
improvement was observed among novices (P = 0.049). The AUC for each of the two
CE reviewers groups with 2-D and 2-D+3-D (as well as the summative ROCs) are
showed in details in Figure 8.4 and Table 8.3.
In 2-D review, the inter-observer agreement (a:) of experts and novices was 0.71 and
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1-Specificity
Area under the ROC curve (AUC)
• Novicel (AUC=077) —♦--- Novice2 (AUC=0.68)
Novice3 (AUC=0.77) —All Novices (AUC=0.50)
Reference
Area under the ROC curve (AUC)
• Novicel (AUC=0.77) — -— Novice2 (AUC=0.68)
Novice3 (AUC=0.82) *-■- All Novices (AUC=0.57)
Reference
Figure 8.4 A: ROC curves for novices reading with 2-D (top figure) and 2-D+3-D videos




Area under the ROC curve (AUC)
• Expertl (AUC=0.87) -- --- Expert2 (AUC=0.87)
»— Expert3 (AUC=0.84) —*-■- All Experts (AUC=0.74)
Reference
Area under the ROC curve (AUC)
<• Expertl (AUC=0.92) —► Expert2 (AUC=0.82)
Expert3 (AUC=0.86) All Experts (AUC=0.70)
Reference
Figure 8.4 B: ROC curves for experts reading with 2-D (top figure) and 2-D+3-D videos
(bottom figure). Abbreviations: ROC, receiver operating characteristics; 2-D, two-
dimensional; 3-D, three-dimensional.
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Type Group AUC [95% CI]
2-D Expert 1 0.87 0.746-0.995 .06
Expert 2 0.87 0.746-0.996 .06
Expert 3 0.84 0.712-0.976 .07
All experts 0.74 0.580-0.902 .08
2-D+3-
D
Expert 1 0.92 0.837-1.0 .04
Expert 2 0.82 0.704-0.923 .06
Expert 3 0.86 0.736-0.977 .06
All experts 0.70 0.561-0.836 .07
2-D Novice 1 0.77 0.617-0.913 .08
Novice 2 0.68 0.520-0.836 .08
Novice 3 0.77 0.612-0.923 .08
All novices 0.50 0.327-0.665 .09
2-D+3-
D
novicel 0.77 0.612-0.923 .08
novice2 0.68 0.520-0.836 .08
novice3 0.82 0.679-0.960 .07
all novices 0.57 0.396-0.750 .09
Table 8.3: Area under the ROC curve (AUC) of novices and experts in reading 2-D and
2-D+3-D reconstructed videos. Abbreviations: 2-D, two-dimensional; 3-D, three-
dimensional; CI, confidence interval; SE, standard error.
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8.4 Discussion
The present study confirms that the distinction between masses and bulges, in the
s2-D small-bowel CE videos, remains a challenging task (even for expert CE
readers); nevertheless, as expected, experienced readers perform better than
novices. Noteworthy is that the addition of 3-D reconstructed video clips to the s2-D
small-bowel CE reading software does not improve the performance of experts,
while it significantly improves the performance of novice readers.
Small-bowel CE is an effective method of evaluating the small-bowel mucosa and it
has been proved to have a higher DY when compared to other diagnostic
techniques for the study of the small-bowel (Wang et al. 2013; Koulaouzidis et al.
2013). Since the advent of wireless CE, the small-bowel tumour detection rate has
risen to 2-9% in those presenting with OGIB (Rondonotti et al. 2008). The greatest
increase was seen in carcinoid tumours, followed by lymphomas and
adenocarcinomas (Rondonotti et al. 2008; Islam et al. 2013). Nevertheless, several
studies showed that SBCE can miss large (often sinister) protruding mucosal lesions
(Postgate et al. 2008; Zagorowicz et al. 2013). The presence of a 'mass' can be the
result of several processes, e.g. mucosal disruption by underlying pathology, a
lesion with intact overlying intact mucosa (either due to submucosal or
extramural/extrinsic origin) and/or false positive findings from bowel contraction,
loop angulation or even intussusception (Mergener et al. 2007; Girelli and Porta
2008). Moreover, it has been shown that both the inter-observer agreement and the
detection rate of significant findings are low, regardless of the readers' experience
(Rondonotti et al. 2012; Zheng et al. 2012). A plausible explanation is that in
conventional endoscopy, air insufflation (together with the ability to probe and/or
take biopsies) are helpful in distinguishing between masses and innocent MB,
whereas in CE this 'luxury' is lacking. Furthermore, a small-bowel lesion can be
depicted only in a few frames and/or a mass may only be seen tangentially and it
cannot be biopsied or probed (Wang et al. 2013; Islam et al. 2013).
False-positive findings are not uncommon either, therefore, the differentiation
between masses and bulges in SBCE is still challenging (Islam et al. 2013). This is
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clearly demonstrated by the performance of expert reviewers in evaluating s2-D
video clips, where the summative diagnostic accuracy is high, albeit <90%.
Furthermore, about 15% of cases are wrongly classified; interestingly, in 9% of cases
a mass is classified as a MB, 'preventing' further work-up and eventually altering
the prognosis of a potentially curable malignancy (Rondonotti et al. 2008). This is
even more evident in the novices group, with a significant lower accuracy and AUC
than the experts, confirming that experience seems to be a key factor in CE,
influencing the correct evaluation of difficult findings.
To overcome the aforementioned confounders, a couple of novel indices/scoring
systems (aiming to discriminate a mucosal bulge from a mass on CE) have been
developed. Shyung et al. (2009) reported a score composed of five parameters, i.e.
bleeding, mucosal disruption, irregular surface, colour and the presence of white
villi. Small-bowel mass lesion is probable with a score >4, while a score of <2
indicates a low probability of a sinister lesion (Mergener et al. 2007; Shyung et al.
2009). However, this index takes into account 'high-risk' features such as bleeding,
mucosal disruption and irregular mucosal surface, i.e. clear endoscopic markers of
malignancy, adopted in the consensus statement (2006/2007) of a panel of
international experts in capsule endoscopy as helpful discriminators (Mergener et
al. 2007). More recently, Girelli and Porta noted that a smooth, round, protruding
'mass' exhibits the following characteristics when it is associated with the innocent
MB: (1) an ill-defined boundary with the surrounding mucosa, (2) a diameter larger
than its height, (3) no visible lumen in the frames in which it appears, and (4) an
image lasting less than 10 minutes (Girelli and Porta 2008; Islam et al. 2013). Based
on this observation, in a subsequent study, Girelli et al. proposed the Smooth
Protruding Index on Capsule Endoscopy (SPICE) score (Girelli et al. 2011). A SPICE
score of >2 has 83% sensitivity and 89% specificity for tumours (Girelli et al. 2011).
Other attempts to differentiate tumours on CE include an automated scale that uses
wavelet-based analysis in CE images; this has a reported 95% sensitivity and
specificity (Kobayashi et al. 2012). Conversely, FICE offers no benefit in this setting
over the standard reviewing mode (Kobayashi et al. 2012; Duque et al. 2012).
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Therefore, we thought that software offering 3-D reconstruction - hence
emphasizing certain endoscopy features such as the perception of depth and
volume differences between the objects - could allow resolution of diagnostic
dilemmas in such a setting. Furthermore, to the best of our knowledge, all previous
studies on 3-D reconstruction were performed with individual frames/images (Fan
et al. 2010; Prasath et al. 2012; Koulaouzidis et al. 2013; Ciaccio et al. 2013). The
majority of these studies focused on technical issues (i.e. image quality,
visualization) rather than on clear clinical issues (Fan et al. 2010; Prasath et al. 2012;
Koulaouzidis et al. 2013). It is well known that in CE the video component is as
crucial in the final intepretation (MB flattens with peristalsis) as cautious reviewing
of still frames. Our data suggest that this new system does not have any impact in
discriminating masses from bulges (when expert readers are involved). One can
argue that the level of expertise of those involved in this study (experts> 1000 small-
bowel CE reviews, longer than 10 years of clinical experience) negatively biased the
contribution of the new software in this subgroup.
Furthermore, the fact that they are used to working with the s2-D software can
explain why the introduction of the new feature might be challenging (Prasad and
Cifu 2011). On the other hand, we selected novices who were already familiar with
the s2-D and received training similar to that proposed by the American Society of
Gastrointestinal Endoscopy (Rajan et al. 2013), but were at the beginning of using
CE. Therefore, our results suggest that, although the new software cannot substitute
clinical and small-bowel CE experience (even after the 3-D reconstruction novices'
performance was poorer than those of experts) it may be helpful in the training
phase by - potentially - shortening the learning curve.
This study has some limitations including small sample size (a consequence of the
relative rarity of small-bowel tumours) and the inflexibility of the selected video
clips review (short video clips in .avi format - it was not possible to modify review
speed or change the angle of view). In addition, we decided to include only patients
whose diagnosis was confirmed by a widely accepted 'hard' RS. Consequently, we
selected cases by excluding all those with endoscopic high-risk 'stigmata' of mass
lesions. However, the time for follow-up of six months may be seen as not adequate
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for a complete assessment of this group.
Another possible limitation is a bias introduced by the combined evaluation of the
3-D reconstruction and the s2-D, instead of the 3-D reconstruction alone, of which
we were fully aware. Nevertheless, we decided to combine 2-D with 3-D as the
reconstruction of an eight-hour-long video in 3-D would require considerable time
and resources. We aimed to simulate a clinical scenario, similar to that of other
advanced endoscopic features (i.e. NBI, iSCAN, FICE), where the reader evaluates
the video in the s2-D mode and applies the new feature (in our study, 3-D
reconstruction) to a region of interest. The first phase of the study was performed to
overcome issues with image angle of view. However, we cannot be certain that the
angle chosen for 3-D applies to all lesions depicted in this current
study. Nevertheless, this means that there are areas of future research in the use of
3-D alone or in combination with other software tools (Iakovidis et al. 2006).
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8.5 Conclusion
The results of the present study confirm that the distinction between masses and
MB in SBCE is still a challenging task even for experienced readers. In this situation,
review experience seems to have a primary role. The addition of 3-D reconstruction
to the s2-D video reading software significantly improves the performance of novice
SBCE readers in distinguishing masses from MB, thus potentially shortening their
learning curve. Further studies are needed to test the feasibility of 3-D
reconstruction in clinical practice and to evaluate the impact on the reviewing
process in terms of both time and DY.
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CHAPTER 9
Conclusions and future directions
Optimal DY in small-bowel CE requires not only optimal visualization of the small-
bowel mucosal surface and lumen, but also complete capsule transits through the
entire small-bowel, i.e. total enteroscopy. Therefore, it is expected that decreasing
GTT and SBTT will allow any capsule model to successfully reach the caecum by the
end of its battery life (currently an average of 10-12 hours should be considered).
The results of the conducted meta-analysis show that the use of prokinetics - and
specifically that of metoclopramide with purgative and/or RTV - in small-bowel CE
improves CR. The issue of improving CR in small-bowel CE is still contentious;
although it is anticipated that in the foreseeable future the use of newer capsule
endoscopes with extended battery life will improve both CR and - potentially - DY,
there is a constant interest in standardizing the small-bowel CE procedure. This can
only be seen, though, as a race against an ever-evolving technology. Historically, the
CR of SBCE has been reported at a low 80% rate. Recently published national
guidelines for the use of bowel preparation before video CE state that the use of
prokinetics in small-bowel CE is not recommended. However, in chapter 2 a
rigorous meta-analysis shows that, the 'smart', selective and judicious use (before as
well as during small-bowel CE) of prokinetics in combination with other modalities,
such as real time and/or purge, in improving the CR of SBCE.
Reading SBCE has certain limitations; firstly, the DY is usually dependent on the
experience of the reader. Secondly, the uncontrolled capsule movement does not
allow visualization of the entire small-bowel mucosa. However, the main limitation
is that an accurate complete review of the generated lengthy video streams is time-
consuming. Although there is no strict guidance for the best standard/conventional
SBCE reading technique and speed, the unique features of SBCE require the reader
to be intensely focused and alert. QV pre-read in urgent cases, but fails to show any
benefit in other clinical scenarios. Although the benefits of QV are outweighed to
some extent by a decrease in the overall diagnostic yield, this mode can be used
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confidently in overt OGIB in an urgent inpatient setting and in outpatients with
occult OGIB or suspected CD. As the usefulness of QV may vary, depending on the
number of small-bowel lesions, standard review settings are still recommended in
all other cases. Furthermore, the present study confirms that BM does not confer
any additional advantage in the QV setting.
Apart from BM, the use of FICE in CE is limited. Its use improved the
visualization/definition of mucosal aphthae/ulcers but made no difference to any
other lesion groups. Conversely, BM improved most of the images (overall image
enhancement 83%), with a range between 73.3% and 100%, in different lesion
groups. BM filter showed promising results and its use as the main viewing mode,
especially in cases of obscure GI bleeding, should be further examined in regard to
feasibility and in connection with the DY.
An improved visualization using 3-D reconstruction was showed only for vascular
lesions. The most difficult lesions to be visualized and categorized are flat/concave
lesions and/or neoplastic lesions where the improvement of 3-D reconstruction
seems to be marginal. One might expect that a 3-D representation would perform
best in enhancing differences between flat and protruding lesions; this was not
evident. A plausible explanation for this is that lack of insufflation in CE often
causes a protruding lesion to appear only in part in the video frames as a 'fold
between folds', i.e. not as a defined luminal protrusion. Until optics technology
matures enough to allow a hardware-enabled 3-D reconstruction of the GI tract, 3-D
representation software offers a plausible alternative for 3-D representation of
conventional CE images.
Furthermore, the validity of this software is in improving decision making in the
clinical scenario that is mass or bulge. The distinction between masses and MB in
SBCE is still a challenging task even for experienced readers. In this situation,
review experience seems to have a primary role. The addition of 3-D reconstruction
to the s2-D video reading software significantly improves the performance of novice
SBCE readers in distinguishing masses from MB, thus potentially shortening their
learning curve. Further studies are needed to test the feasibility of 3-D
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reconstruction in clinical practice and to evaluate the impact on the reviewing
process in terms of both time and DY.
An area of future research remains open for the software tested in this thesis as well
for other developments (software or hardware). However, it should not be forgotten
that true 3-D capability requires dual video images, although the inclusion of two
cameras within the shell of a capsule endoscopy might be unwieldy at present.
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The capsule procedure protocol of our unit
Strict liquid diet the day prior to the test, small-bowel purge (2 litres polyethylene
glycol; Moviprep®) with overnight fast. The capsule is ingested with 40-100 mg of
anti-foam (Simeticone, Infacol®) and Domperidone (usual dose 5 mg of liquid
prokinetic), unless stated otherwise. Prior to 2008, some patients - based on clinical
judgement, were given Metoclopramide.
The patients are allowed to drink clear fluids after 2 hours and consume a light
meal/ snack after 4 hours.
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This review presents issues pertaining to lesion detection in small-bowel capsule endoscopy
(SBCE). The use of prokinetics, chromoendoscopy, diagnostic yield indicators, localization
issues and the use of 3D reconstruction are presented. The authors also review the current
status (and future expectations) in automatic lesion detection software development.
Automatic lesion detection and reporting, and development of an accurate lesion localization
system are the main software challenges of our time. The 'smart', selective and judicious use
(before as well as during SBCE) of prokinetics in combination with other modalities (such as
real time and/or purge) improves the completion rate of SBCE. The tracking of the capsule
within the body is important for the localization of abnormal findings and planning of
further therapeutic interventions. Currently, localization is based on transit time. Recently
proposed software and hardware solutions are proposed herein. Moreover, the feasibility of
software-based 3D representation (attempt for 3D reconstruction) is examined.
Keywords: 3D reconstruction • capsule endoscopy • diagnostic yield • FICE • innovation • lesion detection
• small bowel • software
It has become customary — dare to say almost
cliche — for every review paper on capsule
endoscopy (CE) to start with a statement along
those lines: the advent of wireless capsule
endoscopy has revolutionized the investigation
pathways for the small bowel (i|. Admittedly,
since its official introduction in clinical practice
(2000) (2), CE has drastically changed clinical
decision-making by restructuring our diagnostic
approaches and increasing the diagnostic yield
(DY). A wealth of evidence has confirmed the
validity of the use of CE in obscure gastrointes¬
tinal bleeding (OGIB) — the latter accounts for
60-70% of all small-bowel CE examinations
world-wide — and Crohn's disease (CD),
known and/or suspected [3], Other clinical indi¬
cations, although less common, are celiac dis¬
ease, small-bowel polyposis syndromes and/or
clinical or radiological suspicion of small-bowel
neoplasia 14-8]. To date, more than 2 million
capsules have been ingested worldwide and
>3000 PubMed-listed publications have
appeared in the medical literature (i|.
However, 'nothing endures but change' [9]
and every disruptive technology, such as CE,
brings new solutions together with new chal¬
lenges [io|. For instance, CE approaches an
almost 'physiological or airless endo¬
scopy' [9.11.12], Often, in digestive endoscopy,
air insufflation (especially over-insufflation)
leads to imaging difficulties as it can make
lesion edges difficult to detect [11]. Conversely,
the capsule moves passively - propelled by
bowel peristalsis - and images the intestinal
mucosa in a collapsed state [13], All commer¬
cially available CE devices are constructed fol¬
lowing the same baseline principles.
To begin with, the shape and volume of
any CE device is sufficiently small to allow it
to pass through the main anatomical sphinc¬
ters (cricopharyngeous, lower esophageal
sphincter, pylorus and ileocecal valve) wirhout
becoming an obstruction risk [13]. Nevertheless,
it is this same small size — in conjunction with
the peristaltic movements of the small
bowel - the 'Achilles tendon' of the capsule,
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predisposing the CE to rotate (or tumble) within the small-
bowel lumen. This frequently results in deficient luminal and/
or mucosal coverage [14]. The tumbling movements of the cap¬
sule (oblique-forward, oblique-reverse, perpendicular move¬
ments) often result in temporary visual interference that may
render the images unsuitable for diagnostic purposes [15], Fur¬
thermore, it is already known that even expert reviewers have a
limited ability to recognize the vector of capsule movement in
the small-bowel lumen or through anatomical sphincters [to-is].
The capsules' sheath is made of disposable and biocompati¬
ble plastic material, resistant to digestive fluids (in order to seal
and protect its internal components in the hostile 'milieu' of
the GI tract); the capsule weighs between 3.3 and 6 g (depend¬
ing on the CE model) (Tabu 1) (i). The internal compartment of
any CE device includes a complementary metal oxide semicon¬
ductor (CMOS) imager or a high-resolution charge coupled
device (CCD)-based chip camera, a short focal-length (hemi¬
spheric) and compact multi-element lens, a white-light illumi-
narion system — provided by four to six light-emitting diodes
(LEDs) —, two silver oxide batteries and a transmitter. At first,
it seemed that CMOS had advantages (as compared with
CCD) of lower cost and power consumption (requires about
1% of the energy of CCD), improved foveal activity (the abil¬
ity to select images at different sites on the chip), for them to
be built relatively and integrated 011 production lines with com¬
puter chips, but they had the disadvantage of inferior
quality [9],
The imager, which has no shutter, operates by taking still
frames in a dark environment intermittently illuminated by
LEDs throughout the capsule passage. Capsule endoscopes offer
an 8x magnification, and a minimum size of lesion detection
in the range of 0.1-0.2 mm. The CE device is activated by its
removal from a magnetic holder. Depending on the manufac¬
turer, the operating time of capsules can vary between 8 and
15 h (Tabu 1) [l]. Commercially available small-bowel CE mod¬
els can acquire and transmit between 0.5 and 16 frames per
second (fps) [l]. This results to a total of 50,000-120,000 trans¬
mitted images that are 'stitched' and converted to a continuous
video that gives the illusion of continuous digital video stream
recording without gaps. Two fps is, of course, much lower
than current standard television frame rates. Standard progres¬
sive frame rates have been 24 fps for sound motion pictures
since the 1920s [»|. Furthermore, PAL and SECAM television
is 25 fps and for NTSC television 30 fps. High-definition tele¬
vision systems use standards of 50 or 60 fps. These rates reduce
the perception of flicker by the human eye [9].
In our center, we have experience with two small-bowel CE
systems. Hence, in the next few paragraphs, we will briefly
describe the technical characteristics and specifications of these
two systems.
PillCam®SB
The first commercially available CE device (mouth-to-anus;
M2A®) was developed by Given" Imaging Ltd (Yoqneam,
Israel) and it was approved (for clinical use in humans) in
Europe and the USA in August 2000. Initially, its battery life
was about 6 h. The first generation of PillCamSB (essentially a
renamed M2A) was released in 2001, while the second genera¬
tion of PillCamSB was released in 2007 (PillCamSB2). The
latest commercial small-bowel PillCamSB CE model (Pill-
CamSB3) was released in 2013 17.15]. PillCamSB2, which is still
used in most centers, measures 11 X 26 mm and weighs
<4 g [1,4], It contains a miniature color video CMOS camera
with four illuminating LEDs, two batteries, a radiofrequency
(RF) transmitter and an antenna. Images are captured at a
rate of 2 fps for PiUCamSB2 or 4 fps for PiilCam SB2-4,
while the battery life is between 8 h (PillCamSB) and 12 h
(PillCamSB2ex) (Table 1) 14].
Due to increased field of view (156°), PillCam SB2 has a
broader mucosal coverage, as compared with 140° of its predeces¬
sor, and an effective visibility distance of 30 mm [19], The image
resolution of PillCam SB is 256 x 256 pixels. Advanced optics
and batttomatic automatic light control provide optimal image
quality and illumination. Therefore, at a reference working
distance of 4.5 mm, the coverage mucosal area of PillCam SB2 is
1100 mm2 as compared with 500 mm2 of its predecessor [19].
RAPID TM
The proprietary reading software of Given Imaging Ltd is the
RAPID TM Reader and through repeated developments it has
now reached its eighth version. This software interface provides
single, dual or quadruple window video review as well as addi¬
tional diagnostic features and study reviewing aids. It contains
an improved user interface similar to the ribbon toolbar con¬
cept used in Microsoft2' products, the Lewis Score calculator,
rhe Fujinon Intelligent Colour Enhancement (FICE), the sus¬
pected blood indicator ]ij, QuickView (QV), a thumbnail com¬
parison feature, backward compatibility with studies from
previous RAPIDTM software versions and an improved prog¬
ress indicator/localization guide.
MiroCam®
MiroCant (which stands for Micro Intelligent Robotic Object
Camera) has been developed by the intelligent Microsystem
center established by rhe Korea Ministry of Science & Technol¬
ogy in Seoul, South Korea, which was renamed to IntroMedic
Co Ltd in 2006 lis]. The company's small-bowel CE device
passed the European medical standards and received certifica¬
tion (CE mark) in 2007; it also received the US FDA approval
in May 2011 [3.8]. MiroCam (currently version 2, version 3 to
be released in 2014), utilizes a novel transmission technology,
the electric field propagation. This technology uses rhe capsule
itself to generate an electrical field and the human body as a
conductive medium for data transmission, in the so-called
human body communication. Perhaps this, in conjunction with
the set array of sensors, is the main reason for the persistent
failure of this CE model to capture upper esophageal and gas¬
troesophageal junction (Z-line) images [20].
Specifications of the MiroCam CE device include a size of
10.8 x 24.5 mm, a weight of 3.4 g, a field of view of 170°
doi: 10.1586/17474124.2014.952281 Expert Rev. Gastroenterol. Hehatol
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(150° of the first model), a resolution of 102,400 (320 x 320)
pixels and an image capture rate of 3 fps (Tabu: l) [l]. Illumina¬
tion is provided by six LEDs. As a power-saving method, it
incorporates two external electrodes and a single skin electrode
for electric data conduction across the human body. Hence, it
avoids the need for RF and allows for a long battery life with¬
out any need for image compression and a safer use in a signif¬
icant minority of patients, that is, those with implantable
pacemakers or in situ defibrillator devices [21,22]. Furthermore,
MiroCam remains the smallest commercially available small-
bowel CE device. The extra available space (10% free internal
space) could be used for additional internal components, such
as different sensors or stabilizing components for advanced CE.
The two systems have been repeatedly checked in head-to-head
trials and have been shown to have at least equivalent capabil¬
ity in detecting small-bowel disease [1.23].
MiroView™
MitoView v2.0, the proprietary reading software of
IntroMedic® Co Ltd, offers a variety of tools and functions to
aid reporting process. For instance, the function Range View
displays a range of images to readily identify landmarks in the
GI tract. In this mode, the side bar images will move one
image per second, while the center images will display images
per user selection, that is, 15 fps. Another function, the Map-
View, which is similar to Given Imaging Ltd color bar but
uses different technology and patent, displays a range of
thumbnail images to readily identify landmarks in the GI tract.
Furthermore, the Express View eliminates similar images and
the Range View can be used to identify landmarks and disease
pathologies by viewing a total of nine images before and after
the main image. In the image-enhancement field, MiroView
offers the ALICE and color mode functions. Admittedly, they
have not attracted clinicians' attention or any clinical studies
to date.
Diagnosis, DY & expertise in CE
Essentially, DY in CE is the combination of lesion detection
and lesion interpretation. CE procedure is not operator-
dependent and does not require the same technical skills as
conventional GI endoscopy [11,24]. Indeed, capsule administra¬
tion and swallowing requires only a couple of minutes and no
special skills — apart from obtaining an informed
consent [25] — on behalf of the healthcare professional. There¬
fore, accurate diagnosis and expertise with CE lies purely in
the ability of an individual reviewer to read and interpret the
CE findings [26]. Of note is that key indicators of expert inter¬
pretation (of any type of medical images) are consistent, accu¬
rate and efficient diagnostic performance, which requires not
only formal and dedicated training, but also a certain degree of
talent, aptitude and motivation [27].
So, in the end, despite great technologic advances, it boils
down to the CE reviewer and the act of observation [11].
Hence, vigilance is especially necessary when the task is long
and monotonous [11,28). As CE is a by and large a visual
informahealthcare.com doi: 10.1S80/17474124.2014.952281
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modality, it would seem that in order to optimize training, an
understanding of how visual perception and skills develop and
change as a function of experience would be beneficial (2729,30).
Nonetheless, although the latter is bound to improve with
experience, recent studies showed that the lesion detection is
not improving with the numbers of CE reviews (31).
There are certain reasons behind that. First, the average CE
video footage reading time varies between 30 and 120 min
depending on the small-bowel transit, quality of images and
the experience of the reader (11,23.32], Second, a small-bowel
lesion may only be visible in just a few or even just a single
frame (331. Not surprisingly, most physicians familiar with CE
review are concerned that lesions could easily be missed when
fast reviewing rates are applied [11]. Therefore, at a consensus
conference of CE users (International Conference of Capsule
Endoscopy) in 2002, it was agreed that 13 images per second
is the fastest acceptable rate for CE review (11,34). Conversely,
Fleischer [35] argued that the time required to read the studies
(60—90 min) does not make economic or practical sense [11.35],
Indeed, periods greater than 50 min increase the stress to the
observer no matter what the cue or event rare is [1136], Third,
it has been demonstrated that search patterns are somewhat
unique to the individual and tend neither to be uniform in
image coverage nor to alter with experience [27],
Although relevant work has been performed in other special¬
ties, for example, radiology and pathology, where it has been
shown that specialty experts generally adopt similar visual
search strategies [27], similar research experience in CE is lack¬
ing (apart from experts' opinion papers). Nevertheless, we
know from colonoscopy quality-improvement studies that pro¬
longing scope withdrawal time is associated with increased ade¬
noma detection rate [3738], Therefore, the current notion is that
large amount of visual information, for instance, CE footage,
requires focused and undivided attention for careful evaluation
by the CE reviewer 13239].
However, going (at low reviewing speed) through a rather
monotonous video recording, in a room with deemed lights, is
the perfect way for someone to become hypnotized [32]. To
date, only limited data address errors in CE lesion detec¬
tion [113233], As such, there is still significant heterogeneity in
reviewing modes and interpretation sessions timing and length,
lesion detection rates and reviewer competency, detect and
interpret capsule endoscopy [33,40,41]. Furthermore, there is also
limited published data concerning optimizing operator perfor¬
mance for interpretation of capsule endoscopy [33,42],
One proposed strategy to reduce CE reading times would be
to use trained non-physician readers (e.g., endoscopy assistants/
scientists) to pre-read the CE footage [24,43], (Table 2) [24,43-54],
However, training pre-readers is time consuming, not standard¬
ized and may not be feasible during regular business hours [44],
Furthermore, the majority of studies in this field attempt to
prove non-inferiority lesion detection (by physicians' extenders
or specialty nurses) instead of focusing on lesion interpretation.
The lack of an homogenous approach (viewing speed and/or
mode) in CE review seems to account for some of the reported
discrepancies in DY and inter-observer agreement on CE videos
interpretation [33.41.55], In the majority of these studies, how¬
ever, the gold standard was the physician's detection rate, a ref¬
erence 'shaky' enough as recent studies have shown [31],
Interestingly, there are currently no standardized, validated
training tools for capsule endoscopy. Couple of attempts by
Postgate et til. have not found wider acceptance [42,49],
Another approach is to use to special software programs to
select significant images for subsequent viewing [1,47], In light
of all that, several attempts have been made to develop techni¬
cal software features, in order to make CE video analysis easier
and shorter (without jeopardizing its accuracy or in other words
its DY). The first software feature designed for this purpose
was the suspected blood indicator, an automatic system able to
pick up, in a completely automatic fashion, frames containing
several red pixels and, therefore (theoretically) to detect blood
and or other red-colored lesions such as big angioectasias. Nev¬
ertheless, the accuracy profile of this tool is suboptimal and, at
the present time, it can be used only as supportive/adjunct tool
in CE reporting [l].
In a single-center prospective study, gastroenterology fellows
were trained in capsule endoscopy using a structured program
devised by the American Society of Gastrointestinal Endoscopy
and subsequently evaluated using a newly developed formalized
assessment tool called the Capsule Competency Test [26,56], The
capsule competency test score obtained by staff capsule endo¬
scopists was considered the gold standard; achievement of a
score that was 90% of that achieved by staff members was
taken as optimal competence. Of 39 fellows involved in the
study, the mean scores for trainees with <10, 11-20 and 21—
35 capsule endoscopy interpretations were 79, 79 and 85%,
respectively. Hence, the authors suggest that fellows need to
perform at least 20 supervised capsule endoscopies before they
can be certified as adequately trained [26,56,57],
Localization of capsule & lesion
Capsules do not provide localization information while travers¬
ing the GI tract [14,ss]. The tracking of the capsule within the
body is important for the localization of abnormal findings and
planning of further therapeutic interventions. Currently, locali¬
zation is based on transit time. Once the pylorus and cecum
are identified, the location of a lesion in the small intestine is
an estimate based on the time from one of these two points [ss|.
The output of these localization modules is a graphic trajectory
of the capsule while it moves along the intestinal lumen [8.59],
This method uses signal strength analysis from aerial antennae
attached to the patient's abdomen has been validated on
healthy volunteers against fluoroscopy [59].
However, this technique has been criticized for its inability
to definitively localize small bowel lesions, mainly because it is
prone to inaccuracy due to differences in small-bowel transit
time or variant anatomy [58], The average position error
reported for this technique is 3.77 cm, with a maximum error
reaching 11.4 cm [39.58,59], Most commercially available software
packages provide a 2D tracking application of the capsule
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route. More recently, 30 healrhy volunteers swallowed a CE
(EndoCapsule; Olympus, Japan) and then underwent five sets
of anteroposterior and lateral radiographs every 30 min while
the software calculated the position of the capsule. Average
error (and standard deviation) among the 3D coordinates
was X, 2.00 cm (1.64); Y, 2.64 cm (2.39) and Z, 2.51 cm
(1.83). The average total spatial error among all measurements
was 13.26 cm3 (22.72) [60).
On the other hand, an innovative capsule-based platform,
motility monitoring system (MTS2) by Motilis Medica SA, Lau¬
sanne, Switzerland enables monitoring of regional transit time
and a more accurate recording of capsule position. Furthermore,
in the research domain two main approaches have been explored
to retrieve positional information: magnetic field strength-based
methods and electromagnetic wave-based methods [14.58).
In magnetic field strength-based methods, a permanent mag¬
net is incorporated in the capsule, while an external array of
magnetic sensors is placed outside the patient's body. As the
capsule (with the incorporated magnet) moves, its magnetic
flux changes in magnitude and direction and the external sen¬
sors can measure these magnetic signals. In electromagnetic
wave-based methods, different electromagnetic waves have been
utilized with lower position information accuracy. To date,
only radio (RF) waves, visible waves, x-ray and gamma ray
have been explored in literature because of their high penetra¬
bility through human tissue 114.58).
In order to improve lesion localization in small-bowel CE,
we proposed a modified capsule which could incorporate locali¬
zation and — theoretically — stabilization capabilities. This con¬
ceptual design consists of a capsule fitted with protruding
wheels attached to a spring mechanism. This would act as a
miniature odometer, leading to more accurate lesion localiza¬
tion information in relation to duodenal entry. Furthermore,
this capsule could allow video stabilization as any erratic, non-
forward movement through the gut is minimized [14,61,62].
In 2014, a software capsule localization approach was also
presented [63). This approach is based solely on a video analysis
methodology for visual odometrv. It includes automatic detec¬
tion and tracking of points of interest, in consecutive CE video
frames and application of a motion estimation model to calcu¬
late the displacement and the rotation of the capsule in the GI
tract. Unlike the wheel odometry, visual odometry is not
affected by wheel slip in uneven terrain or other adverse condi¬
tions. It has been demonstrated that it can provide more accu¬
rate measurements, with relative position error ranging from
0.1 to 2% [64). Challenges with respect to its application in CE
include coping with intestine deformability and motility, and
coping with the presence of intestinal content.
DY & indicators
CE has advantages and disadvantages compared with other
diagnostic modalities that evaluate the small intestine. The
main advantage of CE is that it is a non-invasive technique
with little or no side effects or complications [3). Perhaps one
the main disadvantages of CE is that its diagnostic accuracy is
difficult to determine due to a lack of an adequate 'gold stand¬
ard'. Therefore, in the early days of CE, the term diagnostic
accuracy has been substituted with the term DY. Due to the
unique and intriguing nature of CE, DY is defined as the like¬
lihood that a test or procedure will provide the information
needed to establish a diagnosis [65).
In CE, the DY is influenced by several factors, integral to
the capabilities of the capsule device (e.g., CE device technolog¬
ical specifications, quality and percentage of intestinal mucosal
coverage), the challenging 'environment' of the small bowel
and reviewer's performance. To date, human studies have com¬
pared different methods of small-bowel examination, reporting
their comparative DY (l). The true negative diagnostic rate was
defined as the number of cases in which both methods of
examination were negative. This is certainly only an approxi¬
mation of a true yield. Historically, the DY of CE varies
between 38 and 83% [66,67].
One method to determine and — at a second stage attempt
to improve the DY of any diagnostic procedure — is to use
markers (at least some of which are in a difficult position to be
seen) that are present in every intestine and confirmed to be
there with another test. This was first done in 2000, by Apple-
yard et al. [67]. who sewed glass beads into the intestines of
dogs and then performed capsule endoscopy and push entero¬
scopy. The sensitivities were 64 and 37%, respectively. Another
solution (more applicable to humans) is to look for an anatom¬
ical finding, that is, surrogate marker present in everyone [68,69).
Therefore, over the last few years, clinical researchers have
highlighted the use of markers (some are in a position where
they are difficult to spot), which are present in the intestine as
quality assurance indicators in small-bowel CE [69].
The major duodenal papilla, or ampulla of Vater (AoV),
which is present in all individuals who have not undergone duo¬
denal resection and is located on the posteromedial aspect of the
duodenal sweep, 8—10 cm distal to the pylorus, is a reasonable
candidate marker. It is difficult to see, as the translucent dome
of the propelled CE tends to point toward the outer aspect of
sharply angulated bowel loops. On the other hand, choosing the
AoV as the marker and extrapolating the results of the detection
to polyp lesions may not be completely reliable [t,69,70).
The factors that make the AoV difficult to observe, such as
the location, size/lumen protrusion and capsule transit speed in
this intestinal segment, are only part of the reason why small-
bowel lesions such as polyps may be missed in the small-bowel
CE examination [69;'o]. Misinterpretation of a mass for a bulge
is an area of immense research and another potential pitfall of
the CE reader, no matrer what the experience level is [S.KU3,7i].
Moreover, the notion that 'we can only see what the small
intestine offers through its own aiming and propulsion of the
video capsule' has never been more contemporary [69]. Indeed,
with the advent of panoramic/side-viewing CE, it has become
evident that the AoV is not seen in vast majority (as it was
expected) and that the panoramic views (at least at present) are
not panacea in CE [Koulaouzidis A, Bartzis L, Plevris JN. abstract in UEGW
2014, 2014, Unpubushed Data] [72], Maneuverer ability and external
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control of capsule during its entire journey within the small
bowel is the next [73,74] frontier, which should not be far
from realization.
The issue of prokinetics in small-bowel capsule
endoscopy
Maximum DY in small-bowel CE requires not only optimal
visualization of the intestinal mucosal surface, but also com¬
plete capsule transit through the entire small bowel [75.76). Cur¬
rently, one of the major limitations of small-bowel CE is the
high rate of incomplete examinations, that is, the percentage of
cases in which the capsule does not reach the cecum by the
end of the recording period and/or exhaustion of capsule's bat¬
tery life. Recent systematic reviews showed that the completion
rate (CR) of small-bowel CF, varies between 81.3 and 83.5%
(for retrospective and prospective studies, respectively) [1.66]. If
complete enteroscopy is not achieved, concerns remain over
missed small-bowel pathology [77]. This could lead to repeated
or new investigations increasing healthcare costs.
Risk factors for incomplete CE include intestinal dysmotility
(e.g., prior small-bowel surgery, diabetes mellitus), immobility/
hospitalization, patient's age, moderate or poor bowel cleansing
and a delayed gastric transit time >45 min [78-81], Furthermore,
the presence of small intestinal debris, chyme, biliary secretions
and/or ait bubbles can interfere with the visualization quality
and potentially affect the DY. However, reducing small-bowel
transit time may influence the DY of CE. With colonoscopy,
the detection rate of neoplastic lesions is higher when the time
to withdraw the colonoscope is longer [821. It is conceivable
that a similar principle also applies for small-bowel CE.
Therefore, it is expected that decreasing gastric transit time
and small-bowel transit time will allow a capsule to successfully
reach the cecum by the end of its battery life. To this end, a
variety of prokinetic agents has been used. Metoclopramide
remains the most commonly administered prokinetic [1,5.83].
Domperidone, an antidopaminergic agent, on the other hand
has not been widely used in small-bowel capsule endoscopy
and the evidence base is limited [1,5.84], Unlike metoclopramide,
it does not readily cross the blood—brain barrier; hence it lacks
extrapyramidal adverse effects [8i.85]. Recently, few studies evalu¬
ated the use of metoclopramide, erythromycin, mosapride, lubi-
prostone, daikenchuto or even postural 'tricks' and chewing
gum. Prompted by a recent study by Ou et al. [85], we con¬
ducted a meta-analysis demonstrating that there is currently no
evidence to back the use of chewing gum in CE [86],
The issue of improving CR in small-bowel CE is conten¬
tious. Although some evidence exists, current guidelines indi¬
cate that there is no strict recommendation on the use, type
and/or mode of administration of prokinetics in small-bowel
CE [83,87,88]. However, in a recent meta-analysis we showed that
the use of prokinetics for capsule ingestion improves CR in
small-bowel CE [89]. This effect appears to be particularly evi¬
dent with metoclopramide, when used concurrently with purg¬
ing and/or use of real-time monitoring. Furthermore, in a
small number of studies, erythromycin showed — through its
gastrokinetic effect — marginal benefit. However, perhaps the
most important message of our meta-analysis was that none of
the prokinetic in current use has a beneficial effect on small-
bowel CE DY. Although it is anticipated that in the foreseeable
future the use of newer capsule endoscopes (with extended bat¬
tery life) will improve both CR and potentially DY, there is a
constant interest to standardize the CE procedure and lead to
the development and content validation of reporting compe¬
tence, reflective of practice across institutions [89,90]. To this
end, the 'smart', selective and judicious use (before as well as
during small-bowel capsule endoscopy) of prokinetics in combi¬
nation with other modalities, such as real time and/or purge, in
improving the CR of small-bowel CE [90].
FICE & blue mode
In recent years, virtual chromo-endoscopy techniques have been
proposed to enhance microvascular contrast and facilitate min¬
ute resolution of superficial patterns and color differences. In
2005, Fujinon Corp (Saitama, Japan) developed FICE as a
new type of image-enhanced endoscopy with the potential to
improve detection of lesions in the upper GI tract and enhance
differentiation between neoplastic and non-neoplastic tissue [91].
FICE is a digital imaging technology based on arithmetical
processing of ordinaty images; this is executed by external soft¬
ware and allows processing of ordinary images that were cap¬
tured by the standard video CE devices [92]. The spectrum of
wavelength used for creation of optical images is influenced by
several factors such as the light spectrum of the light source,
the optical device and the spectral sensitivity of the sensing ele¬
ments. The wavelengths are associated with laminar structures
and blood flow in the GI mucosa that has been altered by
inflammation or neoplasm, which acts as a scattering element
and interferes with the reflectance spectrum [93].
The FICE software was successfully implemented within the
RAPID® Reader reporting software (Given Imaging Ltd). The
CE reviewer can select flexibly between standard imaging and
three different FICE-enhanced settings with different wave¬
length patterns by a simple push on the relevant toggle but¬
ton [93|. Essentially, FICE can provide high-contrast images by
selecting the wavelength suitable for a specific structure of
mucosal structures or vessels. In CE, three FICE settings with
different spectral specifications (wavelengths) have been intro¬
duced. Data available thus far show that application of FICE
in small-bowel CE videos leads to improved image quality and
definition of the surface texture of small-bowel lesions [1.92.93].
Although this seems to facilitate the visualization of small-
bowel findings, its beneficial effect on lesion detectability, and
overall its clinical impact, is still debatable [1,94]. A similar func¬
tion from Olympus Inc. showed promising results [95].
An additional filter named the RAPID interface offers is the
blue mode (BM) filter. BM filter is a color coefficient shift of
light in the short wavelength range (490-430 nm) superim¬
posed onto a white (red, blue, green; RGB) light image. There
is a growing pool of experts' opinions that BM improves lesion
visualization in the majority of cases. However, our results have
informahealthcare.com doi: 10.1580/17474124.2014.952281
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Figure 1. 3D reconstruction of a capsule endoscopy images
with four different shape-from-shading (SfS) algorithms.
(A) Tsai's, (B) Ciuti's, (C) Barron's, (D) Forreao's.
failed to prove a benefit of applying BM in few clinical
scenarios [96-9S;. Further multicenter studies are required to
guide a more standardize approach in CE review and applica¬
tion of relevant software.
QV & capsule endoscopy
As aforementioned, one of the limitations of small-bowel CE is
the reading time required for the interpretation of lengthy video
streams. QV is a computational tool, which scans all images and
scores them according to the possible level of significance. Even¬
tually, its output is CE images of potential interest to the CE
reader, providing a fast pre-viewing option [99]. The number of
images to be considered 'frames of interest' can be set as a per¬
centage (e.g., 5, 10, 20, 80%, etc.) of the full video. Then,
according to the percentage level set by the user, QV displays a
shortened video as compared with normal mode view. Recently
published data give evidence that this target seems to be accom¬
plished in small-bowel CE video reading with a high sensitivity
in the per-patient per-lesion analysis 1.98,100.101 ].
Recently, we showed that QV pre-read in urgent cases, but
fails to show any benefit in other clinical scenarios. Although
the benefits of QV are outweighed to some extent by a
decrease in the overall DY, this mode can be used confidently
in overt OGIB in an urgent inpatient setting and in outpatients
with occult OGIB or suspected CD. As the usefulness of QV
may vary, depending on the number of small-bowel lesions,
standard review settings are still recommended in all other
cases. Furthermore, we confirm that BM does not confer
any additional advantage in the QV setting [i.9S|. However,
Hailing et al. (loo| suggest that, despite a significant number of
missed lesions, QV-CF. is a safe and time reducing method for
diagnosing small-bowel CD. To avoid false-negative cases, they
recommend viewing the terminal ileum in standard view. Fur¬
thermore, a recent study from Germany [ 101 ] shows that the
reliability of QV in derecting colorectal polyps in colon capsule
endoscopy as compared with regular review reading is notable.
However, if no significant polyp is presented by QV, normal
type reading must be performed afterward.
3D reconstruction in capsule endoscopy
To date, limited research has been carried out in developing
methods and materials that are required to make 3D represen¬
tation of the digestive tract [ 102). Since the capsule needs 6—8 h
to traverse through the small bowel [103.104], cameras within the
currently marketed capsule endoscopes work at a capture rate
of 0.5-3 fps in order to comply with power requirements |iz.sj.
However, this has an adverse effect on the smoothness of
motion between consecutive frames and creates a visually
unpleasant effect to the human eye [13.62.105l. Furthermore,
shape is an important element in human perception; yet,
unlike other diagnostic modalities, that is, computed tomogra¬
phy. MR1, CE suffers from lack of 3D information [105]. 3D
technology is currently in use, for example, a magnetometer
can provide not only acceleration values on the three axes, but
also the 3D orientation of the device. Commercial time-of-
flight range cameras (i.e., Microsoft's Kinect Project), already
exist in the market and in the near future this may be further
improved and miniaturized for use inside a capsule endo¬
scope [io6[. These cameras offer information on depth and
color. Furthermore, we should not forget that 3D guidance sys¬
tems are already used for endoscopic surgeries offering 3D
position information of the sensor. Therefore, using the
acquired information (orientation, acceleration, depth values,
position, etc.) from these miniature sensors in conjunction
with sophisticated registration software algorithms, an accurate
3D representation of the digestive tract could be created
successfully [10s].
For conventional endoscopy systems, stereo technology has
been introduced to capture stereo images and to create depth
information and therefore 3D reconstruction of digestive struc¬
tures. However, due to issues with size, such systems have not
been widely accepted [s.io~]. Likewise, in CE there has been a
hardware approach that provides in real time both 3D informa¬
tion and texture using an infrared projector and a CMOS cam¬
era. The major drawbacks of this system are its size, power
consumption and packaging issues [a].
Therefore, in order to tackle the problem of the current
hardware limitations, a software approach based on monocular
images — shape-from-shading (SfS) — has been proposed to
approximate a 3D representation of digestive tract surface uti¬
lizing current CE technology. The SfS technique, firstly pro¬
posed by Horn [108], is a member of a family of shape recovery
algorithms called shape-from-X techniques [106], which has the
capability to recover the shape of objects presenting a single
image using the gradual variation of shading. The SfS problem
is to compute a 3D shape from a grayscale image fins], How-
ever, this problem has no single solution (105,108]. There are
four publicly available SfS algorithms. In a recent study, we
used three CE experienced reviewers and asked to evaluate 54
2D images (categories: protrusion/inflammation/vascular),
which were transformed to 3D by the aforementioned SfS
algorithms (Figure l) [ 1001. The best algorithm was selected and
inter-rater agreement was calculated. Tsai's algorithm unani¬
mously outperformed other 3D representation software [109].
doi: 10.1586/17474124.2014.952281
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Table 3. Studies of 3D reconstruction in capsule endoscopy.










A system for an accurate 3D
reconstruction in video
endoscopy capsule
An embedded active vision
hardware system that is able to
give in real time both 3D
information and texture
An integrated wireless 3D vision
system based on active stereo-
visSon technique. It uses CMOS




3D representation of the
digestive tract surface in CE
videos
Retrieve 3D shape approximation
from individual CE frames
Use sh^pe-from-shading
technique (TSai's linear method)
on CE frames to.estimate shape
from 'flat' CE frames
[106]
[61]
Ciuti ef al. (2012) Intra-operative monocular 3D
reconstruction for image-guided
navigation in active locomotion
capsule endoscopy
Accurate trajectory planning and




scale factor immediately prior to
a CE procedure
[155]
Prasath etal. (2012) Mucosal region detection and
3D reconstruction in CE videos
using active contours
Obtain a 3D reconstruction of
the mucosal tissues
Use a near-light perspective
shape-from-shading technique
for 3D reconstruction of CE
frames
[116]
Sun ef al. (2010) 3D reconstruction based on
capsule endoscopy image
sequences
Build up 3D model of the
patient's tract, which can supply
exact locating information and






obtained and 3D reconstruction
[H7|
Fan etal. (2010) 3D reconstruction of CE images Create a realistic friendly three
dimension view to help the
physicians to get a better
perception of the Gl tract
Apply SIFT algorithm to extract
the feature points for two
consecutive CE frames. Then
apply the epipolar geometry to
calculate the extrinsic






However, light reflections on the surface of the digestive tract
are still a significant problem. Therefore, we constructed a
phantom model/simulator in an attempt to check the validity
of a highlight suppression algorithm. Our results confirmed
that 3D representation software performs better with simulta¬
neous application of a highlight reduction algorithm. Further¬
more, 3D representation follows a good approximation of the
real distance to the lumen surface [109.110].
Tsai's algorithm was also tested in a phantom simulator, pre¬
pared from readily available materials such as cardboard
boxes (111.112]. To represent the different colors and shapes seen
inside the small intestine, flat or protruding objects in ted, yel¬
low and white were used in the phantom models. Our experi¬
ments showed that the accuracy of the 3D representation was
90, 70 and 45% for red, yellow and white phantom models,
respectively. Subsequendy, 192 CE images were reviewed:
50 vascular, 73 inflammatory and 69 protruding lesions. Visu¬
alization was more enhanced for vascular pathology than it was
for inflammatory or protruding lesions (56 vs 23 vs <10%,
respectively) [111,112].
Of course, improved visualization — or even detection - does
not automatically lead to more accurate diagnosis. The latter is
perhaps more evident when CE reviewers are facing the 'mass or
bulge' diagnostic dilemma [10,113]. The results of a recent study
confirm that the distinction between masses and mucosal bulges
in small-bowel CE is still a challenging task even for experienced
readers. In this situation, review experience seems to have a pri¬
mary role [71.114]. However, the adjunct of 3D reconstruction to
standard 2D video reading software significantly improves the
performance of novice CE readers in distinguishing masses from
bulges, thus potentially shortening tljeir learning and lead to a
reduced rate of false-negative diagnosis in expert hands. Similar
results have been obtained by the application of the same soft¬
ware in esophageal capsule endoscopy [Kowlaotzidb a, B.artzis l, Plevws
JN. abstract in UEGW 2014, Oct 2014. Unbubushed Data]. Further studies are
needed to test the feasibility of 3D reconstruction in clinical
practice and to evaluate the impact on the reviewing process in
terms of both time and DY. In Table 3, the current research in
3D is tabulated [107,115-119]. ,
Construction of panoramic visual summaries
Recently, a revolutionary approach to the visualization of CE
videos has been proposed as a means to artificially broaden the
field of view of capsule endoscopes [119-121]. It is based on an
informahealthcare.com doi: 10.1480/17474124.2014.942281
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Table 4. Recent studies on computer-based detection of abnormalities.
Study (year) Abnormalities Largest dataset Features Best results Ref.
Images/Patients Accuracy Sens/Spec
Sainju et al. (2014) Blood 1500/3 C 81.0-98.0 71.0-99.4/72.1-99.3 1129]
Figueiredo et al. (2013) Blood 4000/10 C 84.9-92.7 62.1-92.9/>90.0 [130]
Pan et al. (2012) Blood 40 C 90.0/97.0 [131]
Charisis et al. (2012) Ulcers 174/6 C, T 95.4 90.9/89.4 [1321
Kumar et al. (2012) CD lesions 533/47 C, T 92.0 [133]
Li & Meng (2012) Tumors 1200 C, T 92.4 [134|
Li & Meng (2012) Tumors 1200 C. T 83.5 ± 1.3 84.7 ± 1.5/82.3 ± 1.9 1135]
Li & Meng. (2011) Tumors 1200 C, T 90.5 92.3/88.7 [136]
Mamonov et al. (2014) Polyps 18,900/5 c, s 81.0/90.0 [137]
Li & Meng (2012) Polyps 1200/10 c, T 91.6 [138]
Karargyris & Bourbakis (2011) Polyps, ulcers 100 C, T, S Polyps: 96.2/70.2
Ulcers: 75.0/73.3
[139]
Szczypinski et al. (2011) Blood ulcers
Petechiae




Szczypinski et al. (2014) Blood
ulcers
613/50 C, T Blood: 100.0/99.0
Ulcers: 83.0/94.0
[141]
Chen et al. (2013) Hookworm 1700/10 C, T 88.7 ± 2.0 84.5 ± 6.4/93.0 ± 2.0 [142]
Segui et al. (2012) Intestinal content 50,000-100,000/50 C, T 91.6 80.1 ± 16.7/93.1 ± 7.9 [143]












image processing and analysis methodology, according to which
consecutive CE video frames are automatically transformed, for
example, rotated and scaled, so as to find matches between
them, and stitched together in a way that they seamlessly form
a panoramic image [121). By repeating this process for consecu¬
tive clusters of video frames over the original CE video, a new
video composed of panoramic video frames is formed. The
new video is composed of fewer frames than the original video
since the frames of the new video are composed of multiple
transformed frames of the original video. Therefore, the new
video can be considered as a summary of the original one, and
it requires shorter reading times by the reviewers. The experi¬
mental evaluation of this methodology on publicly available
CE videos showed that it possible to reduce the number of
images down to less than 15% of the original videos.
A similar approach has been proposed for next-generation cap¬
sule endoscopes equipped with special optics capable ol capturing
360° panoramic images [1221. That study suggests the application
of image stitching as a general approach to form a dissected view
of the whole GI tract. Current approaches are still early; however,
the perspectives of automatic image stitching in CE imaging are
promising. Advances in other domains, such as the endoscopy of
the bladder (123], indicate that it could be extended for the visuali¬
zation of a whole organ as a surface mosaic.
Detection software; the present & the future
In order to improve the DY of CE, a variety of computer-based
medical systems have been proposed. Such systems are capable of
analyzing CE image sequences using algorithms that quantify the
image features discriminating the abnormalities, and classifying
them based on these features, for example, into normal and
abnormal. The image features considered by these systems
mainly include color (C) and texture (T), since these features
have been documented as most discriminative by the endoscop¬
ists [124,125]. The shape (S) of the findings has also been consid¬
ered as a feature for the discrimination of abnormalities;
however, considering the diversity of the lesions and the deform-
ability of the intestine, they may be suitable for the description
of only a limited set of abnormalities, for example, small adeno¬
matous polyps, which usually have an elliptic (2D) or hemispher¬
ical (3D) shape. Image classification is usually based on
supervised machine-learning algorithms, such as neural networks,
and support vector machines 1126). These algorithms are called
supervised because they are trainable with annotated images con¬
sidered as 'gold standard'. These images should include informa¬
tion about the presence, the location and the pathology of their
contents, as assessed, usually, by a group of experts.
Automatic lesion detection methods have first appeared for
polyp detection in flexible endoscopy [127). One of the most
doi: 10.1586/17474124.2014.932281 Expert Rev. GattrnnitrroL HeDatnl
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thorough review studies in this field [lis] indicates that the tech¬
nological revolution of CE led to a consequent increase of scien¬
tific contributions focused mainly on CE. Since then, over
30 different studies have been published on automatic detection^
of abnormalities in CE video sequences. A selection of the most
representative ones is presented in Table 4 [129-145]. For each
study, this table indicates the type of abnormalities being"
detected, the largest dataset used in the study (because some,
studies evaluate their methods in more than a single datitef),!'
the features used and the besr results reported. The results are
presented in terms of average accuracy (number of correctly
detected abnormal samples divided by the total numbdr of sam¬
ples) and/or average sensitivity and specificity. . V •
Most studies investigate methods for the detection of
blood [Bo-132], ulcers [133,140,142). polyps [138-140] or tumors in
general [136,137]. Fewer studies investigate the detection of CD [
lesions [134|, petechiae [141] and hookworms [143], whereas others
aim to discriminate intestinal content, such as bubbles and tur¬
bid [144], or as it is more generally expressed, uninformative
frames, including also dark parts of the images [145],
Hence, Table 4 shows that most studies focus on the detection
of one class of abnormalities, and only a few studies address
two or maximum three classes of abnormalities [140-143]. How¬
ever, this is far from the real clinical problem posed by C.E,
where the detection of tens or even hundreds of abnormalities
is necessary.
A relevant method aims to the detection of suspicious CE
video frames, regardless of the pathology [146]. Instead of aim¬
ing to the detection of specific lesions, this method is capable
of detecting any video frame with content that deviates from
the content of the majority of video frames in a video seg¬
ment. By repeating this process along the whole CE video, a
number of representative video frames is bookmarked as pos¬
sibly suspicious. Another advantage of this method is that it
is unsupervised, that is, it does not require training, since it
is based solely on the relations between the video frames.
A drawback of this method is that it may return many
false positives; however, its sensitivity has been evaluated
high [147].
The results presented by the recent (and older) studies are
generally high. However, a major problem is that they can be
misleading for the actual performance of the investigated meth¬
odologies. Main reasons for that include: the datasets and.the
gold standards are usually unavailable; the evaluation 'may
include bias; the studies rarely clarify if the training and the
test include different images obtained from the same lesion, or
other studies use very small datasets without the application of
re-sampling methods, for example, cross validation.; the accrn.
racy, the sensitivity and the specificity are improper indicators!
of the system's performance, especially if the darasets are
unbalanced [148].
Therefore, another important challenge, beyond the necessity
of systems coping with multiple lesion detection, is the con-
, stfuetion of open access data repositories, which will provide
CE images and videos along with gold standard information
. fej" reproducible experimentation by all researchers.
. iff
New capsules
Several research groups are working to design new models able
to' either actively move or remotely maneuvered through their
journey in the small bowel (1.9). These new capsules would
allow not only recognizing a small-bowel lesion, but also, in a
near future, collection of tissue samples and/or targeted delivery
of drugs (Table 5) [13,149-164].
Expert commentary & five-year view
It is envisaged that longer battery times will lead to a marked
reduction of incomplete small-bowel examinations; at the
same time, cameras with different angle of view should per¬
mit assessment of depth and hence accurate, real 3D luminal
views. The latter should be combined with higher quality
imagers, allowing potentially the ability to zoom and get
closer to the requirement of optical biopsying. The techno¬
logical frenzy of our days will eventually lead to rhe produc¬
tion of remarkable small parts and this might allow the
production of dissolvable capsules, including the use of non¬
toxic batteries. Furthermore, software developments should
facilitate more efficient reporting and minimize false nega¬
tives. A computer-aided lesion detection has the potential to
reduce reporting time and allow a more accurate use of cap¬
sule technology. However, research for automatic lesion
detection can become more essential by providing solid pub¬
lic access to endoscopic data libraries.
The issue of improving the DY in CE has no epilogue. As
with every technological achievement, realizing current limits
is just a step to a subsequent exciting development. However,
it is our opinion that the issue of automatic lesion detection
and interpretation is one of the niche developmental areas
in CE.
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Key issues
Automatic lesion detection and reporting and development of an accurate lesion localization system are the main software challenges
of our days.
The 'smart', selective and judicious use (before as well as during small-bowel capsule endoscopy) of prokinetics, in combination with
other modalities, such as real-time and/or purge, is crucial in improving the completion rate of small bowel capsule endoscopy. Caution
is advised in unnecessary use of domperidone or metoclopramide for the elderly and those on multiple medications to avoid drug inter¬
actions, although such risk is most likely to be present with chronic rather than acute use.
Further studies are needed to test the feasibility of 3D reconstruction in clinical practice and to evaluate the impact on the reviewing
process in terms of both time and diagnostic yield.
The construction of open-access data repositories will provide capsule endoscopy images and videos along with gold standard
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Original article
Detection of the ampulla of Vater in small bowel capsule
endoscopy: Experience with two different systems
Anastasios KOULAOUZIDIS* & John N PLEVRIS*'
*Endoscopy Unit, Center for Liver and Digestive Disorders, Royal Infirmary of Edinburgh, and 'Medical
School, University of Edinburgh, F.dinburgh, UK
OBJECTIVE: The aim of this study was to determine
the detection rate of the ampulla ofVater (AoV) during
small bowel capsule endoscopy (SBCE) examinations
and compare the two SBCE systems used in our center.
METHODS: SBCE procedures performed in our
center from March 2005 to June 2011 were reviewed
retrospectively. A single reviewer, following a detailed
protocol, analyzed 30 min of each recording to iden¬
tify the AoV.
RESULTS: A total of 619 SBCE procedures were
enrolled in the study, including 262 with a PillCam
SB1, 148 with a PillCam SB2 and 209 with a
MiroCam. AoV was identified in 59 SBCE examina¬
tions (9.5%), consisting of 28 with a PillCam SB1
(28/262, 10.7%), 13 with a PillCam SB2 (13/148,
8.8%) and 18 with a MiroCam (18/209, 8.6%)
(P= 0.665). The AoV was visualized in 53.2 frames
(median 12 frames, range 1-1056 frames); and the
detection rate was low regardless of indication,
patients' characteristics, SBCE system used or capsule
transit parameters. Bile spout was associated with a
higher AoV detection (P= 0.003).
CONCLUSIONS: The persistently low AoV detection
rate using two different SBCE systems underlines the
weakness ofnon-steerable capsule endoscopy. Further¬
more, ifAoV detection is taken as a surrogate marker of
small polyp detection, it becomes obvious both that
non-steerable SBCE cannot replace a side-viewing
endoscope in the evaluation of periampullary polyps
in familial adenomatous polyposis and that it is an
infallible method in other small bowel polyposis
states.
KEY WORDS: ampulla, capsule endoscopy, marker, small intestine.
1NTRODLICTION
Over the last decade, capsule endoscopy (CE) has
been established as a very useful tool in the investiga-
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tion of small bowel diseases.1 A recent pooled analysis
has demonstrated that small bowel capsule endoscopy
(SBCE) has a minimal miss rate of <1% for small
bowel ulcer.2 Although SBCE provides a high informa¬
tion yield on mucosal lesions,' it does not permit the
assessment of small bowel wall thickness or extralu-
minal findings.4 Furthermore, concerns have arisen
that SBCE may underestimate the number of small
bowel polyps in patients with a known high polyp
burden, that is, patients with hereditary or familial
polyposis syndromes or other sinister pathological
findings.'"8 Therefore, SBCE is currently far from
perfect due to its technical limitations such
as its rigid structure, inability to insufflate, lack of
621
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directionality or steer control and a set field of view.'
Over the last 5 years clinical researchers have high¬
lighted the use of markers (some in positions where
they are difficult to spot) which are present in intestine
as quality assurance indicators in SBCE.10 The major
duodenal papilla, or ampulla ofVater (AoV), which is
present in all individuals who have not undergone
duodenal resection and is located on the posterome¬
dial aspect of the duodenal sweep,1" 8-10 cm distal to
the pylorus, is a reasonable candidate marker. It is
difficult to see, as the translucent dome of the pro¬
pelled CE tends to point towards the outer aspect of
sharply angulated bowel loops.10
On the other hand, choosing the AoV as the marker
and extrapolating the results of the detection to polyp
lesions may not be completely reliable." The factors
that make the AoV difficult to observe, such as the
location, size/lumen protrusion and capsule transit
speed, are at least part of the reason why small bowel
lesions such as polyps may be missed in the SBCE
examination.
This study aimed to evaluate the detection rate of the
AoV by two different SBCE systems in our cohort and
to compare the results from our center with published
reports.
PATIENTS AND METHODS
Data of all the SBCE procedures that were carried out
in our center from March 2005 to lune 2011 were
reviewed retrospectively. Duplicate examinations,
performed for the purpose of clinical need, were
included. SBCE was performed with a PillCam
SB1/SB2 (Given Imaging, Yokneam, Israel) and/or
a MiroCam (IntroMedic., Seoul, Korea) CE, using
pre-procedural and procedural protocols (small bowel
cleansing with polyethylene glycol, simethicone with
or without prokinetic for CE ingestion). Patients were
allowed to drink clear liquid 2 h after capsule inges¬
tion and to eat a light meal 4 h after capsule ingestion.
This study was conducted in accordance with the
Research Ethics Guidelines of the UK. After being
reviewed by the local ethics committee, further spe¬
cific ethical reviews and approval were not required, as
the study rvas considered to be an audit using data
obtained as part of regular patient care.
All SBCE sequences were reviewed using a detailed
protocol for the identification of the AoV outlined
Journal of Digestive Diseases 2012; 13; 621-627
below with the RAPID v7 (Given Imaging) and the
MiroView v2.0 (IntroMedic). SBCE video sequences
were not de-identified, but any previously captured
thumbnails were deleted. The automatic viewing
mode at a speed of 6 frames per second (fps)
was used on the single frame mode with the reviewer
seated at arm's length from the screen in a room
with dimmed light for maximal pick-up yield. Only
a desktop spotlight was employed, when illumina¬
tion was required, for data input in the data-
collecting Excel 2007 spreadsheet (Microsoft,
Redmond, WA, USA). A 'roll-through' mode was uti¬
lized, where needed, to aid the delineation of
mucosal/surface details.12 Fujinon intelligent color
enhancement or blue mode (in RAPID software),
ALICE or color mode (in MiroView) were not used in
the study.
The predefined settings for the white light CE video
sequence review with RAPID software in our center are
sharpness 1, brightness 1 and color 2. Equivalent set¬
tings for the MiroView software are 2, 0 and 0, respec¬
tively. The duration of review, following the C,E entry
to the duodenal bulb, was prolonged from 15 min in
a previous study13 to 30 min to minimize the possi¬
bility of missing the AoV. Furthermore, the reviewing
time was accordingly adjusted to start from the point
of permanent duodenal entry.11
Age, gender, AoV detection, the number of frames at
which the papilla was visible, the presence of bile
spout, indication and date of the SBCE, the type of CE
used, the type and dose of prokinetics used as well as
transit parameters including the time of duodenal
entry (gastric transit time [GTT]), small bowel transit
time (SBTF) and the transit time from pylorus to first
duodenal papilla frame, the completion to cecum or
not and the quality of small bowel cleansing (and,
where available, the quantity of laxatives used) were
recorded.
To date, there is no standardized bowel cleansing score
for an SBCE, hence we adopted a modified 4-point
grading scale from the study by Park el al.'5 depending
on the proportion ofvisualized mucosa and the extent
of obscuration by intraluminal food debris, turbid
fluids, bubbles or bile: score 3 (veiy good visibility),
>75% mucosa visible; score 2 (good visibility), 50-
75% mucosa visible; score 1 (average visibility),
25-50% mucosa visible; and score 0 (poor visibility),
<25% mucosa visible. Cleansing scores referred to the
first 30 min of the small bowel recording.
© 2012 The Authors
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Statistical analysis
Statistical analyses were carried out with StatsDirect
2.7.8 (StatsDirect, Altrincham, UK). Continuous data
were presented as mean ± standard deviation (SD)
and range. Student's t-test was used to compare para¬
metric variables. A one-way anova for independent
samples was used to compare the papilla detection
rate based on indication and diagnosis. A two-tailed
P value < 0.05 was considered statistically significant.
RESULTS
Baseline characteristics of the patients
A total of 839 SBCE procedures in 758 patients were
performed in our institution between March 2005 and
June 2011. Due to the technical issues (i.e., only initial
written reports available, corrupt SBCE video
sequences stored in compact disks and/or failure to
re-download), 189 SBCE videos were unavailable for
review. Another 22 examinations with gastric or proxi¬
mal duodenal capsule retention and nine of endo¬
scopic capsule delivery in the duodenum were also
excluded. Therefore, a total of 619 SBCE procedures on
533 patients were included in this study for further
analysis.
Of these, 208 (39.0%) were men and 325 (61.0%)
were women, with a mean age of 52.8 years (range
14-90 years). Of the SBCE procedures, 262 examina¬
tions were performed with PillCam SB1, 148 with
PillCam SB2 and the remaining 209 with MiroCam.
Table J. Indications for small bowel capsule endoscopy
(SBCE) in our cohort
Indications for SBCE SBCE procedures, n (%)
Obscure Gf bleeding 138(22.3)
Iron deficiency anemia 206(33.3)
Clinical suspicion of CD 101(16.3)




CD, Crohn's disease; CI. gastrointestinal.
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The indications for SBCE are presented in Table 1.
More than half of the examinations were performed
for overt and/or occult gastrointestinal bleeding.
In 591 procedures (95.5%), pre-procedure bowel
preparation was used. A total of 273 procedures
(44.1%) were performed without tire use of prokinet-
ics. Of the remainder, 267 (43.1%) were done with
the administration of domperidone (mean dose
5.6 mg) and 79 (12.8%) with metoclopramide (mean
dose 5.3 mg).
The mean small bowel cleansing score for the first
30 min was 2.14. Out of the 619 SBCE, 540 CE
(87.2%) were realized at the cecum by the end of the
recording. The positive diagnostic yield for all indica¬
tions was 34.6%.
Detection of AoV
The AoV was detected in 59 SBCE procedures (9.5%;
Table 2, Fig. 1). No difference was observed in the
detection rate between either of the two generations of
PillCam SB (P = 0.609) or the two technically differ¬
ent SBCE systems (PillCam t's MiroCam, P = 0.665).
Furthermore, the mean number of frames of the
duodenal papilla visualized was 53.2 (range 1-1056),
with no significant difference between either of the
two generations of PillCam (P= 0.800) or the two
different SBCE systems (P = 0.247). Bile spout was
detected in 62.2% of SBCE (385/619) and in 81.4% of
the procedures (48/59) in which the AoV was seen
(P= 0.003). The mean time of AoV detection after the
first duodenal image capture was 3.56 min (range
0.05-29.60 min for the whole cohort), and there was
no statistical difference between the two SBCE systems
(3.53 ± 5.65 min for the PillCam us 3.63 ± 5.40 min
for the MiroCam; P= 0.95). The detection rate of
papilla was independent of the indication for SBCE,
type of CE used, diagnostic yield, patients' character¬
istics, and use of prokinetics or gut transit parameters.
Furthermore, there was no significant difference in the
detection rates of the AoV among the SBCE in regard
to either cecal completion or small bowel cleansing
(P< 0.05; Table 3).
Table 2. Number of small bowel examinations per capsule endoscopy
PillCam SB1 PillCam SB2 MiroCam
SBCE (N) 262 148 209
Detection of AoV, n {%) 28(10.7) 13(8.8) 18(8.6)
Frames AoV visible, n(mean ± SD) 36.35 ± 73.24 42.46 ± 69.30 87.20 ± 248.40
AoV, ampulla of Vater; SBCE, small bowel capsule endoscopy; SD, standard deviation.
© 2012 The Authors
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Figure 1. The ampulla of Vater as detected by different
small bowel capsule endoscopy models. First row without
bile spout and second row with bile spout: (a,d) PillCam
SB1, (b,e) PillCam SB2 and (c,f) MiroCam
Interestingly, the detection rate of duodenal papilla in
SBCE performed after bowel preparation was lower
than that in patients who received no bowel prepara¬
tion (SBCR [43/509, 8.4%] w SBCF [6/28, 21.4%];
P = 0.033), probably demonstrating that patients who
received bowel preparation had a more rapid move¬
ment of CE.
Finally, in the group of patients who, for the purpose
of clinical work-up/care (n= 17), had a repeat SBCE
with a different CE system (from that initially
employed), the AoV detection rate was identical
(1:17) for both SBCE systems (PillCam : Miro¬
Cam = 1:17). Eight patients had repeat examinations
with the same type of CE, including four with PillCam
SB1, one with PillCam SB2 and three with MiroCam.
The AoV was not identified in any of the first exami¬
nations and in only one of the repeat studies with
PillCam SB1. Interestingly, four patients underwent
CE examinations with all the three SBCE types, and in
one patient, the AoV was visible with both types of
PillCam but not with the MiroCam.
DISCUSSION
The use of the AoV as a surrogate marker of the detec¬
tion power of SBCE has been suggested after various
reports of polyps or tumors missed by SBCE were
published. ' Since then, evidence of pathology
unidentified by SBCE (detected by device-assisted
enteroscopy, computed tomography enteroclysis or
magnetic resonance imaging) have increased/"'1"
Although the advent of CE has revolutionized the
diagnostic work-up of small bowel diseases, the
amount of information we get (or in fact, do not get)10
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is a combination of various factors such as capsule
technical characteristics, SBTf, the amount and trans¬
parency of intraluminal liquids and, finally, the degree
of small bowel wall contraction.
In the current study, to date the biggest single center
study on the detection rate of the AoV, we included
SBCE with technically different systems and confirmed
results from the existing literature. First, AoV detection
in unselected patients is a difficult task in CE; second,
visualization of the AoV is not related to CF, the indi¬
cations, diagnostic yield, cecal completion, administra¬
tion of prokinetics of CE or patients' characteristics
such as age and gender. Interestingly, the diagnostic
yield in our study, which included more than 300 SBCE
procedures performed for overt/occult gastrointestinal
bleedi ng, was lower than that of a previous report.'This
probably represents not only accumulated experience
in CE reporting but also more widespread use of CE
with easier access to the service and implementation of
CE sooner in the diagnostic work-up.
Bile spout, as described earlier," " is a major herald
of the AoV and the main factor that helps in the
identification of the AoV, although it is believed to
be an accidental phenomenon in endoscopy. A
simple explanation is that the spurting of bile physi¬
ologically occurs when the duodenal wall, together
with the smooth muscle of the sphincter of Oddi, is
relaxing. Therefore, bile spout should be seen as sur¬
rogate marker of reduced mucosal folding, slower
capsule propulsion and hence greater detection
ability from a non-steerable device. Furthermore, it is
likely that patients with slower capsule propulsion
who have not taken a purgative preparation may
explain the higher AoV detection in this group, com¬
pared with those who had been given laxatives for
small bowel cleansing.
Although two different SBCE systems were used, their
performances, as reflected by the detection rate of the
AoV, were similar. Despite the similar size and weight
(PillCam SB; size 11 mm x 26 mm, weight 3.45 g;
MiroCam: size 11 mm x 24 mm, weight 3.4 g), the
two systems have a different transmission technology,
image capture rate and pixel resolution (PillCam SB: 2
fps and 256 x 256 pixels iis MiroCam: 3 fps and
320 x 320 pixels). At a working distance of 2.2 mm
from the tip of the translucent CE dome, PillCam SB1
and SB2 and MiroCam offer a field of view of 140°,
165° and 150°, respectively. Their mucosal coverage
area at 4.5 mm working distance is 500 mm2,
1100 mm- and 202 mm2, respectively.20
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Some researchers propose that the results of the AoV
detection should be extrapolated to the detection rate
of angioectasias (especially when not actively bleed¬
ing) and/or other small bowel pathology (similar in
size to the duodenal papilla such as Brunner gland
adenomas, lipomas or other submucosal tumors,
which are presumed to be randomly distributed),10
thus establishing the AoV as the worse case of possible
misses.
In other words, they recommend the AoV detection
rate as a quality assurance measurement for CE.
Kong et al.u performed a retrospective study on the
detection rate of the AoV in 110 consecutive SBCE
patients. Inclusion criterion was a normal (in shape
and position) duodenal papilla, as confirmed by
conventional esophagogastroduodenoscopy (EGD),
thus, those with an abnormally positioned papilla or
whose papilla was not readily identified by EGD
were excluded. It is, therefore, not surprising that
although they used a high video sequence reviewing
speed (15 fps) and only the first generation M2A
Given Imaging model, they detected the AoV in
43.6% of the patients (48/110). As visualization of
the AoV by conventional front-viewing endoscopes is
not always an easy task, it is likely that this study
suffered from significant selection bias, as only the
more prominent and hence easy to detect AoV were
included for CE.
Clarke et al9 repeated the study with a similar number
(n= 125) of consecutive SBCE patients (again with
M2A; Given Imaging) and a more realistic setting.
Two reviewers, blinded to each other, used the lowest
possible automated viewing speed (5 fps) and found
that the AoV was detected in 10.4% of the patients
(13/125). Wijeratne and Condon21 have demon¬
strated that the AoV is identified only in 6% of SBCE
examinations (9/138). Lee era/.22 reviewed 30 SBCE
performed with PillCam SB and the same number of
examinations with PillCam SB2 and concluded that
the AoV detection rate was 46.6% (28/60), equivalent
for both PillCam types (Table 4). However, other
investigators presented less favourable results."'24
One would think that results should improve with
advanced CE technical characteristics, but the experi¬
ence from the studies using double-headed CE with
improved optics and frame acquisition rate are only
partially concordant.1'' -'1" Furthermore, although dif¬
ferent generations ofsmall bowel PillCam models and
types have been scrutinized (with regard to the AoV
detection rate), other CE systems have not been put
under the test.20,22'"'26
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Table 4. Studies on the ampulla of Vater (AoV) detection rate









mean ± SD Comments
Clarke et al.'' (2008) 125 M2A 13 (10.4) 2 5 n/s
Kong el al.1' (2006) 110 M2A 48(43.6)
•'
2 15 3.5 ± 2.5
Katsinelos et al." (2009) 14 n/s 0(0) 1 n/s n/s l-'AP patients
Nakamura et al.'4 (2009) 96 PillCam SB1 18(18) 2 10 n/s
Koulaouzidis et al.'9 (2011) 11 PillCam ESDI 4(36.4) 1 7 n/s
7 PillCam ES02 1(14.3) 9
Metzger et al.2"{2009) 20 PillCam SB1 1(5) n/s n/s n/s Repeat exams
PillCain SB2 5(25)
Wijeratne and Condon'1 138 n/s 9(6) 1 n/s n/s
(2006 )t
Lee et al.22 (2010) t 30 PillCam SB 13(43.3) n/s n/s n/s
30 PillCam SB2 15(50.0)
Selby and Prakoso" (2011) 50 PillCam SB1 0(0) 2 n/s n/a
50 PillCam SB2 9(18) n/s
8 PillCam ESOl 0(0) n/a
12 PillCam ES02 1(8) n/s
laquinto et al.24 (2008) 23 PillCam SB 0(0) 2 n/s n/a FAP patients
Karagiannis et al." (2010) 10 PillCam Colon 6(60) n/s n/s n/s
Park et al.26 (2012) 30 PillCam SB 13(43.3) n/s n/s n/s
30 PillCam SB2 15(50.0)
tPublished only as abstract.
CE, capsule endoscopy; PAP, familial adenomatous polyposis; fps, frames per second; n/a, not applicable; n/s, not stated.
In conclusion, this study raises awareness regarding
the limitations of CE. More specifically, it raises
important issues on the usefulness of CE in the
detection of periampullary lesions. In such cases,
standard practice remains to use a side-viewing
duodenoscope for inspection of these areas if a stan¬
dard forward-viewing endoscope cannot provide sat¬
isfactory views. This study also highlights the
technical limitations of CE in the identification of
small lesions with a non-steerable device. The limi¬
tations of our study are its retrospective nature and
the use of a single reviewer, although the SBCE
evaluation was performed using a strict protocol and
blinded review to any archived thumbnail images.
Furthermore, a large number of studies were not
available for review due to either corrupt compact
disks or loss of sequences during their transfer from
one large capacity storage device to another. More¬
over, the fact that the comparison was not done on
the same patients (other than a subgroup of 17
patients) and the same day, together with the
unavailability of systematic endoscopic confirmation
of visibility of the papilla by a conventional side-
viewing duodenoscope, might be seen by some as a
further limiting factor.
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Video SI. A rare sighting, the major duodenal papilla
(ampulla of Vater) and the minor duodenal papilla
(accessory pancreatic duct of Santorini) seen in the
same small bowel capsule endoscopy.
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Abstract
Background:
The use of purging for bowel cleansing prior to small-bowel capsule endoscopy (SBCE) has now been
established in clinical practice/Despite that, the number of incomplete SBCEs is still around 15-20%.
To date, the use of prokinetics in SBCE - aiming to improve completion rate (CR) - remains a contentious
issue resulting in lack of consensus among capsule experts.
Methods;
Extensive medical literature searches were conducted (to November 2012), using suitable MeSH terms and
keywords, in search of studies that compared capsule ingestion with prokinetic agents vs. controls or
placebo. We examined the effects of prokinetic administration on SBCE CR (primary end point), as well as on
the following secondary end points: diagnostic yield (DY), gastric transit time (GTT) and small-bowel transit
time (SBTT) by meta-analysis of all relevant studies.
Results:
A total of 17 eligible studies (14 prospective. 3 retrospective) were identified, including 1028 individuals who
ingested the capsule with no prokinetic vs. 876 who received a prokinetic. Overall, there was a higher CR in
patients who ingested the capsule with prokinetics vs. controls (OR [95% CI]: 1.96 [1.38-2.78]). Of the two
most readily available prokinetics, metoclopramide was associated with superior SBCE CR vs. control
(OR [95% p 2.8 [1.35-3.21]), while erythromycin showed no benefit (OR [95% CI]: 1.36 [0.61-3.03]).
Where prokinetics were used alone, neither metoclopramide nor eiythromycin showed any benefit on CR.
There was no benefit of prokinetics (over controls) on DY. However, metoclopramide had a significant
effect on GTT and SBTT.
Limitations:
The majority of the included studies were heterogeneous, and the effect of prokinetics on image quality and
mucosal visualization was not examined.
Conclusion:
Our pooled data shows that the use of prokinetics for capsule ingestion improves CR in SBCE. This effect
appears to be particularly evident with metoclopramide, when used concurrently with purging and/or use
of real-time monitoring. In a small number of studies, erythromycin showed - through its gastrokinetic
effect - marginal benefit. No prokinetic has a beneficial effect on SBCE DY.
Introduction
Optimal diagnostic yield (DY) in small-bowel capsule endoscopy (SBCE)
requires not only optimal visualization of the small-bowel mucosal surface
© 2013 Informa UK Ltd www.cmrojournal.com Prokinetics In small-bowel capsule endoscopy Kou/azu-'f'-zfDd7!,
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and lumen1,2 but also complete capsule transit through the
entire small bowel i.e. total enteroscopy . If results are
negative and/or inconclusive and complete enteroscopy
is not achieved, concerns remain over missed small-
bowel pathology. Recent systematic reviews showed rhat
SBCE completion rate (CR) varies between 81.3—83.5%
(for retrospective and prospective studies, respectively)4,5.
Besides small-bowel structural integrity, hospitalization,
advancing age and diabetes are considered high risk factors
for incomplete enteroscopy with SBCE6-8. Therefore, it is
expected that decreasing gastric transit time (GTT) and
small-bowel transit times (SBTT) will allow a capsule to
successfully reach the caecum by the end of its battery life5.
Hence prokinetics, e.g. metoclopramide and erythro¬
mycin, as well as postural 'tricks', i.e. change of patient
position following capsule ingestion, have been applied
to improve SBCE CR9.
Recent meta-analyses on the use of bowel preparation
in SBCE showed — in subgroup analysis - that there is no
difference in the use of erythromycin10-12. Although some
evidence exists, current guidelines indicate that there is
no strict recommendation on the use, type and/or mode
of administration of prokinetics in SBCE8. Moreover,
no previous systematic review and/or meta-analysis has
been carried our to address whether adding prokinetics
prior to capsule ingestion can increase the CR of the
SBCE and/or the DY. This study was performed to assess
the current evidence base on the use of prokinetics for
CR and explore their effect on GTT and SBTT by meta-
analysing all relevant studies.
Methods
Literature search strategy
A recursive search of PubMed/Medline, Embase and
Scopus databases for studies published up to the end
of November 2012 was performed. The last computer¬
ized search was carried out on 30th November 2012.
No language, start date or age search limits were
applied. In order to capture as many articles as possible,
a broad search strategy was employed, using the MeSH
term 'capsule endoscopy' (with 'automatic explosion'
and 'all fields' search) linked in simple search strings
by 'AND' with the following text terms: 'antiemetic',
'completion', 'domperidone', 'erythromycin', 'gastric
emptying', 'ingestion', 'intramuscular', 'metoclopramide',
'ondensetron', 'oral/liquid', 'preparation', 'prokinetic',
'promotility', 'retention', 'tcgaserod', and 'transit'.
Furthermore, a combined recursive/manual search
of all pertinent review articles and recently published
editorials was performed.
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Publications selection
After retrieving the full text of selected papers, data were
extracted by the first author (A.K.) using a predefined form
and were (at parts) verified by another author (K.J.D.).
A full manual search for potentially suitable references
was also performed in rhe reference list of all retrieved
original studies. As no language restriction was applied,
publications were translated into English as required by
one of the authors (D.E.Y.). In the event of uncertainty,
any discrepancies were resolved by discussion with the
senior co-author and consensus.
Selection criteria
Inclusion and exclusion criteria were drafted before com¬
mencing the literature search. Therefore, studies eligible
for inclusion in this meta-analysis were those meering all
of the following criteria:
(1) published as full articles, reporting (prospective or
retrospective) comparative data
(2) used prokinetics in (at least) one of the reported
patient subgroups
(3) contained information on rhe type of the SBCE
system/model used
(4) specified the type, mode of administration and dose of
prokinerics used, and
(5) contained data on one or more of the following SBCE
parameters: completion rare (to caecum) (CR), DY,
GTT, SBTT.
DY was defined as the total number of positive (diag¬
nostic and suspicious) findings. GTT was defined as
the time interval between the first gastric image and
the first duodenal image. SBTT was defined as the time
interval between the first duodenal images and the first
caecal image.
Studies not meeting the aforementioned inclusion cri¬
teria, those examining the effect of postural 'tricks', and/or
duplicate publications were excluded. We also excluded
cohort studies with no control arm, review articles, and/
or case reports or case series. It was decided that when two
papers reported the same study, the most recent and/or the
more informative publication would be selected.
Statistical analysis
Pooled odds ratios (ORs) and 95% confidence intervals
(CIs) were calculated and outcomes of individual
studies were compared by using the fixed-effects model
(Mantel—Haenszel method)13 unless significant statistical
heterogeneity was detected, where the random-effects
model was applied (DerSimonian—Laird method)14.
Hererogeneity was assessed using the inconsistency index
(l2) and the chi-square (x2) test for heterogeneity; evi¬
dence of heterogeneity was considered to be present if
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PcO.lO'L In case of significant heterogeneity in study
design, results were pooled using the DerSimonian—Laird
random-effects model. This is preferable to a fixed-effects
model (Mantel-Haenszel method), as it takes into account
differences between studies and treatments when estimat¬
ing 95% CI and P values. Apart from adjusting for hetero¬
geneity by applying the random-effects model, reasons for
heterogeneity were explored. This lead to the stratification
of the studies into more homogeneous groups, therefore
more reliable estimates'6. The candidate factors for strati¬
fication were: the randomization quality (Jadad score)1';
the study design (prospective vs. retrospective); the use of
bowel purging (bowel purging and prokinetic vs. proki-
netic alone); and the most readily available (therefore
more frequently used) prokinetics (metoclopramide and
erythromycin vs. the rest).
A sensitivity analysis was performed in order to evalu¬
ate the consistency of our results. First, to evaluate any
possible excessive influence of a single study, we examined
whether the exclusion of this study substantially altered
the magnitude or heterogeneity of the summary estimate.
This was achieved by repeating the meta-analysis with
exclusion of each individual study one at a time, ro
assess the overall effect of the exclusion on the pooled
ORs18. Forest plots were constructed for the visual display
of ORs across selected studies. Statistical analysis was per¬
formed by using the Meran package of Stata version 12.1
(StaraCorp, College Station, TX, USA)1'.
Publication bias assessment
The likelihood of publication bias was assessed by con¬
structing funnel plots, which were obtained by plotting
the log ORs vs. SE (log [OR]) of individual studies20.
Methodological quality assessment
The methodological quality of randomization of the stu¬
dies was assessed and graded according to criteria described
in the Jadad scale which has already been extensively
described elsewhere17. Therefore, the following items
were independently scored for each study:
(1) Was the study described as randomized (this includes
words such as randomly, random, and randomiza¬
tion)? (0/1)
Was the method used to generate the sequence of
randomization described and appropriate (table of
random numbers, computer-generated, etc)? (0/1)
Was the study described as double blind? (0/1)
Was the method of double blinding described and
appropriate (identical placebo, acrive placebo,
dummy, etc.)? (0/1), and






(6) Furthermore, one (1) point was deducted for each of
the following two:
(7) if the method used to generate the sequence of ran¬
domization was described and it was inappropriate
(patients were allocated alternately, or according to
date of birth, hospital number, etc.); and
(8) if the study was described as double blind but the
method of blinding was inappropriate (e.g., compari¬
son of tablet vs. injection with no double dummy)
(Table 1).
Furthermore, it is known that evidence based on retro¬
spective studies begins as low quality, with a potential to
decrease further because of study limitations, inconsist¬
ency of results (heterogeneity), impression and other con¬
siderations (including publications bias)21; therefore, the
overall quality (tor each study) was a combination classi¬
fied as high, moderate or low, according to a combination
of Jadad score and type of study design.
Data extraction
For each included study, the following variables were
extracted and entered into an Excel data sheet: author,
year of publication, number of participants, type of
SRCE system, use of prokinetic/promotility agent, dose,
mode and rime of administration (in regard ro capsule
ingestion), GTT, SBTT, CR or rate of total enteroscopy
and DY. Furthermore, the retention/obstruction rate (RR),
where reported, was extracted. Relevant studies were ana¬
lysed according to the type of prokinetic used with the
following primary and secondary end-points: a) CR, b)
GGT, c) SBTT, and d) DY.
Results
Descriptive assessment and study
characteristics
A flow chart describing the process of data/study identifi¬
cation and selection is shown in Figure 1. A total of 703
tirles were initially identified with the aforementioned
search strategy. Of those, 402 were excluded after prelim¬
inary review of the titles and/or abstracts, leaving 301 art¬
icles for further/detailed evaluation. Of those, 278 were
excluded following thorough review of the abstracts.
Moreover, a further two articles were identified from ref¬
erence review. Therefore, the full text of 26 arricles (with
potentially extractable data) was evaluated further.
Consequently, 17 articles met the inclusion criteria and
entered this meta-analysis22-38. The main characteristics
of the studies eligible for review, including their Jadad
scores'7, are shown in Table 2.
A total of 1899 individuals (1859 patients and 40
healthy participants; 1028 subjects ingested the capsule
with no prokinetic [n = 1008J or placebo [n = 20J and
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876 with a prokinetic; 982 males/917 females; mean
age; 54-73 ±21.1 years) were included in these studies.
Fifteen studies22-30'32-31''38 (n=1690 subjects) were pub¬
lished in English and two51,37 (n = 209 patients) tn
the Chinese language. All, apart from one study27,
were single-centre papers; ten studies (58.8%) were
conducted in the Far East (China: 5 studies23'26,31,34,3',
Japan: 5 studies32,33,35'36,38), two in Australia22 '4 and
one in each of the following countries: Greece, Israel,
Portugal, UK and USA2'3,27-"0. Fourteen of them were
prospective22,24-30,32-'36,38 and three were retrospective
studies23'1,37. Capsule endoscopy was performed with
M2A and/or PillCam SB capsule endoscope models
(Given Imaging Ltd, Yokneam, Israel) in all bur two
Chinese studies - including a total of 286 patients -
where the OMOM capsule endoscope (Jinshan Science
& Technology Company, Chongqing, China) was
used34,37. Furthermore, in one study both EndoCapsule
(Olympus Medical Systems, Tokyo, Japan) and PillCam
were utilized38. Nine studies evaluated the use of metoclo-
pramidc22,28'31'-32'34-3', three of erythromycin23,24,27, two
ofmosapride26,18 and from one the effect of chewing gum25,
lubiprostone29, and the combined effect of daikenchuto +
metoclopramide (post real-time check)33.
All subjects were prepared with overnight fast and
in nine studies purgatives were used either prior to
and/or during capsule endoscopy2'''4,25,28,33-35,37,38.
Furthermore, in five studies simethicone was administered
for capsule ingestion22,23,30,33,35. Lastly, a real-time viewer
(RTV) was utilized in the protocol of five studies33-37,
although external RTV should be considered instrumental
only in the protocol of two metoclopramide studies36,37.
Lastly, eight studies (four on metoclopramide, two on
erythromycin, one on lubiprostone and one on mosa¬
pride)23,26-31 examined the usefulness of the aforemen¬
tioned prokinetics, without potential external
interference/bias effect by laxatives, RTV and/or complex
study protocols, and are considered separately in the
sensitivity analysis (subgroup 1). Overall, in the meta-
analysed studies, there were 17 sets of primary endpoint
data (CR) and 24 sets of secondary endpoints data (GGT:
8, SBTT: 9, and DY: 7).
Primary endpoint: SBCE completion rate
SBCE CR was defined as the capsule reaching the caecum.
All included studies presented such data (17 sets), exam¬
ining the SBCE CR in 1028 subjects who ingested the
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703 potential eligible titles
(generated by the initial literature search)
402 papers excluded (following title/abstract review):
Colon (PillCamColon capsule paper, review, meta-analysis, guidelines): 34
Case report/series: 121
Guidelines, position/opinion/technical papers, reviews/meta-analyses, task
force reports: 139
Motility capsules papers (SmatPill, Motilis): 21
Oesophageal capsules (Bravo, other/s): 27
Other unrelated or non-capsule papers: 54
Radiology papers (CT, MRI): 6
301 papers retrieved
24 papers (with extractable
data) eligible
278 papers excluded
Not relevant: 13, abstracts: 16, duplicate publication/s:
2, review/opinion papers: 28, no use of prokinetics: 218
2 papers (with extractable data)
from manual search 9 papers excluded
17 included
Cohort studies (no control arm): 2, RTV-drivenra:
1, RLP2evaluation: 1, non-relevant/non-
extractable data: 6
Figure 1. Flow diagram of the identification of studies and of the selection process of this meta-analysis. ro-RTV-driven: real-time viewer driven; ERLP: right
lateral position.
capsule without prokinetic as opposed to 876 individuals
who received a prokineric. There was evidence of hetero¬
geneity between study results (i2 = 37.9%, P = 0.058;
Figure 2). Because of heterogeneity, the DerSimonian—
Laird random-effects model was used for pooling of results;
this model is recommended - as the method of choice - by
the International Cochrane Collaboration '54 in order to
avoid unrealistically low 95% Cls that may arise from a
fixed-effects model analysis . The resulrs indicated that
the odds of having a complete SBCE were superior for
patients who ingested the capsule with a prokineric than
for those who did not receive a prokinetic agent; OR (95%
CI)= 1.96 (1.38-2.78), Figure 2. Furthermore, studies of
the same prokinetic were grouped together; for the
erythromycin studies25"24,27, no heterogeneity - in study
design or results - was detected (f =37.6%, P = 0.201;
Figure 2) and the pooled OR (95% CI) was 1.36 (0.61 —
3.03). In the metoclopramide group22'28'10"57, evidence of
heterogeneity between the studies was weak but present
(I2 = 38.3%, P = 0.103; Figure 2); the pooled random-
effect estimate of the OR (95% CI) for SBCE CR was
2.08 (1.35—3.21). Lastly, for the remaining four studies,
some evidence of heterogeneity was detected
(I2 = 58.7%, P = 0.064; Figure 2); the random-effect esti¬
mate of the OR (95% CI) was 1.89 (0.75-4.82).
Studies that used prokinetics with no bowel
purge and a straightforward study protocol (subgroup
1 )23,2<>-3 i were c[losen to investigate further the reasons
for heterogeneity. In order to exclude any possible influ¬
ence of a single study, we repeated the meta-analysis
with exclusion of each individual study one at a time.
This did not alter the pooled results. Moreover, we
performed sensitivity analyses by stratifying studies by
factors which could potentially influence the pooled
results, i.e. study design (prospective vs. retrospective),
use of bowel purge (howel purge + prokinetic vs. proki¬
netic alone), the most frequently and readily available
prokinetics used (metoclopramide vs. erythromycin vs.
rest), and Jadad scores. The results of these subgroup
analyses are shown in Figure 3. The number of included
studies was not sufficient to draw a conclusion regarding
other stratification factors.
© 2013 Informs UK Ltd www.cmrojournal.com Prokinetics in small-bowel capsule endoscopy kou/a—cl (2 To
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Study, year Control Prokinetic
Leung et al.23 No Erythromycin
Niv et al.27 No Erythromycin
Caddy et al.24 No Erythromycin
M-H Subtotal (l-squared = 37.6%, p = 0.201)
D+L Subtotal
MelocloDrarnide
Nakaji et al.33 No DKT + Medoclopramide
Selby22 No Metoclopramide
Song et al.31 No Metocloprarnide
Hosono et at.35 No-No RTV RTV + PEG + Metoclopramide
Zhang et al.34 No Metoclopramide
Almeida et al.30 NO Metoclopramide
Iwamoto et al.32 No Metoclopramide
Xiong et al.3/ NO Metoclopramide
Postgate et al.28 No Metoclopramide
Shiotani et al.38 No RTV(stat) + water(200ml) + RTV(30') + Metoclopramide
M-H Subtotal (l-squared = 38.3%, p = 0.103) RTV(60") + endoscopy
D+L Subtotal
Other orokinetic
Wei et al.28 No Mosapride
Hooks et al.20 Placebo Lubiprostone
Apostolopoulos et al.25 No Chewing-gum
Ida et al.38 No Mosapride
M-H Subtotal (l-squared = 58.7%, p = 0.064)
D+L Subtotal
M-H Subtotal (l-squared = 37.9%, p = 0.058)
♦
♦
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Figure 2. Forest plot of completion rate (CR), showing individual and pooled odds ratio (OR) with 95% confidence interval (CI) of studies comparing capsule







Seven studies22'26'28'30'32'35'36 examined SBCE DY in 401
patients who ingested the capsule with prokinetics (371
metoclopramide/30 mosapride) as opposed to 434 patients
who did not use prokinetics for capsule ingestion. Six of
the seven meta-analysed studies used metoclopramide as
prokinetic. There was no evidence of heterogeneity
between these studies ((' = 0, P = 0.914), therefore the
fixed-effects model was used for synthesis and presentation
of pooled results. There was a weak trend that the SBCE
DY ratio (pooled DY in the group who receive prokinetic/
total number of cases in the prokinetic group)/(pooled DY
in the control group/total number of control cases) was
superior for the patients who received prokinetics for cap¬
sule ingestion as opposed to controls, pooled RR (95%
CI) = 1.10 (0.96-1.27) (Figure 4). This may be due ro
the small number of studies and the heterogeneity due to
the different prokinetic agents used and diverse study
designs.
Gastric transit time (GTT)
Eight studies22'23,25'27'29'32'35'36 measured the average
SBCE GTT (min) in 391 subjects who ingested the capsule
with prokinetics (250 metoclopramide/74 erythromycin/
20 lubiprostone/47 chewing gum) as opposed to 410 sub¬
jects (20 placebo) who used no prokineric for capsule
ingestion. There was evidence of heterogeneity between
studies (l2 = 64-5%, P = 0.006). More specifically, hetero¬
geneity was detected in the erythromycin group23,27
(f2 = 73.8%, P = 0.051) and lubiprostone/chewing gum
studies25,29 (I2 = 87.2%, P = 0.005). However, no differ¬
ence between prokinetic and control in GTT was noted.
In the metoclopramide studies group, there was no evi¬
dence of heterogeneity and the use of meroclopramide
seem to affect GTT over controls; pooled difference in
© 2013 Informa UK Ltd www.crnrajournal.com Prokinetics in small-bowel capsule endoscopy Koulalc-- r. .. 11 77G H T S K4>
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Jadad











M-H Subtotal (l-squared = 0.0%, p = 0.521)
Erythromycin
Leung et al.23 No Erythromycin
Niv et al.27 No Erythromycin
M-H Subtotal (l-squared = 0.0%, p = 0.338)
Other proKinetlc
Wei et al.26 No Mosapride
Hooks et al.29 Placebo Lubiprostone
M-H Subtotal (l-squared = 86.1%, p = 0.007)
D+L Subtotal
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Figure 3. Forest plot of completion rate (CR), showing individual and pooled odd ratios (OR) with 95% confidence intervals (CI) of subgroup 1 studies (studies
with more homogenous protocols in which purging and/or real-time monitoring were not used) comparing capsule ingestion with prokinetics vs. no
prokinetics. In this subgroup of studies, there is no evidence of improved CR when the capsule was ingested with metoclopramide, erythromycin, mosapride
or lubiprostone.
the means in this group (GTT of control - GIT of proki¬
netic group) was 16.8.3 (14.30—19.37) (Figure 5). Ir is note¬
worthy that although the latter group included the two
studies that had RTV in their protocol5'''6, a clear effect
of metoclopramide on GTT was also evident in the stu¬
dies22''2 which did not utilize real-time monitoring.
(pooled difference in the means [95% CI]: —20.41
[—54.28, 13.45]). In the metoclopramide group, there
was no evidence of heterogeneity (/2 = 37.3, P = 0.173)
and its use had an effect on SBTT over controls; pooled
difference in the means (GTT of control - GTT
of prokinetic group) [95% CI]) = 24.30 [20.90-27.70]
(Figure 6).
Small-bowel transit time (SBTT)
Nine studies22'2'''5,27'29"'0'32'"''6 measured the average
SBCE SBTT (min) in 438 subjects who ingested the cap¬
sule with prokinetics (297 metoclopramide/74 erythro¬
mycin/20 lubiprostone/47 chewing gum) and 458
controls (20 placebos) who did not receive prokinetics
for capsule ingestion. There was no evidence of heterogen¬
eity within the prokinetic groups. More specifically, the
erythromycin studies23'24'27 showed 12 = 0%, P = 0.342
(and lubiprostone/chewing gum f" = 0%, P = 0.8616) in
the heterogeneity test. In the erythromycin group, no dif¬
ference between prokinetic and control in S i I was noted
Publication bias
Evidence of publication bias was also present (Figure 7) as,
when looking ar the metoclopramide group, small studies
with small effect were not found in the literature review.
Safety
No fatal complications were reported in any of the studies
included in this meta-analysis. More specifically, cases of
capsule retention were reported", but no capsule aspiration
was recorded and no bowel obstruction (Table 3).
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Figure 4. Forest plot of diagnostic yield (DY), showing individual and pooled relative ratio (RR) with 95% confidence intervals (CI) of studies comparing







Postgate et al.28 No
Iwamoto et al.32 No
Hosono et al.35 No-No RTV
Almeida et al.30 No
Selby22 No
Shiotani et al.3b No
Subtotal (l-squared = 0.0%, p = 0.884)
Other Drokinetic
Wei et al.26 No
Overall (l-squared --- 0.0%, p -- 0.914)
Metoclopramide
Metoclopramide
RTV + PEG + Metoclopramide
Metoclopramide
Metoclopramide
RTV(stat)+water(200ml) +■ RTV (30') + Metoclopramide + RTV (60') &
endoscopy
Mosapride











Favors Control Favors Prokinetic
More importantly, no sinister adverse effects from the use
of prokinetics were reported (Table 3).
Discussion
Since the image quality of SBCE is high40, the DY of SBCE
is only limited by two confounders which hamper SBCE
performance in complete evaluation of small-bowel muco¬
sal features: a) poor luminal visualization, and b) slow gas¬
tric and/or small-bowel transit time, which can prevent the
capsule from reaching the IC valve/caecum within the
capsule's battery life8. Although the latter may appear as
less of a problem, because of new capsule technology with
extended battery life, complete small-bowel transit theor¬
etically offers enhanced DY. Conversely, there has been
data to suggest that it is in fact the prolonged small-bowel
passage that may be associated with increased DY'41'42.
Therefore, various techniques and interventions have
been developed aiming to improve the clinical chances
for total enteroscopy'.
To date, there are three published meta-analyses10-12
showing that purgative cleansing of the small bowel before
SBCE significantly improves the quality of mucosal visu¬
alization, in comparison to clear fluid diet, although it does
not seem to affect the SBCE completion rate". In fact,
data suggest that up to 20-25% of patients undergoing
SBCE have an incomplete examination4. As a direct com¬
parison, if we were to measure colonoscopy caecal intub¬
ation rates <80%, this would undoubtedly be considered
very low, and every effort would be made to improve it'. It
is possible that hypertonic purge regimens may delay gas¬
tric emptying . With all that in mind, several proki-
netics8,9 have been assessed, yet there is still no
consensus on their use in SBCE. At the ICCE Consensus
Meeting in Miami (2006), it was recognized that although
there were several studies involving promotiliry prepar¬
ations and manoeuvres, this remains to date a contentious
issue8'9. Although different in regards to weight/size (3.6g
vs. 6.2g/llx26mm vs. 13 x 27.9mm, for PillCam/
EndoCapsule and OMOM, respectively), all these systems
have comparable battery life (8h)4'.
Erythromycin, a macrolide antibiotic with appealing
safety profile, acts on motilin receptors of the endocrine
cells of the duodenum24 and has well known prokinetic
properties. It induces high amplitude gastric propulsive
contractions. As a result, it accelerates gastric emptying
for both liquids and solids including that of non-digestible
particles''. Its commonest side effect is nausea, which in
the case of SBCE may limit its use22.
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Figure 5. Forest plot of gastric transit time (GTT), showing individual and pooled difference of means with 95% confidence intervals (CI) of studies comparing
capsule ingestion with prokinetics vs. no prokinetics (data from studies reporting relevant data). There was reduced GTT with metoclopramide, less clear













Nlv E et al.*7 No
l-V Subtotal (l-squared = 73.8%, p = 0.051)
D t-L Subtotal
Hooks et al.29 Placebo
Apostolopoulos et al.25 No
l-V Subtotal (l-squared = 87.2%, p = 0.005)
D+L Subtotal
Heterogeneity between groups: p = 0.070
l-V Overall (l-squared = 64.5%, p = 0.006)
D-fL Overall
Metoclopramide
RTV + PEG + Metoclopramide
RTV( stat)+water (200ml)+RTV (30')+Metoclopramide+









GTT (95% CI) (|.v)a
17.10 (14.46, 19.74) 80.79
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7.28 (-0.48, 15.04) 9.35
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15.60(0.51,30.69) 2.47






Metoclopramide, a dopamine D2 receptor agonist, has a
combination action of relaxing the pyloric sphincter and
improving the antro-duodenal co-ordination44. It has a
good rapid oral absorption30, with a peak plasma concen¬
tration at 56 min and half-life of 5 h. Tardive dyskinaesia
and other extra-pyramidal/dystonic reactions have been -
not infrequently - reported as idiosyncratic adverse effect
of its use.
Mosapride citrate is a prokinetic agent that acts as a
serotonin 5-hydroxyrryptamine-4 (5-HT4) agonist that is
mostly available in Asia and increases gastrointestinal
motility. Tegaserod, another 5-HT4 agonist is available
in Western countries'8. The latter was initially approved
by the FDA in 2002, but it was subsequently removed from
the market in 2007 due to FDA concerns about possible
adverse cardiovascular effects4'. A few years earlier, cisa¬
pride - an effective gastrokinetic agent - was associated
with fatal arrhythmias in susceptible individuals and was
withdrawn by the FDA in 199946.
Lubiprostone (Amitiza, Takeda Pharmaceuticals North
America, Deerfiled, 1L, USA) activates selectively the
type 2 chloride channels in the apical membrane of the
GI epithelium, resulting in net fluid secretion2". It has
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been approved by the FDA for the treatment of chronic
idiopathic constipation and constipation-predominant
IBS. Recent studies revealed that it accelerates small-
bowel transit as well as colonic transit time47.
Daikenchuto (DKT) is well known in Japan as an
effective treatment for reduced GI motility, but the mech¬
anism of action remains largely unknown. However, one of
the ingredients in DKT, Sancho (Xanthoxylum piperirum)
promotes acetylcholine release at the neuromuscular junc¬
tion of the digestive tract. It also increases motilin release,
hence gastrointestinal peristalsis .
Chewing gum, as a proxy for sham feeding, acts by a
cephalic—vagal axis. It increases salivary flow leading to
increased gastric emptying. It also increases the motility
of the small bowel and the colon2'. Apostolopoulos ct al.
used commercially available sugarless chewing gum, con-
raining xylitol as sweetener.
Our study demonstrates a lack of consensus in using
prokinetics in SBCE as well as a variety in study designs
which included different mode (oral or parenteral) and
riming of administration of prokinerics9. We found that
erythromycin studies2''24'27 were more homogeneous in
terms of study design (no RTV used, no concurrently
www.cmrojoumal.com 'q'm't S
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l-V Subtotal (l-squared = 37.3%, p = 0.173)
D+L Subtotal
Leung et al.23 No
Niv et al.27 No
l-V Subtotal (l-squared = 0.0%, p = 0.342)
D+L Subtotal
Hooks et al.29 No
Apostolopoulos et al.35 No
l-V Subtotal (l-squared = 0.0%, p = 0.816)
D+L Subtotal
Heterogeneity between groups: p = 0.024
l-V Overall (l-squared = 46.0%, p = 0.063)
D+L Overall










— 42.90 (-0.21, 86.01) 0.61
28.70 (-11.78,69.18) 0.69
34.80 (0.33, 69.27) 0.95
-5.00 (-30.10, 20.10) 1.79
24.60 (21.13, 28.07) 93.23
24.30 (20.90. 27.70) 97.25
22.15(8.63, 35.67)
-43.50 (-101.91, 14.91) 0.33
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-20.41 (54.28, 13.45)
- 30.80 ( 18.29,79.89) 0.47
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Figure 6. Forest plot of small-bowel transit time (SBTT), showing individual and pooled difference of means with 95% confidence intervals (CI) of studies
comparing capsule ingestion with prokinetics vs. no prokinetics (data from studies reporting relevant data). There was improved SBTT with metoclopramide;
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Figure 7. Funnel plot of studies included in this meta-analysis; evidence of publication bias is present.
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administered prokinetic or postural tricks), but there were
only a few studies regarding number ofparticipants. On the
other hand, metoclopramide-based studies22'28'10-17 were
higher in number and larger in terms of participants, yet
they were more heterogeneous in design and mode/rime of
administration of the medication. Lastly, prokinetics used
in a number of studies26'2"'11,18 are not widely avail¬
able26'1118 and/or associated with mild or significant side
effects2" (another one, Tegaserod considered as the
'Western world counterpart' of mosapride, has been with¬
drawn due to cardiovascular side effects)15.
Pooled results on CR show that ingesting the capsule
with prokinetics leads to a higher rate of complete small-
bowel examination than in controls (OR (95% CI]: 1.96
[1.38—2.78]). More specifically, metoclopramide is asso¬
ciated with higher CR (OR [95% CI]: 2.8 [1.35-3.20]);
no such effect is seen with erythromycin (OR [95% CI]:
1.36 [0.61-3.03]). Furthermore, when a smaller group of
'clear' i.e. more homogeneous in design studies was exam¬
ined (subgroup 1), where bowel purging and real time
monitoring were not used21'26-'11, the effect of either pro-
kinetic (metoclopramide and erythromycin) on comple¬
tion rate was not significant (Figure 2); metoclopramide
CR pooled OR (95% CI): 1.16 (0.58-2.33), erythromycin
CR pooled OR (95% CI): 2.27 (0.79-6.47) and for the
whole group pooled OR (95% CI) for CR of prokinetic
vs. control was 1.52 (0.71-3.23).
With regards to capsule transit parameters (GTT and
SBTT), the effect of prokinetics over control was clear for
both parameters. Metoclopramide administration for cap¬
sule ingestion resulted in a shorter GTT and SBTT
(pooled difference in the means [95% CI]: 12.47 [4.98-
19.95] and 19.31 [5.96—32.67], respectively). When the
RR of DY was calculated, there was no evidence that the
use of prokinetics confers any benefit in increasing the DY.
The present study had certain limitations. As with
every meta-analysis, conclusions are as reliable as the
underlying evidence available. The majority of the
included studies were heterogeneous and of low quality
with regards ro randomization and design for the purpose
of meta-analysis. It is noteworthy that patient populations
are heterogeneous as some studies have excluded partici¬
pation of individuals with diabetes mellifus24,26'14, one of
the main patient groups to get benefit from the use of
prokinetics. Furthermore, although we studied the
pooled DY in our meta-analysis, we did not examine the
effect of prokinetics on image quality and mucosal visual¬
ization for two reasons: a) prokinetics are unlikely to have
any significant effect on the intraluminal content (quan¬
tity and/or consistency), and b) there is no standardized or
validated scoring system for visualization/preparation qual¬
ity of SBCE.
In order to avoid further bias, wc have excluded
abstracts and cohort studies that may have reported further
useful results on the field4'. Furthermore, we excluded
studies, published as full papers, that looked mainly at
the effect of positional tricks i.e. right lateral position at
capsule ingestion48'49. There were only four studies using a
more rational and flexible approach by means of external
or integrated real-rime monitoring (nowadays an indis¬
pensable accessory in SBCE practice) and only two used
the combination approach of certain predefined non-inva¬
sive interventions prompted by RTV results. The latter
method should be considered most applicable in selected
inpatients with poor mobility, advanced age and/or dia¬
betes. Moreover, some retrospective studies excluded the
participants who developed gastric capsule retention and/
or prolonged gastric stasis of the capsule. Although it is
unlikely that future research will refute the results of exist¬
ing evidence, it is worth noting that as technology
advances and batteries are getting smaller and more
potent, incomplete SBCE (due to slow transit rime) will
probably be phased out. Furthermore, future studies should
evaluate specifically the benefit of a complete SBCE in
patient management.
In conclusion, the results of this meta-analysis show
that the use of prokinetics - and specifically that of meto¬
clopramide with purgative and/or RTV - in SBCE
improves completion rate. Although CR may appear as
less of a problem, due to new capsule technology wirh
extended battery life, as described in this manuscript, it
is important to conclude the efficacy of prokinetics.
Therefore, our results complement similar and exten¬
sive recent work in the field and relevant guidelines30-5'.
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Letters to the editor
We agree with Singh et al and with the comments of
Wallace4 in the editorial that accompanied our article
that recently developed classifications may prove useful
to characterize SSAs^ and that a single schema that distin¬
guishes hyperplastic polyps, adenomas, and SSAs would
be ideal.
We cannot lose sight of the fact that the first require¬
ment for the appropriate management of an SSA is to
see it. These lesions can be subtle. As Wallace points
out,"1 there is an emerging consensus to remove all
serrated lesions proximal to the sigmoid colon, and all
serrated lesions in the rectosigmoid larger than 5 mm.
Thus, even if these lesions are misclassified on the basis
of optical biopsy, the current standard of care is to remove
them. The bar will be much higher if we ever contemplate
a "diagnose and decide" instead of a "resect and discard"
strategy for these lesions—because the consequence of
misclassification would be to leave an SSA in place. A cur¬
rent priority must be to ensure that these lesions are seen
in the first place.
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Chewing gum and completion rate
in small-bowel capsule endoscopy:
meta-analyzing the data
To the Editor:
We read with great interest the study by Ou et al'
on the use of sugarless chewing gum in video small-
bowel capsule endoscopy (SBCE). Indeed, the authors
showed that chewing gum neither speeds up the
capsule transit nor increases the completion rate (CR)
of SBCE in patients without the "usual" risk factors
for incomplete studies. Recently, we conducted a
detailed meta-analysis of the use of prokinetics in
SBCE and found that their administration improves
the CR of the examination. However, we demonstrated
a current lack of consensus in the use of prokinetics in
SBCE.~ Our pooled results indicated that the odds of a
complete SBCE were superior in patients who ingested
the capsule with a prokinetic agent than in those who
did not receive a prokinetic agent (odds ratio [OR] =
1.96; 95% confidence interval [CI], 1.38-2.78). How¬
ever, because of the use of predefined criteria, we
included only 1 study with chewing gum/
Therefore, prompted by the data presented,1 we
decided to undertake a meta-analysis of a few studies
that examined the use of chewing gum in SBCE.1'3 4
The pooled odds ratios and 95% confidence intervals
were calculated, and the outcomes of individual studies
Funnel plot with pseudo 95% confidence limits
2.5 3 3.5 4 4.5 5
log(OR)
A Apostolopoulos,2008 • Lam,2010 ■ Ou, 2013
Lower CI Upper CI Pooled
Figure 1. Effect of chewing gum on completion rate in small bowel
capsule endoscopy (SBCE).
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Figure 2. Effect of chewing gum on small bowel transit time (SBTT). CI, confidence interval; OR, odds ratio.
were compared by use of the fixed-effects model
(Mantel-Haenszel method)."' Heterogeneity was as¬
sessed by use of the inconsistency index (I2) and
Cochran's Q test for heterogeneity; a low I2 <50%
would suggest that the differences in findings between
studies could be due to chance alone." Evidence of
heterogeneity was considered to be present if P < .10.
The included studies presented 3 sets of data, exam¬
ining the SBCE CR in 208 individuals who acted as con¬
trols, as opposed to 207 individuals who ingested the
capsule and chewed gum during the procedure. The
3 studies were homogeneous (I2 = 0; P = .994)
with a pooled OR = 1.05 (95% CI, 0.79-140), indicating
that there was no evidence that chewing gum affects
CR (Fig. 1). With regard to small-bowel transit time
(SBTT), no evidence of heterogeneity could be detected
(I2 = 27.2%; P = .253), although the latter may have
been due to the small number of studies. Despite that,
SBTT was estimated at a mean of 25.32 (95% CI, 9.07-
41.57), indicating that there was a significant decrease
in the SBTT of patients who chewed gum (Fig. 2). Over¬
all, these data do not support the use of chewing gum in
SBCE.
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Radiofrequency ablation of Barrett's
esophagus with the channel RFA endoscopic
catheter
To the Editor:
Endoscopic radiofrequency ablation (RFA) is an effec¬
tive and safe treatment for dysplastic Barrett's esophagus
(BE).1 Current delivery methods in use include the circum¬
ferential balloon-based (Halo 360) and focal catheter-based
devices (Halo 90, Halo 60).' These devices can be easily
advanced through nonobstructed esophagi. However, in
a patient with a tortuous, deformed, partially stenotic
esophagus or other anatomic abnormalities such as crico-
pharyngeal hypertrophy or cervical osteophytes, the pas¬
sage of the RFA device can be impeded. Here we report
the use of the novel channel RFA endoscopic catheter to
perform RFA.
A 56-year-old man who had undergone radiation and
chemotherapy for T3N0 HPVpl6+ squamous cell carci¬
noma at the base of the tongue was found to have BE
measuring C2 M3. He was planned for RFA treatment
of dysplastic segment on the basis of histologic appear¬
ance. As a result of the previous radiation therapy, his
Figure 1. A, Electrode panel of the endoscopic ablation catheter B, Through-the-scope insertion of the catheter through the working channel of the
endoscope. C, Endoscopic view showing patchy areas of Barrett's esophagus. D, Postablation use of the endoscopic ablation cathether.
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Introduction: Virtual chromoendoscopy is used to enhance surface patterns and colour differences. One
type of virtual chromoendoscopy is the Fuji Intelligent Colour Enhancement (FICE). Although widely
applied in conventional endoscopy, data on FICE application in capsule endoscopy are limited. Further¬
more, the validity of Blue filter (feature of RAPID® software) has not been examined.
Aim/s: We aimed to qualitatively evaluate the use of FICE and Blue filter enhancement, in images of lesions
obtained during small bowel capsule endoscopy, comparing them with similar, conventional (white light)
images.
Methods: A total of 167 images (6 different lesion categories) obtained from 200 capsule endoscopy
examinations. Two gastroenterologists examined the images with white light, FICE and Blue filter in
regards to the visibility ofblood vessels, the contrast of the mucosal surface, and the demarcation of lesion
borders. The agreed scores were: improved, similar, worse. Inter-observer agreement was calculated.
Results: For all lesion categories, Blue filter provided image improvement (compared to white light) in
83%, (inter-observer agreement: 0.786). With FICE 1, improvement was observed in 34%, worse image
in 55.9%, (inter-observer agreement: 0.646). With FICE 2, improvement was observed in 8.6%, worse in
77.5%, (inter-observer agreement: 0.617). With FICE 3, improvement was seen in 7.7%, worse in 79.9%
(inter-observer agreement: 0.669).
Conclusion: Comparing with FICE, Blue filter offers better image enhancement in capsule endoscopy.
© 2011 Editrice Gastroenterologica Italiana S.r.l. Published by Elsevier Ltd. All rights reserved.
1. Introduction
Virtual chromoendoscopy (VC) techniques are applied to
enhance the microvascular contour and improve resolution of sur¬
face patterns and colour differences [1]. The two VC modalities
in current clinical use are narrow-band imaging (NBI) [2] and
computed VC with the Fuji Intelligent Colour Enhancement (FICE)
system [1 ].
Computed VC (CVC) technology, developed at Chiba University
by Miyake et al. [3], is based on the selection of spectral transmit-
tance with a dedicated wavelength by narrowing the bandwidth
of white light to narrowed blue and green light. In contrast to NBI
though, where the bandwidth of the spectral transmittance is nar¬
rowed by optical filters [2], in CVC imaging is based on a new
* Corresponding author. Tel.: +44 131 2421126; fax: +44 131 2421618.
E-mail address: akoulaouzidisOhotmail.com (A Koulaouzidis).
spectral estimation technique that replaces the need for optical
filters.
In essence, the CVC software takes a conventional endoscopic
image from the video processor and arithmetically processes the
reflected photons to reconstitute virtual images for a choice of dif¬
ferent wavelengths [1.3]. Over the past few years, several studies
have examined the efficacy ofVC in the detailed analysis of mucosal
pit pattern, vascular intensity and enhancing detection and dif¬
ferentiation of neoplastic and non-neoplastic lesions of the upper
and the lower GI tract [3-10]. Although discrepant to a degree, the
majority of data point towards a positive effect in using VC.
Since its emergence, capsule endoscopy (CE) has had a major
impact on small-bowel endoscopy practice. Its current indications
include investigation ofobscure gastrointestinal bleeding/iron defi¬
ciency anaemia, assessment of known or suspected small bowel
Crohn's disease, coeliac disease, hereditary polyposis syndromes
and small bowel tumours [11,12].
Although VC is widely applied in conventional bidirectional
endoscopy and recently studied in double-balloon enteroscopy as
1590-8658/$36.00 © 2011 Editrice Gastroenterologica Italiana S.r.l. Published by Elsevier Ltd. All rights reserved,
doi: 10.1016/j.dld.2011.07.018
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well [13], its role in the detection of small bowel lesions has not
yet been clearly established [14], Furthermore, the application of
NB1 in CE - with its current level of technology - is limited. As NBI
is a real-time imaging modality, developmental improvements are
required in order for this technique to be useful in a clinical setting.
In contrast, F1CE does not require re-engineering of the capsule
device as such, but only integration of the FICE software in the
reading platform [1 ]. The integration of the FICE digital processing
system in the RAPID® v6.0 & 7.0 (Given® Imaging Ltd., Yokneam,
Israel) enables an instant switchover between an unmodified image
and a FICE image, at a click of a tab at the workstation. Blue Filter
(BF), an additional setting incorporated into the RAPID® software,
is a colour coefficient shift of light in the short wavelength range
(490-430 nm) superimposed onto a white (red, blue, green; RGB)
light image.
The spectrum of wavelength used for the creation of optical
images differs between flexible endoscopy and CE, thus up to three
mode settings have been selected as most suitable wavelengths
required for the evaluation of the CE [ 14j.
Both the validity of FICE in small bowel CE (SBCE) as well as the
optimal settings for improved image recognition in various small
bowel lesions has been studied only limited to present [14,15].
2. Aim
The aim of this retrospective study was to qualitatively evaluate
the use of FICE and BF enhancement in images of lesions, obtained
during SBCE, comparing them with similar images under white
light (predefined settings-Quick Adjust) without any filters.
3. Materials and methods
We retrospectively evaluated all images of lesions captured
(during SBCE) between December 2008 and January 2010. All
images were selected from video sequences of consecutive patients
who underwent SBCE as part of their regular diagnostic work-up.
SBCE was performed with Pillcam® SB1/SB2 (Given Imaging Ltd,
Yoqneam, Israel) capsule endoscopes, using the predefined for our
unit small bowel preparation regimen and procedural protocol.
One of the authors (SD), with extensive experience in CE, selected
thumbnail frames depicting pathology images from 200 examina¬
tions and group them in 6 different lesion groups. Normal or low
quality images were excluded from further review. This author did
not participate in further evaluation of the images.
Two certified gastroenterologists, both familiar with SBCE
[(CK) with SBCE reviewing experience >50 videos and (AK) with
extensive SBCE reviewing experience >700 CE video sequences],
evaluated the images using the RAPID® ver.7 software and blinded
to each other. Both authors are familiar with FICE and use it regu¬
larly in conventional endoscopy.
The images were initially examined with white light and there¬
after with the FICE mode.
The FICE settings used were as follows:
FICE 1 [RGB wavelength, nm (595, 540, 535)],
FICE 2 [RBG wavelength, nm (420, 520, 530)], and
FICE 3 (RBG wavelength, nm (595, 570,415)].
In addition, BF (wavelength 490-430 nm) was also applied.
Patient demographic, clinical characteristics and indications for
SBCE were also recorded.
We had previously found that a specific combination of sharp¬
ness level (grade 3) and brightness level (grade 0) enhanced all
images, even before the application of any filters and therefore
Table 1
Demographics and indications for small bowel capsule endoscopy (SBCE). type of
lesions examined with white light, FICE and Blue filter. M/F; male/female, SD: stan¬
dard deviation. CI; gastro-intestinal, PHE; portal hypertensive enteropathy.
No. of patients (M/F) 52(21/31)
Age (years) mean - SD, median 56,13 ± 19.13, 58
Indications for SBCE Nine patients presented with more than 1 indication
Iron deficiency anaemia 30
Obscure GI bleeding 9
Chronic abdominal pain 6
Diarrhoea 4
Weight loss 3








Lesions of indeterminate clinical signilicance 13
Lymphangiectasias 13
Polypoid lesion/structure 3







we agreed to adopt those settings as our standard baseline for this
study (Quick Adjust settings).
White light (with Quick Adjust toggle button on) SBCE images
were compared with FICE and BF images applying the following
criteria:
(a) The visibility of blood vessels,
(b) the contrast of the mucosal surface, and
(c) the demarcation of lesion borders.
The side-by-side comparison between white light and FICE or
BF images was qualitatively evaluated using three quality scores:
Improved, Similar and Worse.
Improved was defined as: "improved visualisation, aiding lesion
characterisation, and enhanced delineation of lesion surface or
borders".
Similar was defined as: "no change in any of the aforementioned
parameters".
Worse was defined as: "poor visualisation or inability to charac¬
terise a specific lesion".
The r-test for continuous variables and the chi-square (/2)
test for categorical variables were used. A p value of <0.05
was considered statistically significant. Inter-observer agreement
between two rates was calculated using Cohen's kappa coefficient.
Kappa < 0.4 was considered as poor agreement whereas between
0.41 -0.6 as moderate, 0.61-0.80 substantial and 0.81 -1.00 as excel¬
lent agreement.
4. Results
A total of 167 small bowel images/lesions, from 52 patients
(21M/31F, mean age 56.13 ±19.13 years; median age: 58 years)
who underwent SBCE for a variety of indications, were included in
our study (Fig. 1).
Patient demographics and clinical characteristics, as well as
SBCE indications and types of lesions examined are summarised
in Table 1.
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Fig. 1. Comprehensive table of images with white light. FICE 1, FICE 2, FICE 3 and Blue filter of ulcer row 1. polyp row 2, angiectasia row 3. cobblestone mucosa row 4.
Overall, with BF, as compared with white light, image improve¬
ment was observed in 83%, no change in 12% and worse in 3%. With
FICE 1, improvement was observed in 34%, no change in 8.9% and
worse in 55.9%. With FICE 2, improvement was observed in 8.6%,
no change in 13% and worse in 77.5%. With FICE 3, improvement
observed in 7.7%, no change in 12% and worse in 79.9%.
Inter-observer agreement was 0.786 for BM, 0.646,0.617,0.669
for FICE 1, FICE 2, FICE 3, respectively.
In the ulcer/aphthae images group: BF offered an image
improvement in 93%, no change in 5.8% and made it worse in 3.3%.
With FICE 1, improvement was observed in 36.6%, no change in 9%
and worse in 54%. With FICE 2, an improvement was observed in
3%, no change in 13% and worse in 83%. With FICE 3, improvement
was observed in 3%, no change in 6.6% and worse in 90%.
Inter-observer agreement was 0.476,0.487,0.710 and 0.642 for
BF, FICE 1, FICE 2 and FICE 3, respectively.
In the villous oedema images group: with BF an improvement
observed in 73.5%, no change in 26.4% and worse in 0%. With FICE
1. an improvement was observed in 14.7%, no change in 14.7% and
worse in 70.6%. With FICE 2, an improvement observed in 5.8%, no
change in 14.7% and worse in 79.5%. With FICE 3 an improvement
observed in 14.7%, no change in 0% and worst in 85.3%.
Inter-observer agreement was 0.549, 0.625, 0.553 and 0.767
with BF, FICE 1, FICE 2 and FICE 3, respectively.
In intraluminal blood images group: with BF an improvement
was observed in 73.3%, no change in 20% and worse in 6.7%. With
FICE 1, an improvement was observed in 56.6%, no change in 6.6%
and worse in 30%. With FICE 2 an improvement was seen in 20%,
no change in 6.6% and worse in 73.4%. For FICE 3, an improvement
was observed in 13.3%, no change in 6.6% and worse in 80%.
Inter-observer agreement was 0.4, 0.528, 0.675 and 0.643 with
BM, FICE 1, FICE 2 and FICE 3, respectively.
In lesions of indeterminate clinical significance (LICS) images
group: with BF an improvement was observed in 92.3%, no change
in 7.7% and worse in 0%. For FICE 1, an improvement was seen in
50%, no change in 7.6% and worse in 42.4%. For FICE 2 an improve¬
ment observed in 19.2%, no change in 19.2% and worse in 61.6%. For
FICE 3, an improvement observed in 11.5%, no change in 3.8% and
worse in 84.7%.
Inter-observer agreement was 1, 0.610, 0.604 and 0.536 for BF,
FICE 1, FICE 2 and FICE 3, respectively.
In the angioectasias/arterio-venous malformations (AVM)
images group: with BF an improvement observed in all patients
(100%). For FICE 1 an improvement observed in 77.7%, no change
in 8.3% and worse in 11.1%. For FICE 2 an improvement observed in
27.7%, no change in 13.8% and worst in 50%. For FICE 3 an improve¬
ment observed in 5.5%, no change in 38.8% and worse in 55.57%.
Inter-observer agreement was 1 in BF, 0.557 in FICE 1, 0.688 in
FICE 2 and 0.583 in FICE 3.
In the mucosal cobblestoning images group: with BF an
improvement observed in 86.36%, no change in 13.6% and worse
in 0%. For FICE 1 no improvement observed, no change observed in
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Table 2
Results of the study of F1CE 1,2,3 and Blue filter in image enhancement in SBCE; l/A:
inter-observer agreement, LICS: lesions of indeterminate clinical significance, AVM:
arterio-venous malformations. The presented numbers in the improved, similar and
worse categories are percentages (%).
Improved Similar Worse I/A
FICE 1
Ulcer/aphthae 36.6 9 54 .487
Villous oedema 14.7 14.7 70.6 .625
Blood in lumen 56.6 6.6 30 .528
LICS 50 7.6 42.4 .610
AVM 77.7 8.3 11.1 .557
Cobblestoning 0 13.6 86.36 .621
Overall 34 8.9 55.9 .646
FICE 2
Ulcer/aphthae 3 13 83 .710
Villous oedema 5.8 14.7 79.5 .553
Blood in lumen 20 6.6 73.4 .675
LICS 19.2 19.2 61.6 .610
AVM 27.7 13.8 50 .688
Cobblestoning 9 0 91 .633
Overall 8.6 13 77.5 .617
FICE 3
Ulcer/aphthae 3 6.6 90 .642
Villous oedema 14.7 0 85.3 .767
Blood in lumen 13.3 6.6 80 .643
LICS 11.5 3.8 84.7 .536
AVM 5.5 38.8 55.57 .557
Cobblestoning 0 0 100 1.0
Overall 7.7 12 79.9 .669
Blue filter
Ulcer/aphthae 93 5.8 3.3 .476
Villous oedema 73.5 26.5 0 .549
Blood in lumen 73.3 20 6.7 .4
LICS 92.3 7.7 0 1.0
AVM 100 0 0 1.0
Cobblestoning 86.36 13.6 0 .621
Overall 83 12 3 .786
13.6% and worse in 86.36%. For FiCE 2 an improvement observed
in 9%, no change in 0% and worst in 91%. For FICE 3 worse images
observed in all patients.
Inter-observer agreement was 0.621 in BF, 0.621 in FICE 1,0.633
in FICE 2 and 1 in FICE 3. A summary of the results is presented in
Table 2.
S. Discussion
gastric mucosa and the early gastric cancers was 530 nm. The
score of the FICE observation improved in 46% of cases [16],
In transnasal endoscopy, the FICE system wavelengths settings
[RBG; 470nm, 500nm, 550nm) enables greater colour difference
between palisade vessels and provides better contrasting images of
the demarcation between the BE mucosa and the gastric mucosa,
and thus contributes to easier diagnosis of endoscopic BE compar¬
ing with white light endoscopy (6).
There are only limited data in literature evaluating the use of
FICE system in small bowel capsule images [14,15). Furthermore,
there are no studies examining the validity of BM in image enhance¬
ment. We conducted a study of the newly developed CVC system
(incorporated in RAPID® version 6 and 7) that enhances the con¬
trast of the mucosal surface. BM improved most of the images
(overall image enhancement 83%), with a range between 73.3 and
100%, in different lesions groups. Although we report an overall
substantial inter-observer agreement of0.786, the k coefficient var¬
ied between different groups. Ulcers, villous oedema, and blood
in lumen presented a moderate inter-observer agreement, Crohn's
mucosal cobblestoning substantial agreement, whereas angioec-
tasias/AVMs and LICS excellent agreement.
Moreover, FICE 1 improved the definition in 34% of the images.
FICE was effective in improving images in 56.6, 50 and 77.7% in
blood in lumen, LICS and AVM, respectively. The inter-observer
agreement was similar in these three subgroups. The results regard¬
ing AVM are comparable to the recent study by Oka et al. [15],
reporting an improvement in 87% of cases.
FICE was only partially effective in ulcer/aphthae group with an
image improvement in 36.6% of cases. In that respect, our results
differ from those reported in study by Oka et al. [ 15], where a much
higher image enhancement rate (55.3%) was perceived. There was
no significant image improvement in other lesion subgroups.
FICE 2 and FICE 3 was ineffective to improve images (overall 8.6
and 7.7% improvement in FICE 2 and 3, respectively) with a sig¬
nificant agreement between the two readers. These results differs
completely from the study by Oka et al. [15), reporting image qual¬
ity improvement of FICE 2 settings in 87% and 25.5% of AVM and
ulcerations, respectively. Thus, our opinion is that the use of FICE
in the small bowel capsule is limited. On the contrary, BF showed
promising results and its use as the main viewing mode, espe¬
cially in cases of obscure GI bleeding, should be further examined
in regards to feasibility and in connection with the diagnostic yield.
CVC technique is based on narrowing the bandwidth of the
conventional endoscopic image arithmetically, using spectral esti¬
mation technology [ 1 ]. FICE has been used both in upper and lower
GI endoscopy and proved to be effective in improving diagnos¬
tic yield by enhancing contrast between background and surface
abnormalities. Currently in the published literature, there is no
agreement evaluating the accuracy of FICE, especially in regards
to the optimal wavelength filters [15].
In one recent study, FICE-filter 4 [red, green, and blue (RGB)
wavelengths of 520, 500, and 405 nm, respectively] with magnifi¬
cation has been shown to improve the image quality of the colonic
vascular patterns obtained with white light endoscopy [8].
In another one, the combination of the following 3 FICE wave¬
lengths (RBG): 420nm, 490nm, and 540 nm proved to be superior
to conventional endoscopy for capillary-pattern diagnosis but not
adding much to pit-pattern diagnosis, in regards to prediction of
histology for small colorectal polyps [7 ].
The classification of colorectal tumours by FICE (RGB wave¬
lengths of 540,460, and 460 nm) with magnification correlated well
with the histopathological diagnoses, whereas the findings were
similar to NBI magnification [10].
In the upper GI tract, the wavelength that generated the opti¬
mal difference of the spectral reflectance between the normal
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QuickView in small-bowel capsule endoscopy is useful in
certain clinical settings, but QuickView with Blue Mode
is of no additional benefit
Anastasios Koulaouzidis3, Alexandros Smirnidis3, Sarah Douglas3
and John N. Plevris3,b
Background Analysis of small-bowel capsule endoscopy
(SBCE) is time-consuming. QuickView (QV) has been
added to the RAPID software to reduce the reading times.
However, its validity is still under intense review. Recently,
we have shown that Blue Mode (BM) provides
improvements in images for most lesion categories.
Aim To assess the validity of QuickView with white light
(QVWL) and QuickView with Blue Mode (QVBM) reading, in
a group of patients who underwent SBCE in our centre, by
comparing it with the standard video sequence review
(used as reference) by experienced SBCE readers.
Methods This was a retrospective study; all SBCE
(August 2008-November 2011), performed with PillCam
SB, with complete small-bowel visualization were included.
A clinician with previous SBCE experience, unaware of the
SBCE reports, reviewed prospectively the video streams
on RAPID platform using QVWL and QVBM. All SBCE had
been reported previously using the standard mode; these
reports were considered as the reference. There were
106 cases of obscure gastrointestinal bleeding (OGIB),
81 cases of known or suspected Crohn's disease (CD)
and 10 cases of polyposis syndromes.
Results The mean small-bowel evaluation was 475
(±270) s and 450 (±156)s for QVWL and QVBM,
respectively. In the OGIB (n = 106; 21 overt/85 occult), with
QVWL, 54 [P0 (28), P1 (18), P2 (8)] lesions were detected,
63 [P0 (48), P1 (13), P2 (2)] with QVBM, as compared with
98 [P0 (67), P1 (23), P2 (8)] by standard (reference)
Introduction
Small-bowel capsule endoscopy (SBCE) has revolutionized
the investigation of the small bowel. Recent meta-analyses
have shown that SBCE has a higher diagnostic yield in
obscure gastrointestinal bleeding (OGIB), known or
suspected Crohn's disease (CD) and small-bowel polyposis,
compared with most radiological imaging modalities [1-3],
Furthermore, in most centres, it remains the first-line
option over more invasive tools that is, deep (or device-
assisted) enteroscopy [4]. Nevertheless, one of the
limitations of SBCE is the reading time required for the
interpretation of lengthy video streams. It is generally
accepted that the average time for video sequence analysis
is between 40 and 120min, depending on the overall
recording time and the reviewer's experience [5].
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reporting. For P1 + P2 lesions, the sensitivity, specificity,
positive predictive value and negative predictive value for
QVWL (as compared with reference reporting) were 92.3,
96.3, 96 and 92.8%, respectively. For QVBM, the above
values were 91, 96, 96.2 and 90.6%, respectively. Eighty-
one (n=81) patients underwent SBCE for small-bowel
evaluation on the basis of a clinical history of suspected or
known CD. With QVWL, 71 mucosal ulcers were detected,
68 with QVBM, as compared with 155 mucosal ulcers with
reference reading. Finally, in the polyposis category with
QVWL and QVBM, four polypoid lesions were detected
compared with seven with standard (reference) review.
Conclusion QV can be used confidently in OGIB in an
urgent inpatient setting and in outpatients with occult
OGIB or suspected CD. Furthermore, BM does not
confer any additional advantage in the QV setting.
Standard review settings should be used in all other
cases. Eur J Gastroenterol Hepatol 24:1099-1104 © 2012
Wolters Kluwer Health | Lippincott Williams & Wilkins.
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Because of high workloads, attempts have been made to
reduce physician involvement through the use of assistants/
extenders for the preliminary review of the video sequence
or through the use of software that aids interpretation [5,6].
The main question with the latter approach is whether a
rapid review, where a percentage of images are discarded,
would miss clinically relevant pathology. The current
version of RAPID capsule review software incorporates
the QuickView (QV) mode, allowing a speedy video review.
However, the QV mode is still under clinical validation and
there are only four studies that have examined the utility
of this informatic algorithm [5,7-10]. Recently, we have
shown that SBCE evaluation with Blue Mode (BM) yields
promising results and have recommended further study of
this, as the main viewing mode, especially in cases of
DOI: 10.1097/MEG.0b013e32835563ab
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OGIB [11]. BM or a blue filter is a colour coefficient shift
of light in the short wavelength range (490-430 nm)
superimposed onto a white light (WL) [red, blue, green
(RGB)] image. It can be applied easily through the quick
adjust toggle button menu.
Aim
To assess the validity of QuickView under white light
(QVWL) and QuickView under Blue Mode (QVBM)
reading mode, in a group of patients who had undergone
SBCE in our centre, by comparing it with the standard
(reference) video sequence review by experienced SBCE
readers.
Materials and methods
Patients and small-bowel capsule endoscopy procedure
Between August 2008 and November 2011, 248 patients
underwent SBCE with PillCam SB in our centre (132
performed with PillCam SB1 and 116 with PillCam SB2;
Given Imaging Ltd, Yokneam, Israel). The demographics
and clinical characteristics of this group are presented
in Table 1. Our standard procedure protocol involves a
strict liquid diet 12 h before the test and 2 litres of a
polyethylene glycol-based purgative for small-bowel
cleansing, with an overnight fast (Moviprep; Norgine,
Harefield, Uxbridge, UK). The capsule is ingested with
40-100 mg of antifoam (simethicone) and 5 mg of liquid
prokinetic (domperidone), except under exceptional
circumstances. The patients are allowed to drink clear
fluids after 2h and consume a light meal/snack after 4h.
For the purpose of this study, only SBCE videos with
complete small-bowel transit were included for further
QV analysis. The videos had already been reviewed - for
the purpose of regular clinical care - by at least one of
two experienced in SBCE readers (A.K. and S.D. >800
reviews each). Our standard viewing mode is SingleView
or DualView on automatic speed at 12-20 frames
per second (fps), respectively.
A research fellow (with experience in both conventional
and capsule endoscopy; > 200 SBCE reviews), who had not
been involved in either patient care or the initial SBCE
review, analysed the video sequences with QV (under hoth
WL and BM). The reviewer was blinded to any previously
captured landmark or thumbnailed findings and to patients'
clinical history and indications for the test.
QV mode reading SBCE analysis was performed using the
RAPID 7 workstation (Given Imaging Ltd). One of the
authors (A.S.) used only QV selecting landmarks and
thumbnailing abnormal images. All pathological images
and times were entered in a spreadsheet. The reviewer
used QVWL first (for the entire cohort) and QVBM
second, reviewing sequences in a random order to
minimize observer bias. He used QV with an image
sampling rate (sensitivity) of 35% in the DualView
display mode at 18 fps, sitting arms-length from a
Table 1 Demographics and indications for small-bowel capsule
endoscopy in the study cohort
W(%)
Complete SBCE Incomplete SBCE
Participants 200 (included) 48 (excluded)
Male 85 (42.5) 22 (45.8)
Age (±SD) 57.5 (±14.2) 63.1 (±13)
SBCE with PillCam SB1 1 25 (62.5) 30 (62.5)
Indications for SBCE
OGIB 106 (53) 21 (43.7)
CD (suspected or known) 81 (40.5) 26 (54.2)
Polyposis syndromes 4 (2) 0
Coeliac disease 3 (1.5) 0
Possible SB lesion or mass 6 (3) 1 (3.4)
CD, Crohn's disease; OGIB, obscure gastrointestinal bleeding; SBCE, small-
bowel capsule endoscopy.
19-inch monitor in a quiet room with dimmed lights.
The small-bowel evaluation time (time from entry to exit
from the small bowel) was recorded for each patient. This
included both the reading time and the thumbnail
capture time for each of the two QV modes. To minimize
reviewer tiredness, reviewing sessions were restricted to
10 video sequences per day. The results of QVWL and
QVBM reviews were compared with the results of the
conventional (reference) reviews, by checking each
thumbnail against all previously captured thumbnails,
by two reviewers (A.K. and A.S.).
Classification of lesions
Findings in the OGIB group were classified as P0
(nonpathological), PI (low/intermediate) or P2 (high
bleeding potential) lesions [12]. To avoid reporting bias,
in the suspected or the known CD group, only the most
objective capsule endoscopy parameters and descriptors
of mucosal inflammation were used, that is ulcer (defined
as any pale or yellow-based mucosal break surrounded by
a red or a pink collar) less than 1/4 of the intestinal lumen
circumference, ulcer 1/4-1/2 of the lumen circumference,
ulcer more than 1/2 of the lumen circumference± luminal
stenosis, as defined by the Lewis score [13], The
performance of QV was defined as concordance between
frames thumbnailed by the QV reader and frames
selected during the standard/conventional review.
The sensitivity, specificity, negative predictive value
(NPV) and positive predictive value (PPV) for QVWL
and QVBM - compared with the reference review — for
clinically relevant (i.e. P1/P2) vascular lesions and for
mucosal ulcers of any size were calculated in the OGIB
and suspected/known CD referral groups, respectively.
Ethics consideration
This study was carried out in accordance with UK
research ethics guidelines. After review by the local
ethics committee, further specific ethical review and
approval were not required, as the study was considered a
retrospective clinical audit work using data already
obtained as part of regular patient care.
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Statistical analysis
Values are expressed as mean±SD. A two-sided P value
less than 0.05 was considered statistically significant.
Statistical analysis was performed using the GraphPad




A total of 200 SBCE examinations were complete to
caecum and included in this study. The mean evaluation
time (including reading and time to mark thumbnails) in
this cohort was 475 (±270) s and 450 (±156) s for QVWL
and QVBM, respectively (P= 0.363). If all findings (i.e.
any P category lesion, any size ulcer and any size polyp)
were counted, QVWL detected 129 lesions (49.6%),
QVBM detected 135 lesions (51.9%) and the conventional
(reference) review detected 260 lesions (P < 0.0001)
(Table 2).
Obscure gastrointestinal bleeding
One hundred and six (53%) SBCE were performed for
OGIB, 21 (10.5% included videos) for overt OGIB and 85
(42.5% of included videos) for occult OGIB. With QVWL,
54 (55.1%) lesions [P0 (28), PI (18), P2 (8)] were
detected, whereas with QVBM, 63 (64.3%) lesions were
detected [P0 (48), PI (13), P2 (2)]. Standard (reference)
SBCE reading detected 98 lesions [P0 (67), PI (23), P2
(8)] (P = 0.0506).
Concordant results (normal SBCE i.e. no findings and/or P0
lesions only) between QVWL and reference reading were
observed in 101/106 (95.3%) cases and discordant results in
five (4.71%), 4/5 false negative with QVWL. With QVBM
reading, concordant results (for no findings and/or only P0
lesions) between QVBM and reference reading were
observed in 89/106 (84%) cases and discordant results in
17 (16%), 14/17 false negative with QVBM.
For QVWL, the sensitivity, specificity, PPV and NPV for
PI + P2 lesions (as compared with reference reporting)
were 92.3, 96.3, 96 and 92.8%, respectively. For QVBM, the
above values were 91, 96, 96.2 and 90.6%, respectively.
Suspected/known Crohn's disease
Eighty-one (40.5%) patients underwent SBCE for small-
bowel evaluation on the basis of a clinical history of
suspected or known CD. With QVWL, 71 (45.8%) [< 1/4
(62), 1/4—1/2 (3), >1/2 (6)] mucosal ulcers were detected,
68 (43.9%) [< 1/4 (51), 1/4-1/2 (9), >1/2 (8)) with QVBM,
as compared with 155 [< 1/4 (137), 1/4-1/2 (10), >1/2 (8)]
ulcers with reference reading, P = 0.0003.
Concordant negative results (i.e. no findings/nonspecific
findings and/or <3 small ulcers) between QVWL and
reference reading were observed in 73 (90%) and discordant
results in eight (9.9%), 8/8 false negative with QVWL.
Concordant negative results between QVBM and reference
reading were observed in 73 (90%) and discordant results in
eight (9.9%), 7/8 false negative with QVBM.
In the suspected CD category (15 patients; 12 mucosal
ulcers with reference review of which ulcers <1/4: 10,
ulcers > 1/4: 2), the overlooked lesions (ulcers < 1/4: 6)
would have potentially changed the diagnosis in one case.
When analysing QVWL and ulcer size (i.e. <1/2, 1/4—1/2
and >1/2 luminal circumference), the sensitivity was
42%, PPV 97% (as compared with reference reporting),
increasing to 100% for large ulcers (1/4—1/2 and >1/2).
For QVBM, the sensitivity and PPV were 52 and 91%,
respectively, again increasing to 100% for large ulcers
(1/4-1/2 and >1/2).
Polyposis syndromes
Ten (5%) patients underwent SBCE for the evaluation
of polyposis syndromes or because of a strong clinical
suspicion of a primary or a secondary small-bowel mass/
tumour lesion. With QVWL and QVBM, four polypoid
lesions were detected (the same individual lesions for
both modes) compared with seven with standard
(reference) review.
Discussion
Reading SBCE has certain limitations. First, the diag¬
nostic yield is usually dependent on the experience of the
reader. Second, the uncontrolled capsule movement does
not allow visualization of the entire small-bowel mucosa.
However, the main limitation is that an accurate com¬
plete review of the generated videos is time-consuming,
especially in a busy specialist GI department setting.
Various strategies have been suggested to deal with the
latter. The use of endoscopy nurses and physician
assistants/extenders has been advocated [6,14,15] as, for
many, SBCE represents a straightforward extension of
existing endoscopic skills [16]. Although there is no strict
guidance for the best standard/conventional SBCE read¬
ing technique and speed, the unique features of SBCE
require the reader to be intensely focused and alert [16].
Nevertheless, lapses in concentration or distractions
cannot be prevented in lengthy reading sessions.
In most tertiary, high case-volume centres, SBCE are
usually reviewed by examiners who may not be further
involved in the patient's management. This requires a
quick turnaround time from capsule-to-report (for the
nonurgent cases) and reviewer availability/flexibility [16].
Furthermore, there are clinical settings where a timely
report is crucial for further clinical management that is,
inpatients with OGIB and patients with severe CD.
Therefore, there is immense interest in techniques and
methods that reduce the evaluation time in capsule
endoscope without jeopardizing diagnostic accuracy.
Software approaches have been developed to fulfil this
requirement. One example is the QV reading mode. QV
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Table 2 Angioectasias, ulcers and polyps detected with each of the study's viewing modes
Angioectasias (A/) Mucosal ulcers (circumference-luminal size)
Type of lesions P0 P1 P2 <1/4 1/4-1/2 >1/2 Polyps Total
Viewing mode
Standard view 67 23 8 137 10 8 7 260
QVWL 28 18 8 62 3 6 4 129
QVBM 48 13 2 51 9 8 4 135
QVBM, QuickView with Blue Mode; QVWL, QuickView with white light.
creates a preview of the entire video sequence, thus
allowing a fast-forward-type review of interesting sites. It
highlights sample images, using different sampling rates,
within each region of the video by analysing colours and
patterns. RAPID current version allows the reviewer to
set the QV sampling rate from 5 to 80% of video images at
5% increments. To date, studies have shown conflicting
results in the clinical use of QV [5,7-10,17-19] (Table 3).
Recently, virtual chromoendoscopy (VC) has been reported
to improve the performance of SBCE. We have shown that
BM, a form of VC that is incorporated into the RAPID
software, improves the definition of mucosal lesions and
possibly increases the detection rate [11,20]. The two
features, that is, QV and B\1 should be considered as
'quantitative' and 'qualitative' as they aim to decrease the
reviewing time and enhance the detection of small-bowel
lesions, respectively. The combination of QVand VC (BM)
has not been studied to date.
Consequently, we aimed to evaluate the utility of
combining the QV mode with BM and WL. Notably, this
is the first study to check the QV reading on version 7 of
the RAPID software. Moreover, a detailed and strict
protocol was followed (single reviewer, not more than 10
video reviews/session, low reading speed of 18fps on the
viewing speed slider and DualView frame mode for all
reviews), we included a large number of SBCE and did
not restrict the study to a single indication to have a
realistic representation of everyday clinical scenarios.
In our OGIB group, all P2 lesions were detected with
QVWL; therefore, when urgent SBCE analysis is neces¬
sary - for further immediate management planning - the
QV mode can provide an accurate diagnosis within a few
minutes in the majority of cases. Furthermore, in this
clinical setting, our study shows that BM does not confer
any additional advantage over WL. QV has a high PPV (all
P2 lesions and large ulcers were detected); however, the
NPV was just above 90% (for small angioectasias),
although this should be interpreted with caution as the
clinical relevance of missing such lesions is not necessa¬
rily significant on clinical grounds [21-23].
Conversely, QV showed only 50% sensitivity for small
ulcers and aphthae in the known/suspected CD group. In
the suspected CD category, lesions that were detected
with the reference review and missed by QVWL or
QVBM review would have resulted in a different
diagnosis in only one case. These results are in agreement
with those of Westerhof et al. [9], who advocate the use of
QV solely in the suspected CD group, when multiple and
widespread lesions of mucosal inflammation are present.
Moreover, we found that BM, despite excellent results in
lesion characterization [11], does not confer any addi¬
tional benefit (over WL) in lesion detection in a QV
setting. This is not dissimilar to a recently published
study from our centre, where BM did not confer any
added benefit over WL in Lewis score calculation [24].
Furthermore, this is not in agreement with recently
reported data of Abdelaal et al. [25], although admittedly,
the video-reviewing setting was different.
An inherent limitation of this study, similar to previous
studies, is that QV has been compared against 'conven¬
tional/standard' viewing. Although the initial review was
performed by experienced capsule endoscopists and at a
low speed for the purpose of regular clinical care, it is not
possible to determine whether strict reviewing conditions
(similar to those applied by AS in the QVWL/QVBM
review) were implemented constantly. Another intrinsic
limitation of the present study is the use of a single, less
experienced reviewer, for both QV modes (QVWL and
QVBM, albeit not in a consecutive manner for each video
stream), which increases the risk of interpretation bias.
Moreover, although the review was performed in a
random order, this has not offset the potential for
observer bias. However, it is noteworthy that recent
studies have shown that the SBCE detection rate is not
necessarily linked to medical background or reviewer
experience [14,15,26]. We should also acknowledge that
by including only SBCE with complete small-bowel
transit, we have introduced potential applicability limita¬
tions. Furthermore, two generations of PillCam SB have
been used in this study and one should keep in mind the
improvement in the field of view from SB1 to SB2
(although this does not alter our results). Finally, this
paper is based on the number of lesions detected; as it is
common to find several 'repetitive' lesions in the same
patient, an overestimation of the concordance between
the two reading modes may occur. In an attempt to
overcome this, we reported the change in the diagnosis of
patients with suspected CD.
Conclusion
Our study confirms the safety of QV preread in urgent
cases, but fails to show any benefit in other clinical
Copyright © Lippincott Williams & Wilkins. Unauthorized reproduction of this article is prohibited.
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Table 3 Studies evaluating QuickView to date
Average Missed
QV QV reading reading Comparison QV QV lesion
sampling frame mode time read frame RAPID No Cases OGIB CD Polyposis sensitivity specificity (no
References rate (%) speed (min) mode speed ver reviewers total cases cases cases Other (%) (%) cases)
Schmelkin [17]a N/S N/S N/S N/S 4.0 1 47 47 N/S N/A N/A 100 100 N/A
Diaz et al. [18]a N/S N/S
25, 15,
5 fps
N/S N/S 2 57 37 12 N/S 10 N/S N/S N/S
Appalaneni N/S Single 3 N/S 2 50 N/S N/S N/S N/S N/S N/S 2
et al. [19]a 25 fps
Westerhof High (17) N/S 4.4 Conventional 4.0 2 100 56 30 2 12 N/S N/S 13
et al. [9] (median) DualView
18 fps
Hosoe et al. [8] Normal N/S N/S N/S 5.0 3 45 N/S N/S N/S 14 N/S N/S N/A
Shiotani High (17) Single 6 fps 17.9 N/S 5.0 3 44 N/S N/S N/S 14 N/S N/S 10
et al. [5]
Saurin et al. [7]b N/S N/S 11.6 Conventional
N/S
5.0 12 106 106 N/A N/A N/A 89.2 84.7 8
Shiotani (5, 15, Single N/S N/S N/S 6.5 4 87 N/S N/S N/S N/S N/S N/S N/S
et al. [10] 25,35)
CD, Crohn's disease; fps, frames per second; N/A, not applicable; N/S, not stated; OGIB, obscure gastrointestinal bleeding (overt + occult); QV, QuickView.
aStudies presented only as abstracts.
bMulticentre study.
scenarios. Although the benefits of QV are outweighed to
some extent by a decrease in the overall diagnostic yield,
this mode can be used confidently in overt OGIB in an
urgent inpatient setting and in outpatients with occult
OGIB or suspected CD. As the usefulness of QV may vary,
depending on the number of small-bowel lesions, standard
review settings are still recommended in all other cases.
Furthermore, the present study confirms that BM does not
confer any additional advantage in the QV setting.
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Abstract
AIM: To evaluate the three-dimensional (3-D) repre¬
sentation performance of 4 publicly available Shape-
from-Shading (SfS) algorithms in small-bowel capsule
endoscopy (SBCE).
METHODS: SfS techniques recover the shape of ob¬
jects using the gradual variation of shading. There are
4 publicly available SfS algorithms. To the best of our
knowledge, no comparative study with images obtained
during clinical SBCE has been performed to date. Three
experienced reviewers were asked to evaluate 54 two-
dimensional (2-D) images (categories: protrusion/in¬
flammation/vascular) transformed to 3-D by the afore¬
mentioned SfS 3-D algorithms. The best algorithm was
selected and inter-rater agreement was calculated.
RESULTS: Four publicly available SfS algorithms were
compared. Tsai's SfS algorithm outperformed the rest
(selected as best performing in 45/54 SBCE images),
followed by Ciuti's algorithm (best performing in 7/54
images) and Torreao's (in 1/54 images). In 26/54 im¬
ages; Tsai's algorithm was unanimously selected as
the best performing 3-D representation SfS software.
Tsai's 3-D algorithm superiority was independent of
lesion category (protrusion/inflammatory/vascular; P
= 0.678) and/or CE system used to obtain the 2-D im¬
ages (MiroCamVPiHCam*; P = 0.558). Lastly, the inter-
observer agreement was good {kappa = 0.55).
CONCLUSION: 3-D representation software offers a
plausible alternative for 3-D representation of conven¬
tional capsule endoscopy images (until optics technol¬
ogy matures enough to allow hardware enabled-"real"
3-D reconstruction of the gastrointestinal tract).
© 2013 Baishideng Publishing Group Co., Limited. All rights
reserved.
Key words: Capsule endoscopy; Small-bowel; Three-
dimensional; Software; Algorithm; Reconstruction;
Technology; Advance
Core tip: Accurate three-dimensional (3-D) reconstruc¬
tion of the gastrointestinal tract requires the use of
stereo-cameras that can simulate human binocular
vision. In the absence of such technology in capsule
endoscopy, we rely on software approaches [such as
the Shape-from-Shading (SfS) algorithms] to obtain 3-D
representation of digestive tract structures. In the pres¬
ent study, we evaluated the use of 4 publically avail¬
able SfS in capsule endoscopy. 3 experienced/experts
reviewers concluded that Tsai's approach is the best of
the four available algorithms.
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Capsule endoscopy (CE) has changed our diagnostic
approach for small-bowel diseases'1,2'. Although more ac¬
curate and of higher diagnostic yield than other modali¬
ties'3,4', there are still occasions where pathology is either
missed or misinterpreted1' 7'. Furthermore, reports have
shown that three-dimensional (3-D) reconstruction can
facilitate diagnosis by enhancing textural features of mu¬
cosal structures or intestinal abnormalities'8,''. However,
accurate 3-D reconstruction of the gastrointestinal (GI)
tract requires the use of stereoscopic cameras that can
simulate human binocular vision'10,11'. With the current
level of technological investment in CE though i.e., cam¬
era size, packaging constraints and power consumption,
accurate 3-D imaging of the intestinal lumen in small-
bowel capsule endoscopy (SBCE) is still unfeasible''1"'.
Therefore, software approaches that offer 3-D rep¬
resentation of conventional monocular two-dimensional
(2-D) CE frames have been developed'13' and proposed
for use in CE'14'. Such approaches e.g., Shape-from-Shad-
ing (SfS) algorithms, arc members of a family of shape
recovery algorithms called shape-from-X techniques
(Figure l)'13'. Given a single 2-D image, these algorithms
recover the shape of objects using the gradual variation
of shading'13'. Essentially, surface "reconstruction" with
SfS is achieved through a mathematical representation
that is inverted in order to recover dense surface distance
and normal information by the gradual variation of shad¬
ing'13'. We were able to retrieve 4 publicly available SfS
algorithms'1"18'. To the best of our knowledge, no com¬
parative study with images obtained during clinical SBCE
has been performed to date'1'1. We aimed to evaluate the
3-D representation performance of 4 publicly available
SfS algorithms by comparing them with their equivalent
2-D images of small-bowel structures/lesions obtained
during SBCE, in order to identify the algorithm more
helpful in facilitating identification and distinction be¬
tween lesion and surrounding mucosa.
MATERIALS AND METHODS
Between January 2011 and January 2012, 262 SBCE pro¬
cedures were performed at the Royal Infirmary of Ed¬
inburgh (tertiary referral centre for CE for the southeast
of Scotland, United Kingdom) in 249 patients (mean age:
52.6 ±12.1 years), as already described elsewhere''1. Out
of them, 140 were performed with PiUCam8SB2 (Given
® Imaging Ltd., Yokneam, Israel) and 122 witli MiroCam®
(IntroMedic®Co, Seoul, South Korea). A total of 54 were
selected images (27 obtained with MiroCam® and 27
with PillCam*SB) on the basis of the overall quality i.e.,
brightness, absence of air bubbles, debris, or opaque lu¬
minal fluid and clarity of findings (lesions or structures).
Thereafter, images were classified in the following image
groups: (1) vascular lesions i.e., angioectasias (» = 16);
(2) inflammatory lesions i.e., ulcers, erosions, aphthae,
cobblestone, fold and/or villous oedema (n = 18); and (3)
protruding lesions/structures i.e., polyp/mass, nodular
lymphoid hyperplasia, cluster of focal lymphangiectasia,
chylous cysts, and ampulla of Vater, (n — 20).
3-D image representation software
All selected images were reconstructed in 3-D by means
of all 4 SfS algorithms. Three reviewers (Rondonotti E,
Mandelli G, Koulaouzidis A) with extensive CE experi¬
ence and blinded to each other participated in this study.
In order to facilitate the evaluation process, a Mathworks0
Matlab program with a graphic user interface (GUI) was
developed (Figure 2; a video presenting the evaluation
process is provided as supplementary material via this
link: https://dl.dropboxusercontent.eom/u/7591304/
EvaluationYideo.mov). The program consisted of two
windows in which the conventional 2-D SBCIi image
(Figure 2, single frame at the right side/window of the
GUI screen) and its corresponding 3-D represented im¬
ages (four, one for each of the 4 SfS under evaluation)
arc presented to the reviewer (Figure 2, left side/window
of the GUI screen).
The 3-D SfS representations appeared in random or¬
der. The reviewers had the ability and freedom to rotate
and zoom in each of the 3-D represented images. At
the bottom of the GUI screen, a single "task request":
"Choose the 3-D representation you consider most help¬
ful in distinguishing the finding (seen in 2-D) from the
surrounding mucosa" appeared. This prompted reviewers
to choose one among the four 3-D 'reconstructed' im¬
ages, each generated by a different 3-D algorithm. After
selecting the best SfS representation, the reviewer had
to click "next" to proceed to the next case. This process
was repeated until the program reached the last case after
which each separate evaluation was concluded.
Outcome measures
Reviewers were asked to evaluate 54 images. The follow¬
ing subgroup analyses were performed: (1) evaluation
of 3-D representation according to the type of finding
(vascular vs inflammatory vs protruding); and (2) evalu¬
ation according to the system generating the 2-D image
(PillCam® vs Mirocam®). Furthermore, inter-observer
agreement was calculated.
Ethics consideration
This study was conducted in accordance with United
Kingdom research ethics guidelines. After review by the
local ethics committee further specific ethical review and
approval were not required, as the study was considered
an evaluation of previously collected endoscopy images,
using data already obtained as part of regular clinical care120'.
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Figure 2 For the evaluation phase, a Mathworks Matlab program with a graphic user interface was developed. The program consists of two windows in which
the conventional two-dimensional capsule endoscopy image (single frame at the right side/window of the graphic user interface screen) and its corresponding three-
dimensional represented images (four, one for each of the 4 shape-from-shading under evaluation) were presented to the reviewer.
Surface
Figure 1 Shape-from-Shading function. Capturing a surface
using a camera removes depth information. Shape-from-Shading
(SfS) techniques try to reproduce the missing depth information
from a given two-dimensional (2-D) image.
Photo
Table t Results of the Shape-from-Shading method per lesion
category
SfS Vascular Inflammatory Protrusion
method
PillCam* MiroCam" PillCamk MiroCam1 PillCam' MiroCam*
Tsai 7 7 7 6 8 10
Ciuti 1 0 1 0 1 4
TorreSo 0 0 1 0 0 0
Barron 0 0 0 0 0 0
None
selected
0 1 0 0 0 0
SfS: Shape-from-Shading.
Statistical analysis
For numerical variables, values are presented as mean ±
SD. Where necessary, the Fisher exact test was calculated.
A two-tailed P value < 0.05 was considered statistically
significant. Inter-observer agreement was calculated using
an online kappa calculator (available from http://justus-
randolph.net/kappa/) which provides the calculation of
Randolph's free-marginal multiratcr kappa applicable
when raters are not forced to assign a certain number of
cases to each category. Values of kappa can range from
-1.0 to 1.0, with -1.0 indicating perfect disagreement
below chance, 0.0 indicating agreement equal to chance,
and 1.0 indicating perfect agreement above chance. More
specifically, the inte is classified per kappa as poor < 0.20,
fair 0.2-0.40, good 0.41-0.60, very good 0.61-0.80 and,
excellent 0.81 -1.001 '. All other statistical analyses were
performed using a statistical package, StatsDirect, Stats-
Direct Ltd, Altrincham, (iheshire, United Kingdom.
RESULTS
Of the 4 SfS algorithms, Tsai's 3-D algorithm outper¬
formed the rest (selected as best in 45/54 images), fol¬
lowed bv Ciuti's (best performing SfS in 7/54 linages)
and Torreao's (in 1/54 images); there was a single image
for which each reviewer selected (as best performing)
a different 3-D representation algorithm. Of note, not
once was Barron's 3-D algorithm selected as best per¬
forming ("Fable 1, Figure 3).
In 26/54 images, Tsai's algorithm was unanimously
a:
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Figure 3 Assessment results for the 4






selected as the best performing 3-D representation SfS
software. Tsai's 3-D algorithm superiority was indepen¬
dent of lesion category (protrusion/inflammatory/vas-
cular; P = 0.678) and/or CL system used to obtain the
2-D images (MiroCamR/PillCamR; P — 0.538). Lastly, the
inter-observer agreement was good [kappa — 0.55).
DISCUSSION
In the present study, we compared the performance of
4 publicly available 3-D "reconstruction" algorithms'1'
(SfS software) using 54 conventional 2-D ( i images. The
evaluation criterion was subjective i.e., perceived visuali¬
sation improvement (3-D representations offered over
the corresponding conventional 2-D images) by 3 ex¬
perienced CM reviewers. Based on this evaluation, Tsai's
algorithm is the 3-D representation model recommended
for use in CI '.. This outcome directly supports Tsai's SfS
model theoretical advantages: (1) able to produce good
results for round surfaces, which are the case for most
digestive tract shapes; and (2) it behaves quite well with
bright surfaces'"1.
Depth information is an important aspect of human
vision; it helps human brain to analyse and comprehend
the surrounding environment. Images captured with con
ventional (non-stereoscopic) cameras "discard" the 3"'
dimension (depth) as conventional cameras can only save
2 dimensions (height and width). Therefore depth infor¬
mation is lost; and moreover, most imaging algorithms
perform less efficiently.
To date, engineers have not been able to equip capsule
endoscopes with stereoscopic cameras for the following
reasons: (1) packaging/space limitations; (2) low depth
resolution of stereoscopic or time-of-flight cameras'"'"
and (3) power consumption issues. However, it is almost
certain that in the foreseeable future these hardware-
related limitations will be overcome'11' and eventually 3-D
CI', will be a commodity. Nevertheless, until hardware
changes are widely implemented, several efforts have
been made to convert 2-D images into 3-D images (3-D
representation or "reconstruction") through software and
dedicated algorithms. There are software algorithms that
offer a fair trade-off between 2-D images and hardware-
enabled 3-D images. These algonthms are part of a fam¬
ily of shape recovery algorithms called Shape-from-X
techniques'1 . Basically a SfS algorithm recovers the shape
of objects, given a single monocular image, using the
gradual variation of shading'*"'.
SfS algorithms can be divided into four groups: (1)
minimization approaches'" '*'; (2) propagation approach¬
es; (3) local approaches; and (4) linear approaches'1*'. It is
important to remember that each of the 4 SfS algorithms
evaluated herein utilizes a different approach to recover
the shape from a conventional 2-D image.
More specifically, Tsai «•/«('*' described an repetitive
update of the depth using a linear approximation of the
reflectance function. Ciuti et a/"' used a camera model
with perspective projection and a light source close to
the surface and away from the optical centre to measure
depth. Torreao et a}^ applied a linear-nonlinear biological
model that mimics neuronal responses to estimate shape,
f inally, Barron et a/'*' proposed a unified model for re¬
covering shape, reflectance and optional illumination
while using local smoothness, global scarcity or entropy,
and the absolute colour of each pixel. Although 'Tsai's'1 "*'
method is very straightforward and to an extent simplis¬
tic, it provides satisfy ing results. Cuiti's et ul'"] algorithm,
on the other hand, uses a more advanced model (incor¬
porating a camera model with perspective projection) that
makes things in the background appear further back than
in Tsai's model (Figure 4).
Since for a given 2-D image, light source and surface
shape are not known, these algonthms try to model how
the 2-D image was created from the 3-D environment
to finally produce an approximation this 3-D depth. The
above modelling has a significant impact on the resulting
3-D representation. During SfS process additional con¬
straints need to be applied on the surface shape parame¬
ters or the light conditions to find the surface characteristics.
In conclusion, we showed previously that 3-D repre¬
sentation software offers a plausible alternative for 3-D
representation of conventional CM images (until optics
technology matures enough to allow a hardware enabled-
"real" 3-D reconstruction of the Cll tract)'1. In the prcs
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Figure 4 Ciuti's algorithm (left) and
Tsai's method (right). Although Tsai's
method is very straightforward and to an
extent simplistic, it provides satisfying
results. Ciuti's et a/'61 algorithm, on the
other hand, uses a more advanced model
that makes things in the background ap¬
pear darker than in Tsai's model.
cnt study we compared 4 publicly available SIS methods.
3-D reconstruction is attracting interest in capsule endos-
copv!* ' especially as newly developed and/or under
development CF, become available, with greater potential
(due to imager and optics) for 3-D software1"'].
COMMENTS
Background
Over the past decade, conventional endoscope technology has advanced with
the use of three-dimensional (3-D) cameras offering increased diagnostic and
interventional capabilities. Unfortunately, due to hardware limitations, 3-D small-
bowel capsule endoscopy (SBCE) is still an open technological challenge. It is
aspired that 3-D SBCE will be able to offer similar benefits to conventional 3-D
endoscopy. Therefore, information technology engineers suggested the use
of software techniques (Shape-from-Shading, SfS) methods that simulate 3-D
reconstruction i.e., 3-D representation in SBCE images. To date, various SfS
approaches have been proposed; each aims to retrieve depth information from
2-D images (shape recovery) through different mathematical transformations,
hence offering different shape approximations.
Research frontiers
The authors aimed to evaluate the 3-D representation performance of 4 publicly
available SfS algorithms by comparing them with their equivalent 2-D images
of small-bowel structures/lesions obtained during SBCE, in order to identify the
algorithm more helpful in facilitating identification and distinction between the
lesion and the surrounding mucosa.
Innovations and breakthroughs
This study, in conjunction with further similar work in the field, is useful in the
assessing the potential validity of integrating 3-D representation in capsule en¬
doscopy reviewing software.
Applications
Software-enabled 3-D representation is a promising approach that enables 3-D
imaging at no additional cost. The authors have shown that SfS application
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Accuracy
Core tip: In an attempt to approximate a three-
dimensional (3-D) reconstruction of the digestive tract
surface, a software that recovers information-using
gradual variation of shading - from monocular two-
dimensional capsule endoscopy images has been pro¬
posed. Light reflections on the surface of the digestive
tract are still a significant problem. Therefore, a phan¬
tom model and simulator has been constructed in an
attempt to check the validity of a highlight suppression
algorithm. Our results confirm that 3-D representation
software performs better with simultaneous application
of a highlight reduction algorithm. Furthermore, 3-D
representation follows a good approximation of the real
distance to the lumen surface.
Abstract
In capsule endoscopy (CE), there is research to develop
hardware that enables "real" three-dimensional (3-D)
video. However, it should not be forgotten that "true" 3-D
requires dual video images. Inclusion of two cameras
within the shell of a capsule endoscope though might
be unwieldy at present. Therefore, in an attempt to ap¬
proximate a 3-D reconstruction of the digestive tract sur¬
face, a software that recovers information-using gradual
variation of shading-from monocular two-dimensional
CE images has been proposed. Light reflections on the
surface of the digestive tract are still a significant prob¬
lem. Therefore, a phantom model and simulator has
been constructed in an attempt to check the validity of a
highlight suppression algorithm. Our results confirm that
3-D representation software performs better with simul¬
taneous application of a highlight reduction algorithm.
Furthermore, 3-D representation follows a good approxi¬
mation of the real distance to the lumen surface.
Koulaouzidis A, Karargyris A. Use of enhancement algorithm to
suppress reflections in 3-D reconstructed capsule endoscopy im¬




In capsule endoscopy (CE), there is research to develop
hardware that enables "real" three-dimensional (3-D) video
by using an infrared projector and a CMOS camera1'"'.
However, it should not be forgotten that "true" 3-D re¬
quires dual video-images; furthermore, the inclusion of
two cameras within the shell of a capsule endoscope might
be unwieldy at present'3'. 1'herefore, major drawbacks at
present are size, power consumption and packaging is¬
sues'4'. In an attempt to approximate a 3-D reconstruc-
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Figure 1 Phantom model (A) and task simulator setting (B). A: The arrow points to the gastric ulcer ("1/2 diameter and 3/16" depth).
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Figure 3 Relative distance of three-dimensional representation calculated
over images taken from various distances of the capsule from the models.
sion algorithm' 1 has been applied onto CE images.
To test this algorithm, a phantom task simulator was
created. A Stomach Ulcer Anatomical Model (manufac¬
turer: Anatomical ("hart Company G200) was used; the
O Regular 3-D
□ Specular free 3-D
Figure 2 Three-dimensional representation of images captured for the
3 models: red, white and yellow. A: Original three-dimensional (3-D) repre¬
sented images; B: The processed 3-D represented images using the highlight
suppression algorithm.
tion of the digestive tract surface, Koulaouzidis et <"//'' and
Karargyris et proposed the use of a software [Shape -
from-Shading (S/S)] that utilizes monocular CE frames. Es¬
sentially, S/S algonthms recover information -using gradual
variation of shading'on the shape of objects given a
single two-dimensional (2-D) image. 3-1) representation
may be helpful in conjunction with other image enhance
ment tools e.g., virtual chromoendoscopy (EICE) and/or
color (blue) mode analysis of CE videos'8'.
However, light reflections on the surface of the
digestive tract are still a significant problem, not only
for 3-D representation but also for traditional 2-1) CK.
When light falls on to a surface, some of the beams are
reflected back straightaway -specular reflection- while the
rest of the beams penetrate it before reflected (diffuse
reflection). As most digestive tract structures/surfaces are
di electric and homogeneous, they display both types of
reflections'4'. To reduce reflections, a highlight suppres-
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stomach model has an red-colored base ulcer (1/^"diam¬
eter and 3/16"depth; Figure 1A); the latter was thereafter
colored buttercup yellow using quick-drying spray paint
(Tor Coatings"Ltd., United Kingdom) and white (using
flat white spray from Plasti-Kote*Ltd.). A PillCamsSB2
(Given^Imaging Ltd., Yoqneam, Israel) was mounted on a
plastic tube and held (with the use of regular lab stand) at
0, 5, 10, 15 and 20 mm from the ulcer base (usual work¬
ing distance of the CE in vivo, Figure IB). The images
were uploaded to a workstation and they were categorized
based on distance and ulcer base color (red, yellow and
white). We aimed to check whether the ulcer models ap¬
pear closer or further based on their 3-D representation.
Tsai's S/S'910' algorithm was applied on each image in
order to reconstruct its 3-D representation with (Figure
2A) or without (Figure 2B) software highlight suppres¬
sion'9'. Tsai's S/5 algorithm cannot measure the real dis¬
tance of the camera to the model's surface but it gives
the relative distance (z) to the black frame background.
For each image, we selected the region of interest (ROI)
of the ulcer model on the 3-D representation and we cal¬
culated the average depth (z) for each ROI.
The results (charts, Figure 3) confirm that the dis¬
tance of the camera from the model surface increases so
does the relative distance (z) on the 3-D representation.
This effect is more evident for the white and yellow ul¬
cer models. I lowever, relative distance does not follow a
similar trend for the red-based ulcer model. This is likely
due to the saturation of the red color creating variations
to the shading: red color appears darker or lighter. Finally,
from the charts we conclude that the highlight suppres¬
sion algorithm improved the quality of the images.
In conclusion, 3-D representation software seems to
perform better with simultaneous application of a high¬
light reduction algorithm. Furthermore, 3-D representa¬
tion follows a good approximation of the real distance to
the lumen surface.
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Background: Three-dimensional imaging in capsule endoscopy is not currently feasible due to hard¬
ware limitations. However, software algorithms that enable three-dimensional reconstruction in capsule
endoscopy are available.
Methods: Feasibility study. A phantom was designed to test the accuracy of three-dimensional recon¬
struction. Thereafter, 192 small-bowel capsule endoscopy images (of vascular: 50; inflammatory: 73;
protruding structures: 69) were reviewed with the aid of a purpose-built three-dimensional reconstruc¬
tion software. Seven endoscopists rated visualisation improved or non-improved. Subgroup analyses
performed for diagnostic category, diagnosis, image surface morphology and colour and SBCE equipment
used (PillCam® vs. MiroCam®).
Results: Overall, phantom experiments showed that the three-dimensional reconstruction software was
accurate at 90% of red, 70% of yellow and 45% of white phantom models. Enhanced visualisation for
56% of vascular, 23% of inflammatory and <10% of protruding structures was noted (P=0.007, 0.172
and 0.008, respectively). Furthermore, three-dimensional software application enhanced 53.7% of red,
21.8% of white, 17.3% of red and white, and 9.2% of images of lesions with colour similar to that of the
surrounding mucosa. P<0.0001.
Conclusions: Application of a three-dimensional reconstruction software in capsule endoscopy leads to
image enhancement for a significant proportion of vascular, but less so for inflammatory and protruding
lesions. Until optics technology allows hardware-enabled three-dimensional reconstruction, it seems a
plausible alternative.
Crown Copyright ©2013 Published by Elsevier Ltd on behalf of Editrice Gastroenterologica Italiana S.r.l.
All rights reserved.
1. Introduction
Over the past decade, capsule endoscopy (CE) has revolu¬
tionised the evaluation of small-bowel diseases (1,2). In recent
years, research has been carried out to produce three-dimensional
(3D) reconstruction of the gastrointestinal (Gl) tract in conventional
video endoscopy using stereoscopic cameras 13,4]; several reports
* Corresponding author at: Endoscopy Unit, The Royal Infirmary of Edinburgh. 51
Little France Crescent, Old Dalkeith Road, Edinburgh EH16 4SA, UK.
Tel.: +44 131 2421126; fax: +44 131 2421618.
E-mail address: akoulaouzidis@hotmail.com (A. Koulaouzidis).
have shown that it can facilitate diagnosis by enhancing mucosal
textural features and abnormalities (5.G],
However, due to current technological limitations of capsule
endoscopes (i.e. packaging and size constraints, power consump¬
tion) hardware enabled 3D reconstruction of the intestinal lumen
in small-bowel capsule endoscopy (SBCE) is yet to be available.
Therefore, a software-based approach [Shape-from-Shading (SfS)]
has been proposed that helps approximate a 3D representation
from monocular two-dimensional (2D) images. These algorithms
recover the shape of objects from 2D images using gradual vari¬
ation of shading [7], Eventually, amongst 4 publicly available SfS
algorithms [8-11 ], Tsai's method performed better based on pre¬
liminary results (unpublished authors' data).
1590-8658/$36.00 Crown Copyright © 2013 Published by Elsevier Ltd on behalf of Editrice Gastroenterologica Italiana S.r.l. All rights reserved.
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Fig. 1. Phantom simulator (A) and phantom models (B).
We conducted a two-phase, feasibility study in order to assess:
1) The accuracy of 3D representation, by using CE images from
phantom paradigms (phase 1).
2) Whether 3D representation improves visualization (of sur-
face/textural aspects) of small-intestine structures/lesions, by
using of a group of selected SBCE images from clinical practice
(phase 2).
2. Methods
2,1. Phase 1 - phantom simulator
For the accuracy assessment of the software, a task simulator
was constructed; 2D images of phantom models were obtained
by using CE and compared with their 3D representation counter¬
parts. Overall, the simulator was designed based on the following
principles: (a) to be constructed with readily available materials,
e.g. cardboard boxes and stationary office supplies; (b) to allow
minimal external light for simulation of clinical CE; and lastly (c)
phantom models to be representative of the variety of colours and
shapes of structures/lesions encountered in SBCE. A cuboid card¬
board box(12cm x 30 cm x 45 cm)was used to simulate abdominal
wall and allow placement of CE sensors for video capture. A frame
was cut open at the top side of the box to allow insertion of
a cardboard cuboid tube (6 cm x 9 cm x 42 cm) which was to act
as the main function chamber/bowel simulator. Furthermore, a
4cm x 6 cm rectangular frame was cut open in the lower part the
side of the tube facing the open lids of the box. This was done
to allow placement of the phantom-models plates on the review¬
ing surface during CE video capture (Fig. 1A). Finally, following
placement of CE sensors, a real-time viewer was used to monitor
progress of video/images capture.
A PillCam®SB2 CE was mounted on a small hemispheric plastic
cap with Pritt® sticky fixer and a commercial cotton string was used
to suspend the capsule 1.5 cm above the phantom object plates. As
aforementioned, phantoms were made with commercially avail¬
able stationary material. Therefore, red, yellow and white coloured,
flat-headed drawing pins (Fig. IB), as well as blocks of white, red
and yellow Pritt® sticky tack (Henkel AC & Co. KGaA, Dusseldorf,
Germany) and a ibuprofen tablet (Nurofen® 400 mg) were used as
phantom models. Phantoms were placed on cardboard panels of
equal size in such a way that the model would be either protruding
or at a level with the plate surface. From the video obtained, 60 2D
images of high quality (20 for each of the 3 colours, i.e. red, yellow
and white) were selected by one of the authors (AK), converted in
3D images and reviewed for evaluation by the second co-author
(AK) who was unaware of the surface type of each image, i.e. if the
imaged object was flat or protruding.
2.2. Phase 2 - clinical study
2.2.1. SBCE 2D images: patients, image selection and classification
From January 2011 to January 2012, 262 SBCE procedures
in 249 patients (67 males/182 females; mean age: 52.6± 12.1
years) have been performed at the Royal Infirmary of Edinburgh
(University Hospital and referral centre for CE for the south¬
east of Scotland, UK). Out of those, 140 were performed with
PillCam® (Given®lmaging Ltd., Yokneam, Israel) and 122 with
MiroCam® (IntroMedic® Co., Seoul, South Korea). An experienced
SBCE provider (SD), familiar with both aforementioned SBCE sys¬
tems, selected and de-identified a group of images by reviewing
the thumbnails of all 262 videos. Images were selected on the basis
of their overall quality, i.e. brightness, no bubbles and/or luminal
debris or opaque luminal fluid and findings (lesions or structures)
clarity. An expert CE reviewer (ER) acted as second selector. Eventu¬
ally, only images for which there was complete agreement between
the 2 reviewers in terms of image quality, colour and type of
depicted finding were included.
Therefore, a total of 192 SBCE images (84 obtained with
PillCam®SB2/l 08 obtained with MiroCam®), covering a wider spec¬
trum of findings seen in SBCE, entered 3D reconstruction. These
images were classified as per:
1. Predominant colour of the depicted structure/lesion into 4
image-groups: red, white, mixed (red + white) and a group with
lesion colour similar to that of the surrounding mucosa.
2. Surface morphology of the depicted structure/lesion into
the following groups: (a) Convex surface morphology, i.e.
polyp/neoplastic, chylous cysts, NLH, fold oedema, and AoV
(n = 67); (b) flat or concave surface morphology, i.e. mucosal
ulcer, erosion, aphthae, villous oedema and angioectasias
(n = 103); and (c) combi-surface morphology, i.e. cobblestone
and lymphangiectasias (n = 22).
3. Diagnostic category into the following groups: (a) vascular, i.e.
angioectasias (n = 50), (b) inflammatory, i.e. ulcers, erosions, aph¬
thae, cobblestone, fold/villous oedema (n = 73), and (c) luminal
protrusion, i.e. polyp/neoplastic, nodular lymphoid hyperpla¬
sia (NLH), cluster of focal lymphangiectasias, chylous cysts, and
ampulla of Vater (AoV) (n = 69) (Table 1).
4. Lastly, each diagnosis was examined separately.
2.2.2. SBCE procedures
The technical characteristics of capsules, CE procedure and
methodology for review of CE images have been described in
detail previously [12,1 31. In essence, SBCE was performed with
PillCam®SB2 and MiroCam® capsule endoscopes using an estab¬
lished for our unit procedure protocol, i.e. strict liquid diet the
day prior to the test, combined with purge (2 1 polyethylene gly¬
col; Moviprep®, Norgine Ltd., Middlesex, UK) and overnight fast.
The capsule is ingested with 100 mg of anti-foam (Simethicone)
and 5mg of liquid prokinetic suspension (Domperidone), unless
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Table 1
Evaluated images, in total and per SBCE system used (PillCam®/MiroCam®); AoV:
ampulla of Vater; N: number: SBCE: small-bowel capsule endoscopy.
Diagnostic category N SBCE PillCam®-MiroCam® P value
VASCULAR (N = 50) 25-25 1.0
Angioectasias 50 25-25
INFLAMMATORY (N = 73) 28-45 0.359
Mucosal cobblestone 9 4-5
Mucosal breaks/aphthae 21 11-10
Mucosal ulcers 25 7-18
Mucosal fold/villous oedema 18 6-12
PROTRUDING (N» 69) 31-38 0.435
Lymphomas 3 0-3
Polyps 10 5-5
Chylous cysts 11 5-6
Lymphangiectasias 13 8-5
Lymphoid hyperplasia 15 5-10
AoV 17 8-9
in exceptional circumstances. The patients are allowed to drink
clear fluids after 2 h and consume a light meal/snack after 4 h. Writ¬
ten informed consent was obtained from all patients prior to the
procedure as part of their regular clinical care.
2.2.3. 3D image representation software
3D visualisation software was developed in
Mathworks®Matiab; it can process a 576 x 576 image in less
than 2 s. The software allows a reviewer to load capsule endoscopy
images from a folder. Then the software processes each image and
exports its corresponding 3D represented image in a proprietary
format of Matlab® (.fig extension). For the evaluation process,
another Matlab® programme with a user interface was devised.
The programme consists of two windows in which the conven¬
tional 2D SBCE image and its corresponding 3D represented image
are given (Fig. 2). The reviewer can rotate and zoom in the 3D
images. At the bottom of the screen, a single question regarding the
efficiency of the 3D representation is given. Five possible answers
to choose from are also presented. After selecting the desired
answer the reviewer clicks next to proceed to the next case. This
process is performed until the programme reaches the last case
after which each separate evaluation is concluded.
2.2.4. Raters and outcome measures
Seven reviewers - each with substantial experience in GI
endoscopy but variable experience in interpretation ofSBCE images
- participated in phase 2. Reviewers were unaware to each other's
evaluation.
Each of the 3D representation images were scored for textu-
ral enhancement of the depicted finding and therefore categorized
as improved/non improved. To evaluate whether the 3D represen¬
tation tool improves visualisation of SBCE images, reviewers were
asked to compare each 3D represented image with a corresponding
2D counterpart and to rate it according to the following scale: +2
(definitely improved), +1 (somewhat improved), 0 (no different or
equivalent to conventional 2D image), -1 (somewhat worse), -2
(definitely worse) [14]. Thereafter, reviewers' scores were tallied
and the average score for each image was calculated. To simplify
analysis the data are presented into three categories:
• improved if average score >1;
• same if average score was 0.99 to -0.99; and,
• worse if average score <-1.
The following subgroup analyses were performed: evaluation
of 3D representation according to groups described above, i.e.
predominant colour of depicted structure, surface morphology,
diagnostic category and diagnosis; the equipment generating the
2D image (PillCam® vs. Mirocam®); and, the CE experience of raters.
Inter-observer agreement was calculated for each image group
(vascular, inflammatory and protuberant).
Furthermore, reviewers were advised to leave each 3D image at
an angle most consistent with their grading so that mean angles for
right/left and up/down (for each image group) could be calculated.
2.3. Ethics consideration
This study was conducted in accordance with UK research ethics
guidelines. After review by the local ethics committee further spe¬
cific ethical review and approval were not required, as the study
was considered an evaluation of previously collected images, using
data already obtained as part of regular patient care.
2.4. Statistical analysis
For numerical variables, values are expressed as mean
(istandard deviation, SD). The t-test for continuous variables and
the chi-square (x2) test for categorical variables were used. A
two-tailed P value <0.05 was considered statistically significant.
Pearson's agreement correlation was used for phase 1 of this study.
For phase 2, inter-observer agreement was measured by free-
marginal multirater kappa statistics [15], using an online Kappa
Calculator, available at http://justusrandolph.net/kappa/ (retrieved
November 24, 2012). A sample size of 192 images provides a mar¬
gin of error of 7.04% (as calculated by and online sample size
calculator, available at http://www.raosoft.com/samplesize.html).
kappa <0.4 was considered as slight agreement whereas between
0.41 and 0.6 as moderate, 0.61-0.80 substantial and 0.81-1.00 as
excellent agreement. All other statistical analyses were performed




Overall, phantom experiments showed that the SfS algorithm
was 90,70 and 45% (P = 0.14) accurate in interpreting the protruding
or non-protruding surface nature of red, yellow and white phan¬
tom models, respectively (Figure SI). Sensitivity and specificity of
the above evaluation was 80 and 100% for red-coloured objects;
81.3 and 25% for yellow-coloured objects; 100 and 21.3% for white-
coloured objects. Lastly, Pearson's correlation was 0.93, 0.63 and
0.35 for red, yellow and white, respectively.
3.2. Phase 2
3.2.1. Selected images
The number of images selected for each category, according
to the SBCE system used and the type of findings is tabulated
in Table 1. Overall, there was no statistically significant differ¬
ence in the number of images included per diagnostic category for
vascular, inflammatory and protruding structures/lesions (P=1.0,
0.359,0.435, respectively).
3.2.2. 3D images evaluation
For the entire image group (n = 192) and all (n = 7) review¬
ers, 51/192 (27.6%) were evaluated as improved (better) with 3D
representation and 141/192 (73.4%) as equivalent to their 2D coun¬
terparts.
Sub-analysis per predominant colour revealed that 3D represen¬
tation improved red, white, mixed and lesions with colour similar
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Fig. 2. The 3D image representation software evaluation interface in a Matlab® environment.
to the surrounding mucosa in 53.7% (29/54), 21.8% (12/55), 17.3%
(5/29) and 9.2% (5/54) of cases (P< 0.0001).
Sub-analysis per surface morphology showed that 3D represen¬
tation was felt to improve evaluation in 14/67 (20.9%) of convex
findings, 33/103 (32%) of flat/concave findings and 4/22 (18.2%) of
combi-surface morphology findings, P= 0.1929.
Sub-analysis per diagnostic category; 56% (28/50) of vascu¬
lar, 23.2% (16/69) of protruding, and 9.6% (7/73) of inflammatory
lesions were evaluated as showing enhanced textural features on
3D representation (Figure S2-5, Table 2).
Sub-analysis per diagnosis revealed that evaluation of angioec-
tasias with 3D representation showed improved visualisation
in 56% (28/50); chylous cysts 36.36% (4/11); polyps/neoplastic
lesions 30.76% (4/13), LNH 26.6% (4/15), mucosal cobblestone
22.2% (2/9), lymphangiectasias 15.38% (2/13), AoV 11.76% (2/17),
mucosal ulcers/erosions/aphthae 8.69% (4/46) and villous/fold
oedema 5.55% (1 /18) (P< 0.0001).
Sub-analysis per SBCE system revealed that 3D representation
led to enhanced visualisation in 20.2% (17/84) of images obtained
Table 2
Image enhancement with the three-dimensional image representation software,
as per small-bowel capsule endoscopy system, image group and colour of
structure/finding.
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with PillCam® and 31.5%(34/l 08) of images captured by Mirocam®,
P = 0.099.
Sub-analysis per CE reviewer experience (for the entire image
series); there was statistically significant difference between the
rating from experienced CE and non-CE readers (77/192 vs. 51/192,
P<0.007). For both evaluators' sub-groups though, no image
was perceived as worse to its 2D equivalent. The results of the
comparison between CE and non-CE readers according to type of
lesion and SBCE equipment generating the 2D images are summa¬
rized in Table 3.
Inter-observer agreement was at <0.4 for the entire group of
images, as well as when each diagnostic category was examined
separately. The kappa statistics for all raters, CE-readers and non-CE
readers is presented in Table 4.
4. Discussion
Hardware-based reconstruction is based on stereoscopic vision,
where multiple image sensors are used to provide the necessary
information for depth retrieval. Stereoscopic approaches utilise
at least two Images - of the same target - at two different
angles of view. Hence, a typical 3D-inraging system comprises two
independent cameras, each camera contributing one viewpoint.
However, inclusion of two cameras within a CE device to create a
stereo-image can be unwieldy [2). Therefore, a couple of important
3D hardware-enabled endoscopy technologies have been pro¬
posed. Kolar et al. (16] presented a system that can give - in real
time - both 3D and texture information using an infrared projec¬
tor and a CMOS camera; the major disadvantages of this system
are its size and power consumption. Shahinian et al. [17] reported
a promising new technique for endoscopic 3D imaging that uses
a single lens system. This technique creates two viewpoints in a
single-lens camera by placing a bipartite-filter at the limiting aper¬
ture, but this is still to be incorporated in a SBCE device.
Therefore, in the current absence of a hardware-enabled 3D
reconstruction, Karargyris et al. [ 18 ] recently proposed the use of a
3D software-enabled technique (SfS) for CE videos. The algorithm is
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Table 3
Sub-groups analyses performed for capsule endoscopy and non-capsule endoscopy readers.
Type of finding Capsule endoscopy readers (%) Non-capsule endoscopy readers (%) P value
Vascular 38/50 (76.0) 24/50 (48.0) 0.007"
Protuberant 31/69(44.9) 12/69(17.4) 0.008
Inflammatory 8/73(10.9) 15/73(20.5) 0.172
Overall 77/192(40.1) 51/192(26.6) 0.006
Statistically significant.
very fast and "behaves" reasonably well with specular textures [19],
Eventually, all SfS techniques, such as the linear method ofTsai, take
a single 2D input-signal, i.e. a conventional SBCE image and through
a series of mathematical transformations (energy minimization)
produce a corresponding 3D representation image. Strictly from
a mathematical point of view, since 3D represented images are
derived from monocular 2D conventional CE images, only visual¬
ization change. Essentially, this means that the image information
does not change.
In order to assess the usefulness of this 3D representation
approach in SBCE, we conducted a feasibility study includ¬
ing (a) a task simulator and (b) a clinical part. In the latter,
we included reviewers from a wider endoscopic audience and
not only CE readers. Moreover, the clinical SBCE images we
selected cover a wide range of findings in CE and they were
categorised as per group/type of finding and type of SBCE
system used to produce the 2D image. Overall, the simulator
showed that 3D representation software gives a 90, 70 and 45%
accuracy when it comes to predicting the protruding or not nature
of red, yellow and white phantom models, respectively. Further¬
more, the clinical study showed that using 3D representation
software in images obtained from SBCE, about a quarter (26%) of
them present enhanced visualisation features, as compared to their
2D conventional counterparts. This effect is independent to the type
of SBCE system used, Table 2.
Having observed increased accuracy of the 3D software for red
coloured phantoms and less so for yellow and white, it is surpris¬
ing that major improvement is observed for vascular lesions (56%),
whereas moderate (23%) and low (<10%) is noted for inflamma¬
tory and protruding findings, respectively. Recently, Liao et al. [20]
showed that vascular lesions represent the majority of small-bowel
pathology identified by means of capsule endoscopy and account
for about 50% of SCBE diagnostic yield in patients with obscure
GI bleeding. An improved visualization using 3D reconstruction
was showed only for vascular lesions. It is of course to an extent
inopportune that findings presenting better delineation with 3D
enhancement, i.e. angioectasias are those most easy to recognize
using a standard visualization. This is likely due to the fact that
vascular lesions, even those of small size, present a clear margin, a
well-defined lesion border and a definite colour difference with the
surrounding mucosa. One could argue that by regularly implemen¬
ting this image enhancement tool in SBCE, could lead to improved
vascular lesion detection. Furthermore, perhaps it would be clini¬
cally relevant to further investigate whether 3D representation may
provide a classification of such lesions in order to identify those at
higher risk of bleeding [21],
Table 4
Inter-observer agreement for all reviewers (and per CE reviewing experience
groups) for all images and per diagnostic category; CE: capsule endoscopy.
Raters groups All images Diagnostic category
Vascular Inflammatory Protruberant
Ail raters (n« 7) 0.182 0.163 0.193 0.185
CE-readers (n»3) 0.164 0.358 0.115 0.082
Non-CE readers (n = 4) 0.301 0.3 0.318 0.29
The most difficult lesions to be visualized and categorized are
fiat/concave lesions and/or neoplastic lesions where the improve¬
ment of 3D reconstruction seems to be marginal. One might expect
that a 3D representation would perform best in enhancing differ¬
ences between flat and protruding lesions; certainly, the results
of the task simulator were reassuring in this aspect. This has not
become evident though in our second-stage (clinical) assessment.
A plausible explanation is that real life protruding small-bowel
structures or lesions are not necessarily entirely or solely red and
more likely to have a mixed colour or similar to that of the sur¬
rounding mucosa (e.g. AoV, small-bowel polyps or masses, etc.).
Furthermore, lack of insufflation in SBCE often causes a protruding
lesion to appear only in part in the video frames as a "fold between
folds", i.e. not as defined luminal protrusion. Even for experienced
CE readers, protruding lesions often represent a significant diag¬
nostic challenge, particularly when the distinction between masses
and bulges is at stake [22]. Nevertheless, readers with CE experience
noted a significantly higher improvement as compared to non-CE
readers (44.9% vs. 17.4%).
Interestingly, when we analysed the evaluation results based
on the assessors SBCE experience, it became obvious that physi¬
cians experienced in CE review, i.e. assessors most used to 2D
SBCE images of small-bowel pathology, described a significantly
higher image improvement with the use of the 3D enhancement
tool, 38/50 vs. 24/50 (P=0.007) and 31/69 vs. 12/69 (P-0.008), for
angioectasias and protruding findings, respectively. Conversely, in
the inflammatory lesions image group, both CE and non-CE readers
agreed that 3D offered only a limited textural/feature enhance¬
ment with 8/73 vs. 15/73, respectively, P = 0.172. These results
may simply reflect familiarity with SBCE reviewing software and/or
image manipulation or merely enthusiasm bias. In that respect, we
believe that including a diverse group of GI endoscopists - all with
advanced image interpretation skills but variable experience in CE
images interpretation - provides a more balanced evaluation of this
enhancement tool.
The present study has few limitations; first, in order to test
the performance of the 3D software, we selected high clarity SBCE
images; hence, we do not know if our results can be reproduced
with images obtained in the everyday SCBE practice, where the
presence of intraluminal debris or opaque fluid can affect the
overall visibility and a 3D representation of small-bowel findings.
Second, the heterogeneous group of raters/assessors could be con¬
sidered by some as potential limitation of this evaluation. Third,
although we attempted a subgroup analysis per type of SBCE sys¬
tem, raters where not blinded to the brand of SBCE used to obtain
the 2D image, as eventually the two SBCE systems produce images
of different characteristics. Furthermore, some inherit limitations
of the software should be taken into account, i.e. many objects in the
real world are dielectric and homogeneous, hence displaying dual
reflections. In fact, this might be responsible for the only fair inter-
observer agreement of this study. Most digestive structures fall into
this category. Therefore, when the light beams fall on to such an
object, some of them reflect back immediately creating the spec¬
ular reflection; the rest first penetrate the object and then reflect
creating the diffuse reflection. This phenomenon creates highlights,
which distort the outcome of any 3D image representation.
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Until optics technology matures enough to allow a hardware-
enabled 3D reconstruction of the Gl tract [23,24], 3D representation
software offers a plausible alternative for 3D representation of con¬
ventional CE images. Work is underway on measuring its precision
not by visual inspection but by strict mathematical approach. How¬
ever, the present study is its first of its kind to examine the potential
usefulness of 3D representation. Further studies are needed to eval¬
uate the effect of this software in lesion detection and in patient
management/clinical course.
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ORIGINAL ARTICLE: Clinical Endoscopy
Utility of 3-dimensional image reconstruction in the diagnosis
of small-bowel masses in capsule endoscopy (with video) Qq
Emanuele Rondonotti, MD, PhD,1 Anastasios Koulaouzidis, MD, FRCP,2 Alexandres Karargyris, PhD,'
Andry Giannakou, PhD,* Lucia Fini, MD, Marco Soncini, MD,'' Marco Pennazio, MD, Sarah Douglas, BSc,2
Aman Shams, MD, MRCP,2 Neil Lachlan, MBChB, MRCP,2 Ali Zahid, MBChB, MRCP,J
Giovanna Mandelli, MD,' Carlo Girelli, MD
Como, Busto Arsizio, Milan, Turin, Italy; Edinburgh, Scotland, UK; Bethesda, Maryland, USA; Nicosia, Cyprus
Background: In small-bowel capsule endoscopy (SBCE), differentiating masses (ie, lesions of higher probability
for neoplasia) requiring more aggressive intervention from bulges (essentially, false-positive findings) is a chal¬
lenging task; recently, software that enables 3-dimensional (3D) reconstruction has become available.
Objective: To evaluate whether "coupling" 3D reconstructed video clips with the standard 2-dimensional (s2D)
counterparts helps in distinguishing masses from bulges.
Design: Three expert and 3 novice SBCE readers, blind to others and in a random order, reviewed the s2D video
clips and subsequently the s2D clips coupled with their 3D reconstruction (2D+3D).
Setting: Multicenter study in 3 community hospitals in Italy and a university hospital in Scotland.
Patients: Thirty-two deidentified 5-minute video clips, containing mucosal bulging (19) or masses (13).
Intervention: 3D reconstruction of s2D SBCE video clips.
Main Outcome Measure: Differentiation of masses from bulges with s2D and 2D+3D video clips, estimated by
the area under the receiver operating characteristic curve (AUC); interobserver agreement.
Results: AUC for experts and novices for s2D video clips was .74 and .5, respectively (P = .0053). AUC for experts
and novices with 2D+3D was .70 (compared with s2D: P = .245) and .57 (compared s2D; P = .049), respectively.
AUC for experts and novices with 2D+3D was similar (P = . 1846). The interobserver agreement was good for both
experts and novices with the s2D(& = .71 and .54, respectively) and the 2D+3D video clips (k = .58 in both groups).
Limitations: Few, short video clips; fixed angle of 3D reconstruction.
Conclusions: The adjunction of a 3D reconstruction to the s2D video reading platform does not improve the
performance of expert SBCE readers, although it significantly increases the performance of novices in distinguish¬
ing masses from bulging. (Gastrointest Endosc 2014;80:642-51.)
Abbreviations: 2D, 2-dimensional; 3D, 3-dimensional; AUC, area under
the (ROC) curve; CE, capsule endoscopy; MB, mucosal bulge; ROC,
receiver operating characteristic; s2D, standard 2D; SBCE, small-bowel
capsule endoscopy.
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Since its introduction in clinical practice in 2001, small-
bowel capsule endoscopy (SBCE) has become a prime
mode for the evaluation of the small bowel in several clin¬
ical settings, such as obscure GI bleeding and Crohn's dis¬
ease. 1 In this context, SBCE has a high yield of findings and
a positive impact on diagnosis and patient management
(ie, cost-effectiveness)." ' The most common small-bowel
findings (ie, angioectasias, ulcers, and/or luminal stenosis)
are easy to recognize and are rarely missed.4 Conversely,
large small-bowel protruding lesions (eg, small-bowel
mass lesions) can be missed by capsule endoscopy (CE),
and the value of a negative SBCE in excluding sinister
small-bowel pathology remains unclear." 1 Furthermore,
those of us who routinely read SBCE studies can attest
that luminal protrusions in SBCE are a common finding.
The presence of a "mass" can be the result of several
processes, for example, mucosal disruption by underlying
pathology, a lesion with intact overlying intact mucosa
(either because of submucosal or extramural/extrinsic
origin), and/or a false-positive finding from bowel contrac¬
tion, loop angulation, or even intussusception.11 1 Luminal
protrusions with changes in color (erythema) and signs of
mucosal disruption (exudates, erosions, and ulcers) are
highly suggestive of a neoplastic process; however, in
most cases the CE appearance of masses (ie, clinically sig¬
nificant lesions of higher probability for neoplasia) is not
dissimilar to that of innocent mucosal bulges (MBs). MBs
are defined as round, smooth, large-based luminal protru¬
sions with ill-defined boundaries, resulting either from
loop angulations and/or impression from adjacent loops/
structures.10 They are benign endoscopic findings of no
clinical significance, essentially false-positive findings.1 1J
Furthermore, a small-bowel lesion can be depicted only
in few frames and/or a mass may only be seen tangentially,
and it cannot be sampled or probed.' " Therefore, an ac¬
curate distinction between masses and MBs is crucial,
because missing a tumor can eventually jeopardize a cura¬
tive resection and patient prognosis. On the other hand,
misclassifying an innocent small-bowel MB as a neoplastic
mass may lead to unnecessary, invasive, and—most of
the time—expensive procedures. Girelli and Porta'" noted
that a smooth, round, protruding "mass" exhibits the
following characteristics when it is associated with the
innocent MB: (1) an ill-defined boundary with the sur¬
rounding mucosa, (2) a diameter larger than its height,
(3) no visible lumen in the frames in which it appears,
and (4) an image lasting less than 10 minutes."1''"
Software tools (eg, flexible spectral imaging color
enhancement, Blue mode, and/or suspected blood indica¬
tor) have been developed to assist capsule reviewers with
so-called difficult to characterize small-bowel lesions.'
Research has been carried out to produce 3-dimensional
(3D) reconstruction of the GI tract using stereoscopic vision
methods.'1 However, because of technologic limitations
inherit to SBCE (ie, packaging in capsule-size endoscopes
and power consumption constraints),1" hardware-enabled
Take-home Message
• The distinction between masses and innocent mucosal
bulging at small-bowel capsule endoscopy (SBCE) is a
difficult task even for experienced readers. The
adjunction of a 3D reconstruction software to the
standard capsule endoscopy (CE) 2D view significantly
improves the performance of novice readers in
distinguish between masses and bulging.
• The use of a 3D reconstruction software could be useful
in the training of novice CE readers.
3D reconstruction of the intestinal lumen is yet to be avail¬
able."' Over the last few years, software that enables 3D
representation/approximation (Shape-from-Shading) from
monocular 2-dimensional (2D) SBCE images has been
developed.' This software recovers the shape of objects
from 2D images using gradual variation of shading.1"
Recently, we showed that application of such software in
SBCE leads to image enhancement for a significant propor¬
tion of vascular and protruding small-bowel lesions.' How¬
ever, to the best of our knowledge, this reconstruction has
been applied only to still images (not to video segments);
furthermore, most studies performed thus far focused
more on technical aspects (ie, quality of images/visualiza¬
tion)1 1 than on clinical issues (ie, reaching a diagnosis).""
In this 2-phase study we aimed to evaluate whether
coupling the standard 2D (s2D) video clips with a 3D
reconstruction enhanced the performance of SBCE readers
(with different level of SBCE experience) in distinguishing
masses from innocent MB.
METHODS
Phase 1: choosing the optimal angle for 3D
video reconstruction
PillCam SB2 (Given Imaging Ltd, Yoqneam, Israel) cap¬
tures two 2D frames per second. These images are dis¬
played in sequence, as the relevant proprietary software
(RAPID; Given Imaging Ltd, Yoqneam, Israel) generates a
video that gives the impression of movement of the
capsule through the small bowel. To re-create 3D video
clips for the purpose of this study, short 2D video seg¬
ments were selected and broken down into the frames
that constituted them. Individual frames were 3D recon¬
structed and recompressed to respective 3D videos. For
this task, dedicated 3D visualization software was devel¬
oped in a Mathworks Matlab (MathWorks Inc, Natick,
Mass, USA) environment. It should be noted that when a
single image is reconstructed in 3D, the user can manipu¬
late the viewing angle and rotate at 360 degrees and zoom
in or out, whereas there is no freedom to rotate the
viewing angle of all the 3D images stitched together in a
3D video. For this reason, before proceeding with the
main evaluation, it was necessary to decide the optimal
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viewing angle for 3D reconstruction of individual frames
before they were stitched back again into a 3D video.
To select the best angle for reconstruction, ten 3-minute
2D SBCE videos (containing about 360 frames each) de¬
picting small-bowel luminal protrusions (small-bowel can¬
cer, 1; polyps, 3; bulging, 4; ampulla of Vater, 2) were
selected by an expert SBCE reviewer (G.M.), deidentified,
and stored in a folder for further processing. For each
s2D video clip, a corresponding 3D clip was reconstructed
at 25, 35, 45, 55, 65, 75, and 85 degrees by using the afore¬
mentioned software. The angles were, to an extent, arbi¬
trarily chosen, because evaluating the full spectrum of
angles from 1 to 90 degrees would have been impractical
and counterproductive. This resulted in a total of 70 short
3D video clips (Fig. 1).
Three reviewers (A.K., S.D., E.R.), all with extensive
experience in SBCE and blinded to each other (but
aware of the finding depicted in each video clip), re¬
viewed the clips in random order. Prompted by the
question, "Is this 3D reconstructed video clip helpful in
facilitating the elevated lesion/structure from the sur¬
rounding mucosa in the clip?" they were asked to assign
a number between 1 (not helpful) and 5 (very helpful),
for each of the 7 different angles of 3D reconstruction
of each 2D video. No time limit was used, and each
reviewer was allowed to spend as much time as he or
she needed to grade the videos. Thereafter, the scores
were tallied (the maximum score for each group of ten
3D reconstructed videos, at a certain angle, was 50),
and the 3D reconstruction angle with the higher score
was used for the rest of 3D video reconstructions in
phase 2 of this study (Fig. 2).
Phase 2: evaluation of 3D videos review
Video selection. For phase 2 of this study, 3 gastroenter-
ologists who were experts in SBCE (C.G., M.S., L.F.) selected
and deidentified short (5-minute) video clips (from an equal
number of SBCE examinations performed in 2 centers: C.G.
and L.F., Ospedale Busto Arsizio, Milano; M.S., Ospedale
San Carlo Borromeo, Milan, Italy) containing either masses
or MBs. If obvious endoscopic markers of possible malig¬
nancy (ie, mucosal disruption, surface ulceration, active
bleeding) were identified, the videos were excluded. All
SBCE examinations were performed with the capsule system
used in the first phase of the study. SBCE was carried out after
an overnight fast and bowel cleansing by 2 liters of polyeth¬
ylene glycol solution taken the afternoon before the SBCE
investigation. As per manufacturer protocol, liquids are al¬
lowed 2 hours into the study and a light meal 4 hours after
the ingestion of the capsule endoscope.
Video evaluation. Videos clips were deidentified, en¬
coded to ensure blind review, and stored in a dedicated
Dropbox (Dropbox Inc, San Francisco, Calif, USA) folder.
The Matlab software reconstructed the 3D videos at the
optimal 3D viewing angle (as per the first phase of the
study). These videos were uploaded to the shared folder
on Dropbox. The folder was shared among the reviewers
for easier access.
Two SBCE readers groups were involved in the evalua¬
tion: a group of SBCE experts (n = 3: all > 1000 SBCE re¬
views with > 10 years of experience) and a group of
novice readers (n = 3; competent in conventional diges¬
tive endoscopy, familiar with the SBCE system, who
received training on CE for the purpose of this study, but
not completed > 10 SBCE reviews neither working with
SBCE in routine clinical practice)."' The 2 readers groups,
with diametrically opposite SBCE exposure, were chosen
to examine the potential validity of 3D software as an
adjunct tool through the realistic clinical scenarios of
limited exposure/learning phase and expert SBCE review.
To avoid any possible referral bias in evaluating the video
clips, the readers were unaware of the clinical indication
to SBCE.
All readers, blind to each other and in a random order,
reviewed first the s2D SBCE videos (provided to them in
Audio Video Interleave format) and then (5 to 7 days later
to minimize the "recall" bias) the combined 2D+3D video
clips. In the combined 2D+3D view the reader was able
to visualize side to side the 2D and the reconstructed
3D video of the same patient; the reader was free to visu¬
alize them in sequence or at the same time and to repeat
the visualization several times (Fig. 3, Video 1 |available
online at www.giejournal.org]). No time limit was used in
the video review phase, and each reviewer was allowed
to spend as much time as needed with each video clip.
For each case, the diagnosis (mass or MB) reached after
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Figure 2. Flowchart of study phase 1. SBCE, small-bowel capsule endoscopy.
s2D and 2D+3D review by each individual reader and the
group was compared with that of the reference standard
(Fig. 4).
period of 6 months before medical discharge, and the
finding identified by SBCE was therefore defined as an
innocent MB.
Reference standard
In our study, the presence of a small-bowel mass had to
be confirmed by histology (reference standard for positive
diagnosis) or excluded after a complete diagnostic
workup and/or clinical follow-up (reference standard for
negative diagnosis). Therefore, all included patients
received an individualized diagnostic workup (including
CT enterography and/or magnetic resonance enterogra-
phy followed by deep enteroscopy or surgical exploration,
as necessary) for evaluation of the entire small bowel and
specifically the area of interest depicted in SBCE as
possible mass/bulging. If after the diagnostic workup no
mass was found, patients were clinically followed for a
Statistics
Individual and per-reader group (experts and novices)
sensitivity, specificity, and positive and negative likelihood
ratios were calculated for each of the reviewers. Diagnostic
accuracy (true positive + true negative/true positive +
false positive + false negative + true negative) and preci¬
sion (true positive/true positive -I- false positive) were
also calculated. In addition, individual and summative
receiver operating characteristic (ROC) analysis was under¬
taken. The ROC curve is initially constructed by plotting
the sensitivity and the false positivity (1-specificity) for
each reviewer. The ROC curve is constructed to fit these
points. The area under the ROC curve (AUC) is then
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Figure 3. Two SBCE frames depicting a mass (A) and bulging (B) with their corresponding 55-degree 3D reconstruction. SBCE, small-bowel capsule
endoscopy; 3D, three-dimensional.
calculated. An AUC close to 1.0 signifies that the test has
near perfect discrimination, whereas an AUC close to .5
suggests poor discrimination. The AUC comparison was
performed by comparing the square of their standardized
difference with the quartiles of the y2 distribution. The an¬
alyses were performed with Stata 13 (Copyright 1996-2013
StataCorp LP, College Station, Tex) using the function "roc-
comp" as described in detail elsewhere.-"
Interobserver agreement, for each group and for each
reviewing session, was measured by the kappa statistic us¬
ing the Randolph's free-marginal multirater kappa; k)r
Brennan and Prediger suggested using free-marginal k
when raters are not forced to assign a certain number of
cases to each category and using fixed-marginal k when
they are. A negative value represents agreement worse
than chance, whereas values in the range of 0 to .25, .25
to 0.50, .50 to .75, and .75 to 1.00 represent poor, fair,
good and near-perfect agreement, respectively.-'
Ethics consideration
This study was conducted in accordance with estab¬
lished research ethics guidelines. After review by the local
ethics committee, further specific ethical review and
approval were not required because the study was consid¬
ered an evaluation of previously collected endoscopy im¬
ages, using data already obtained as part of regular
clinical care. Patients gave their written, informed consent
for the studies undertaken a part of clinical workup.
RESULTS
Phase 1: choosing the optimal angle for 3D
reconstruction
The 3D video reconstruction at 55 degrees obtained the
highest score by each of 3 expert individually (38/50, 28/50,
and 33/50, respectively) as well as summative (109/150)
and mean score (3.7/5).
Phase 2: distinguishing between mass and
bulge (with 3D review)
Thirty-two short videos were selected (25 contributed
by C.G. and L.F. and 8 by M.S.). Thirteen of them were
classified by the reference standard as depicting masses
and 19 MBs. More specifically, 6 neuroendocrine tumors,
5 GI stromal tumors, and 2 adenocarcinomas were finally
diagnosed.
The sensitivity, specificity, and positive and negative
likelihood ratios for individual reviewers are presented in
Table 1. In the 2D video review, the summative diagnostic
accuracy/precision for experts and novices were .S7/.65 and
.79/.5, respectively. In the combined 2D+3D video review,
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Figure 4. Flowchart of study phase 2. SBCE, small-bowel capsule endos¬
copy; AUC, area under the (ROC) curve.
the relevant values for experts and novices were .81/.52
and .S7/.79, respectively.
The summative AUC for the experts and novices groups
for s2D review was .74 and .5, respectively (P = .0053).
The summative AUC for the expert and novice groups
for combined 2D+3D review was .70 and .57, respectively
(P = .1846). Comparing the 2D and the 2D+3D video re¬
view, no statistical difference in the AUC was observed
among experts, (P = .245), whereas a significant improve¬
ment was observed among novices (P = .049). The AUCs
(summative ROCs) for each of the 2 CE reviewer groups
for the 2D and 2D+3D video reviews are showed in
Figure 5 and details of individual assessments in Table 2.
For the 2D review, the interobserver agreement (k) of
experts and novices was .71 and .54, respectively. For the
2D+3D review, the k value for experts and novices was
.58 for both groups.
DISCUSSION
The present study confirms that the distinction between
masses and bulges, in the s2D SBCE videos, remains a chal¬
lenging (even for expert SBCE readers) task; nevertheless,
as expected, experienced readers performed better than
novices. It is noteworthy that the adjunction of 3D recon¬
structed video clips to the s2D SBCE reading software did
not improve performance of experts (AUC from .74 to .7;
P = .245), whereas it significantly improved the perfor¬
mance of novice readers (AUC from .5 to .57; P = .049).
However, it should be noted that when a false-negative
diagnosis (per evaluation, not per case) was examined,
3D led to a marked reduction from 6 to 1 in the experts
group, whereas in the novice group the application of
3D false negative resulted in an increase of false-negative
evaluations by 13% (from 13 to 15). False negatives are
considered to be crucial in this scenario, because they
are likely to lead to a situation where further essential
workup and therapy (for a clinically significant lesion) is
held back. Of course, the spotlight here is on the expert
group, because no one would expect that novices would
have to read/interpret SBCE on their own, especially at
this stage in their SBCE training.
Since the advent of wireless CE, the small-bowel tumor
detection rate has risen to 2% to 9% in those presenting
with obscure GI bleeding. The greatest increase was seen
in carcinoid tumors, followed by lymphomas and adenocar¬
cinomas. 1"30 Nevertheless, several studies showed that
SBCE can miss large (often sinister) protruding mucosal le¬
sions." ' Moreover, it has been shown that both the inter¬
observer agreement and the detection rate of significant
findings are low, regardless of the readers' experience.11"52
A plausible explanation is that in conventional endoscopy,
air insufflation (together with the ability to probe and/or
take biopsy specimens) is helpful in distinguishing be¬
tween masses and innocent MBs, whereas in CE this "lux¬
ury" is lacking. Hence, false-positive findings are not
uncommon, and the differentiation between masses and
bulges in SBCE is still challenging.12 This is clearly demon¬
strated in our study by the performance of expert re¬
viewers in evaluating s2D video clips, where the
summative diagnostic accuracy is high, albeit < 90%.
This is even more evident in the novice group, with a sig¬
nificant lower accuracy and AUC than the experts, confirm¬
ing that experience seems to be a key factor in CE,
influencing the correct evaluation of difficult findings.
To overcome the aforementioned confounders, a
couple of novel indices/scoring systems (aiming to discrim¬
inate a MB from a mass on CE) have been developed.
Shyung et ah1 reported a score composed of 5 parameters
(ie, bleeding, mucosal disruption, irregular surface, color,
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TABLE 1. Performances (sensitivity, specificity, and positive and negative likelihood ratios) of novices and experts In reading 2D
and 2D+3D reconstructed videos
2D 2D + 3D 2D 2D + 3D 2D 2D + 3D 2D 2D + 3D
Sensitivity (%) Sensitivity (%) Specificity (%) Specificity (%) ( + )LR ( + )LR (-)LR (-)LR
Reviewers (95% CI) (95% CI) (95% CI) (95% CI) (95% CI) (95% CI) (95% CI) (95% CI)
Expert 1 83 100 90 84 83 100 90 84
(70.0-96.0) (90.6-100.0) (79.6-100.0) (71.3-96.7) (70.0-96.0) (90.6-100.0) (79.6-100.0) (71.3-96.7)
Expert 2 83 100 90 63 83 100 90 63
(70.0-96.0) (90.6-100.0) (79.6-100.0) (46.3-79.9) (70.0-96.0) (90.6-100.0) (79.6-100.0) (46.3-79.9)
Expert 3 83 92 85 79 83 92 85 79
(70.0-96.0) (82.6-100.0) (72.6-97.4) (64.9-93.1) (70.0-96.0) (82.6-100.0) (72.6-97.4) (64.9-93.1)
Novice 1 85 69 68 84 85 69 68 84
(72.6-97.4) (53.0-85.0) (52.8-84.0) (71.3-96.7) (72.6-97.4) (53.0-85.0) (52.8-84.0) (71.3-96.7)
Novice 2 69 64 84 100 69 64 84 100
(53.0-85.0) (47.4-80.6) (71.2-96.7) (90.6-100.0) (53.0-85.0) (47.4-80.6) (71.2-96.7) (90.6-100.0)
Novice 3 46 46 89 89 46 46 89 89
(28.7-63.3) (28.7-63.3) (78.1-99.8) (78.1-99.8) (28.7-63.3) (28.7-63.3) (78.1-99.8) (78.1-99.8)
2D, 2-dimensional; 3D, three-dimensional; CI, confidence interval; LR, likelihood ratio.
1-Specificity 1-Specificity








Figure 5. ROC curves of video reading with s2D and 2D-I-3D for novices (A) and experts (B), respectively. ROC, receiver operating characteristic;
s2D, standard 2-dimensional; 3D, 3-dimensional.
and the presence of white villi). A small-bowel mass lesion
is probable with a score > 4, whereas a score < 2 indi¬
cates a low probability of a sinister lesion." " However,
this index takes into account "high-risk" features such as
bleeding, mucosal disruption, and irregular mucosal sur¬
face (ie, clear endoscopic markers of malignancy, adopted
in the consensus statement [2006/2007] of a panel of inter¬
national experts in CE as helpful discriminators"). Girelli
et al 1 proposed the Smooth Protruding Index on Capsule
Endoscopy score " in which a score > 2 has 83% sensi¬
tivity and 89% specificity for tumors. Other attempts to
differentiate tumors on CE include an automated scale
that uses wavelet-based analysis in CE images; this has a re¬
ported 95% sensitivity and specificity." " Conversely, flex¬
ible spectral imaging color enhancement offers no benefit
in this setting over the standard reviewing mode.
Therefore, we thought that software offering 3D recon¬
struction, and hence emphasizing certain endoscopy
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TABLE 2. Detailed individual assessment per reader with s2D and 20+3D software
Video case Expert 1 Ex pert 2 Expert 3 Novice 1 Novice 2 Novice 3
REVIEW mode s2D 2D+3D s2D 2D+3D s2D 2D+3D s2D 2D+3D s2D 2D+3D s2D ! 2D+3D
Bulge • • • • • • • • •
Bulge • • • • • • • • • •
Bulge • • • • • • • • • • • •
Bulge • • • • • • • •
Bulge • • • • • • • • •
Bulge • • • • • • • • • • • •
Bulge • • • • • • • • • • •
Bulge • • • • • • • • • • •
Bulge • • • • • • • • •
Bulge • • • • • • • •
Bulge • • • • • • • • •
Bulge • • • • • • • • • • • •
Bulge • • • • • • • • • • •
Bulge • •
Bulge • • • • • • • • • • •
Bulge • • • • • • • • • • •
Bulge • • • • • • • • •
Bulge • • • • • • • • • • • •
Bulge • • • • • • • •
Mass • • • • • • • • • •
Mass • • • • • • • • • • •
Mass © • • • • • • • o • •
Mass • • • • • • • • • • •
Mass • • • • • • • • • • • •
Mass • • • • • • • • • • • •
Mass • • • • • • • • • • • •
Mass • • • • • • • • • • • •
Mass • • • • • • • • • • • •
Mass • • • • • • • • • • • •
Mass • • • • • • • • • © • •
Mass • • • • • • • • €4 •
Mass • • • • •
"
© •
|^, correct diagnosis; , false positive; false negative.
features such as the perception of depth and volume differ¬
ences between the objects, could allow resolution of diag¬
nostic dilemmas in such a setting. Furthermore, to the best
of our knowledge, all previous studies on 3D reconstruc¬
tion were performed with individual frames/images.1
Most of these studies focused on technical issues (ie,
image quality, visualization) rather than on clear clinical is¬
sues.1 ' ~ It is well known that in CE the video component
is as crucial in final interpretation (MB flattens with peri¬
stalsis) as cautious reviewing of still frames. Our data sug¬
gest that although 3D software does not have any
significant impact on accurately discriminating masses
from bulges (when expert readers are involved), it can
potentially allow them to reduce the false-negative evalu¬
ations by 8396. One can argue that the level of expertise
of those involved in this study (experts > 1000 SBCE
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reviews and > 10 years clinical experience) negatively
biased the contribution of the new software in this sub¬
group. Furthermore, the fact that they are accustomed
to working with the s2D software explains why the new
feature might be challenging."
On the other hand, we selected novices who were
already familiar with the s2D and received training similar
to that proposed by ASGE-' but were beginners at using
CE. Therefore, our results suggest that although the new
software cannot substitute clinical and SBCE experience
(even after the 3D reconstruction, novices' performance
was poorer than those of experts), it may be helpful in
the training phase by potentially shortening the learning
curve. Furthermore, the combination of other enhance¬
ment tools such as Blue mode3's might improve the perfor¬
mance of 3D reconstruction. Moreover, similar to the
inclusion of the Lewis Score calculator, we recommend
that an atlas and scoring systems (ie, Smooth Protruding
Index on Capsule Endoscopy) are embedded in commer¬
cially available reading software to assist expert and novice
readers in achieving higher performance.
This study has some limitations, including small sample
size (a consequence of the relative rarity of small-bowel tu¬
mors) and the inflexibility of the selected video clips re¬
view (short video clips in Audio Video Interleave format;
it was not possible to modify review speed or change the
angle of view). In addition, we decided to include only
patients whose diagnosis was confirmed by a widely
accepted "hard" reference standard. Consequently, we
selected cases by excluding all those with endoscopic
high-risk "stigma" of mass lesions. Another possible limita¬
tion is a bias introduced by the combined evaluation of
the 3D reconstruction and the s2D, instead of the 3D
reconstruction alone, of which we were fully aware. Never¬
theless, we decided to combine 2D with 3D because the
reconstruction of an 8-hour-long video in 3D would
require considerable time and resource.
Our goal was to simulate a clinical scenario, similar to
that of other advanced endoscopic features (ie, narrow¬
band imaging |NBI], iSCAN, flexible spectral imaging color
enhancement) where the reader evaluates the video in the
s2D mode and applies the new feature (in our study, 3D
reconstruction) to a region of interest. The first phase of
the study was performed to overcome issues with image
angle of view. However, we cannot be certain that the
angle chosen for 3D applies to all lesions depicted in this
current study. Nevertheless, this means there are areas of
future research in the use of 3D alone or in combination
with other software tools."9
In conclusion, the results of the present study confirm
that the distinction between masses and MBs in SBCE is
still a challenging task even for experienced readers. In
this situation, review experience seems to have a primary
role. However, the adjunct of 3D reconstruction to the
s2D video reading software significantly improves the per¬
formance of novice SBCE readers in distinguishing masses
from MBs, thus potentially shortening their learning curve
and leading to a reduced rate of false-negative diagnoses
in expert hands. Further studies are needed to test the
feasibility of 3D reconstruction in clinical practice and to
evaluate the impact on the reviewing process in terms of
both time and diagnostic yield.
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